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Abstract 
 
A shared property of several neurodegenerative diseases is the neuronal 
accumulation of aggregated tau protein. These include Alzheimer’s disease (AD) 
and frontotemporal dementia (FTD). Many studies have suggested that aggregated 
tau accumulation in AD brains involves: (i) internalisation of extracellular tau 
(aggregated or not) into neurons; (ii) induction of endogenous tau aggregation by 
the internalised tau; and (iii) secretion of part or whole of this aggregated tau 
complex. This complex then initiates a new cycle of internalisation, aggregation 
and secretion. While this AD mechanism has strong evidential support, it is unclear 
if it applies to FTD. It was therefore investigated if and how two FTD-associated 
tau mutations, V337M and N279K, affect in vitro wild type (WT) tau aggregation 
and conformation, and studied the cell biological effects of their respective 
extracellular oligomers.  
 
A library of 43 plasmids for expressing full-length and truncated tau and their FTD 
variants were created, in conjunction with the establishment of a new high-yield 
tau purification method. Consequently, in vitro biochemical assays showed that the 
FTD variants distinctively altered the immunological reactivity, the stages of 
aggregation, and the structural phenotypes of aggregated WT tau four-repeat 
domain, K18. Internalisation of WT and FTD tau K18 extracellular oligomers was 
significantly different in human neuroblastoma cells and human stem-cell derived 
neurons. Internalisation seemed to occur by endocytosis, and the internalised 
oligomers localised to the nucleus and cytoplasm of human neuroblastoma cells 
and the soma and neurites of stem cell-derived neurons. Moreover, internalised 
oligomers co-localised with endogenous tau and the nuclear protein nucleolin, 
without inducing cell death.  
 
These findings provide new perspectives to the cell-to-cell propagation theory of 
aggregated tau, by demonstrating that cellular internalisation of tau variants may 
be tightly regulated by the given protein’s folding and aggregation characteristics. 
This may help to explain several enigmatic aspects of the molecular pathogenesis 
found in different tauopathies.  
 - 1 - 
 
1| Introduction  
 
A major function of tau protein is to support the intact neuronal cytoskeleton, 
enabling efficient trafficking between sub-neuronal compartments. The 
dysfunction of tau is, however, implicated in the pathogenesis of many 
neurodegenerative diseases including the focus of this thesis, frontotemporal 
dementia (FTD). Whilst there is strong evidence supporting the mechanisms of 
disease, it is currently unclear if and how single nucleotide polymorphisms in tau 
associated with different forms of FTD may influence disease onset and 
progression. This introduction covers the structural biochemistry of tau and its 
functions in physiological and pathophysiological conditions. Furthermore, the 
mechanisms by which abnormal tau protein may lead to distinct forms of disease 
and the probable therapeutic targets involved are discussed. The chapter 
concludes with the aims of this study. 
 
1.1 Tau protein: structure, isoforms and functional fragments  
 
In physiological conditions, tau, encoded by the microtubule associated protein 
tau (MAPT) gene, supports microtubule (MT) assembly by inducing MTs to 
polymerise (Brandt et al., 1995; Drechsel et al., 1992). The human MAPT gene 
consists of 16 exons and is located on chromosome 17q21.3 (Andreadis et al., 
1992; Neve et al., 1986). These exons are alternatively spliced, producing 
isoforms that are differentially expressed in tissues and in development (Goedert 
et al., 1988, 1989). There are six tau isoforms in the adult human brain, produced 
from alternative splicing of exons 2, 3 and 10 (Fig. 1.1). The gene structure 
consists of two major regions: the N-terminus projection domain, and the 
assembly domain (consisting of the MT-stabilisation region and the C-terminus), 
with the number of N- and C-terminus repeats differing between isoforms (Fig. 
1.1). Exons 2 and 3 each encodes 29-amino acid inserts at the N-terminus: 
alternative splicing of these exons produces isoforms with zero, one or two N-
terminus repeats (0N, 1N or 2N respectively; Fig. 1.1). Similarly, alternative 
splicing of exon 10 produces isoforms with either three MT-binding repeats (R1, 
R3, R4 = 3R-tau) due to exclusion of exon 10 or four repeats (R1, R2, R3, R4 = 
 - 2 - 
4R-tau) due to exon 10 inclusion (Goedert and Jakes, 1990). Several tauopathies 
are associated with this irregular splicing of exon 10, by influencing the 3R:4R 
ratio (section 1.3).  
 
Tau monomers in physiological conditions have little or no propensity to 
aggregate owing to their random, intrinsically disordered conformation. Using X-
ray scattering and solution nuclear magnetic resonance (NMR), it has been 
demonstrated that tau lacks significant amounts of secondary structure (Mukrasch 
et al., 2009). Tau is a highly dynamic protein in terms of solubility and 
adaptability to different solution conditions: this property may have been acquired 
due to the protein’s flexible disordered character. Tau has an overall hydrophilic 
nature and is therefore highly soluble in water (Jeganathan et al., 2008; Mukrasch 
et al., 2009). The protein can also adapt to high temperatures and high acidity, 
which adds to its flexibility (Jeganathan et al., 2008). Nonetheless, the amino acid 
charge distribution varies between the different regions: the N terminus, the C 
terminus and the MT binding region are mainly acidic, neutral and basic 
respectively (Kolarova et al., 2012). These differences are believed to contribute 
to the protein’s varied functions in physiology and pathophysiology. Moreover, 
the tau isoforms have an anomalous behaviour with sodium dodecyl sulphate 
(SDS) which leads to a decrease in their mobility on SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) (Guo et al., 2017).  
 
Due to the importance of the MT repeat region to both the physiological and the 
pathophysiological functions of tau (section 1.2), tau fragments made of specific 
repeat region sequences are frequently used to model aspects of the protein’s 
function in vitro. These include the 4R and the 3R repeat domains commonly 
referred to as K18 and K19 (Fig. 1.1). These fragments are sufficient for 
reproducing many tau functions (section 1.2) (Stöhr et al., 2017; von Bergen et 
al., 2005).  
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1.2 Physiological and pathophysiological functions of tau  
 
Tau is widely known for its physiological function in stabilising MTs. 
Nonetheless, the protein has other physiological functions. Moreover, disease-
causing properties of the protein can be manifested through multiple pathways.  
 
N1 N2 P1 P2 R1 R2 R3 R4
N CRepeat domainProline-rich region
N1 P1 P2 R1 R2 R3 R4
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Figure 1.1. A schematic illustration of tau isoforms and functional fragments. 
Alternative splicing of exons 2, 3 and 10 (colour-coded) produces six isoforms 
with different combinations of N terminus inserts and the C-terminus repeat 
domains (namely 0N3R, 1N3R, 2N3R, 0N4R, 1N4R and 2N4R). Due to the 
significance of the repeat domains in binding to and stabilising MTs, tau 
fragment constructs consisting of the two possible repeat domain combinations 
(repeats R1 – R4 referred to as K18 and R1-R3-R4 known as K19) are often used 
as functional truncation forms of tau for biochemical and cellular studies.  
 
 
1.2.1 Physiological functions of tau 
 
Tau in the adult human brain is mostly found in axons where it binds to MTs and 
supports MT assembly and stability (Brandt and Lee, 1993). MTs are dynamic 
helical assemblies of α- and β-tubulin which serve as tracks for axonal transport 
(Conde and Cáceres, 2009). The binding of tau to MTs occurs at the α- and β-
tubulin heterodimer interface, with specific amino acid stretches located in the 
repeat domain region being responsible for this function: residues 224-237 and 
245-253 in R1, 275 – 284 in R2, and 300 – 317 between R2 and R3 (Kadavath et 
al., 2015). After the tau-MT complex is formed, a local hairpin structure 
involving residues 275VQIINK280 and 306VQIVYK311 becomes evident (Kadavath 
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et al., 2015). These two hexapeptide motifs are critical for tau aggregation, and 
therefore suggests that MT binding and self-aggregation are conflicting functions 
of tau (section 1.2.2.2). Due to its extra repeat region, 4R tau binds MTs more 
efficiently than 3R tau (Goedert and Jakes, 1990; Zhong et al., 2012). The 
projection domain binds to the neuronal plasma membrane and may contribute to 
neurite development (Brandt et al., 1995). Moreover, the length of the projection 
domain is a determining factor of axon diameter and MT filament spacing length 
(Chen et al., 1992). Deleting or reducing MAPT expression leads to impaired MT 
density and morphology, indicating that intact tau may be essential for cellular 
function (Bolkan and Kretzschmar, 2014).  
 
Tau can also regulate axonal transport, by modulating the actions of the motor 
proteins dynein and kinesin, which function to ensure efficient protein trafficking 
from the axon to the soma (retrograde) and from the soma to the axon 
(anterograde) respectively (Dixit et al., 2008; Stamer et al., 2002). This is 
achieved through competition of tau with dynein and kinesin for MT binding, 
moderating retrograde and anterograde transport and altering the accumulation of 
cargo in the soma (Dixit et al., 2008; Stamer et al., 2002). As a result, tau can 
influence the number of kinesin molecules bound to MTs by occupying binding 
sites on MTs or by the interaction of its N-terminus with specific enzymes that 
regulate MT-kinesin binding (Kanaan et al., 2011). Furthermore, tau can 
modulate axonal transport by binding to the dynein interacting partner, dynactin 
(Magnani et al., 2007). As the functions of dynein and kinesin oppose each other 
(Belyy et al., 2016), tau is able to contribute to the control of both anterograde 
and retrograde transport.  
 
While most neuronal tau is located in axons, small quantities of dendritic tau have 
recently been reported (Frandemiche et al., 2014). Dendritic tau is thought to have 
a crucial role in controlling synaptic plasticity: electrical stimulation of synapses 
causes tau in cultured mouse neurons to migrate to dendritic spines, where its 
interaction with actin may contribute to spine remodelling that triggers synaptic 
plasticity (Frandemiche et al., 2014). 
 
 - 5 - 
Tau has also been found in eukaryotic nuclei, both in neurons and non-neuronal 
cells (Loomis et al., 1990; Sultan et al., 2011). Nuclear tau in human and monkey 
kidney cell lines co-localise with Tau-1, a pan-isoform tau antibody (Loomis et 
al., 1990). In these cells, Tau-1 co-localisation occurs in the nucleolar organiser 
region of the chromosome, suggesting that tau may have a role in regulating 
genomic deoxyribonucleic acid (DNA) (Loomis et al., 1990). Notably, tau 
homologues were not found in non-primate cells, possibly due to a conserved 
function of nuclear tau in primates (Loomis et al., 1990). Fig. 1.2 provides a 
schematic illustration of the neuronal location and physiological functions of tau.  
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Figure 1.2. Physiological functions of tau. 
(A) The most widely characterised role of tau is the stabilisation of MTs and the 
promotion of MT assembly.  (B) In the nucleus, tau binds to specific chromosomal 
regions and possibly regulates the integrity and activity of genomic DNA. (C) 
Another function of axonal tau is the modulation of axon-soma shuttling of 
cellular material through the anterograde and the retrograde transport 
mechanisms, by regulating the interaction between MTs and the motor proteins 
kinesin and dynein required for these processes. (D) Synaptic tau is believed to be 
important for synaptic plasticity, although little is known about this property. 
Figure design concept taken from Wang and Mandelkow (2016). 
 
 
1.2.2 Pathophysiological functions of tau 
 
Tau dysfunction has been identified as a cause of several neurodegenerative 
diseases. The main pathways to tau pathophysiology can be grouped into two: 
either due to loss of its physiological functions or gain of new abnormal 
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functions. Loss of function effects of tau include: (i) decrease in tau expression 
levels, which reduces the amount of tau required for efficient MT stabilisation; 
and (ii) loss of the MT stabilisation function due to abnormal phosphorylation. 
Examples of the gain of function effects include: (i) self-polymerisation of 
soluble, free tau to form disease-associated aggregates; (ii) disease-associated 
mutations that change disease-causing pathways; and (iii) extracellular release 
and trans-synaptic propagation of misfolded tau.  
 
1.2.2.1 Pathophysiology arising from loss of physiological functions 
 
Elimination or reduction of tau levels 
Reducing or abolishing tau expression can lead to disease-related manifestations. 
Although other MT-associated proteins may be able to compensate for the MT 
stabilisation function in the absence of tau, this seems inadequate as aged tau 
knock-out mice exhibit behavioural dysfunction reminiscent of those observed in 
neurodegeneration (Lei et al., 2014). For example, the levels of the MT-associated 
protein MAP1A is increased in several tau knock-out mice lines at birth, but 
decreases with age when motor and behavioural deficits become evident (Dawson 
et al., 2001; Fujio et al., 2007; Harada et al., 1994; Lei et al., 2014).  It would 
therefore appear that the need for a critical level of physiological forms of tau 
increases with age, which high levels of MAP1A cannot necessarily account for. 
In neuronal cultures, tau reduction using antisense ribonucleic acid blocks axonal 
extensions (Caceres and Kosik, 1990). These data suggest that a certain level of 
tau expression is required to maintain MT integrity and efficient axonal transport 
throughout development and growth, and that reduction or elimination of protein 
expression has detrimental consequences. Experiments aimed at silencing tau 
expression using small interfering ribonucleic acid strategies have produced 
mixed results. Whilst it led to no evidence of neurotoxicity (Xu et al., 2014) and 
even neuroprotection (Vossel et al., 2015) in some cases, others reported 
enhanced mitochondrial dysfunction (Manczak and Reddy, 2013). 
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Loss of the MT stabilisation function 
 
Adjacent to the MT-binding region are proline-rich regions (P1 and P2 in Fig. 
1.1) that contain many phosphorylation sites, although many other sites are 
distributed across the entire tau sequence (Hanger et al., 2007). Excessive 
phosphorylation of tau reduces its ability to bind to MTs, hence disrupting the 
protein’s main physiological function (Wang et al., 2013). Increasing levels of 
phosphorylation may lead to a complete loss of the protein’s affinity to MTs, 
resulting in soluble tau accumulation in neurons, impairing neuronal homeostasis 
either by the sheer space occupied or by interfering with specific processes such 
as the protein degradation system (Stoothoff and Johnson, 2005). Moreover, the 
loss of tau’s MT binding affinity can lead to MT disassembly, disrupting cargo 
transport. Because the extent of tau phosphorylation directly corresponds to 
reduction in MT binding, which may have disease-causing implications 
(Stoothoff and Johnson, 2005), the amount of phosphorylated tau is used as a 
biomarker in staging AD and other tau-positive diseases (Hampel et al., 2010). 
Importantly for this thesis, free forms of MT-detached tau can self-aggregate into 
large structures that may define disease progression (section 1.2.2.2).  
 
1.2.2.2 Pathophysiology arising from gain of new toxic functions 
Self-polymerisation of free tau to form aggregates 
 
In its hyperphosphorylated state, the MT domain of tau cannot effectively bind 
MTs: this results in free floating forms of soluble tau (Fig. 1.3). These MT-
unbound forms of tau can lead to disease through self-aggregation. The two 
hexapeptide motifs 275VQIINK280 and 306VQIVYK311 at the beginning of repeats 
R2 and R3 respectively are critical for the ability of monomeric tau molecules to 
aggregate. Removal of one or both motifs reduces or abolishes tau’s aggregation 
competence (Bergen et al., 2000; Li and Lee, 2006). These motifs modulate the 
structural conversion of natively unfolded monomeric tau to b-sheet-rich 
aggregates; b-sheet content increases proportionally with cumulative aggregation 
(von Bergen et al., 2005). Data from solid state NMR experiments have shown 
that the 306VQIVYK311 motif is an essential site for the initial monomer-monomer 
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contacts leading to tau aggregation (Xiang et al., 2017), suggesting that this motif 
regulates tau aggregation. It is therefore unsurprising that this structural peptide is 
capable of forming tau aggregates independently of the surrounding tau  
sequences (Stöhr et al., 2017), and that tau protein lacking this structural peptide 
is unable to aggregate (Li and Lee, 2006).  
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Figure 1.3. Pathophysiological functions of tau. 
Dysfunctional tau, generated due to overproduction or abnormal 
phosphorylation, can lead to disease through different routes, such as: (A) 
presynaptic terminal mislocalisation, causing spine loss through a cascade of 
events; (B) lost affinity to MTs resulting in MT disassembly, impaired axonal 
transport and tau aggregation; (C) aggregated tau acting as seeds or templates to 
induce further aggregation; and (D) impaired neurotransmission by affecting the 
production and/or activity of specific post-synaptic proteins. Figure design 
concept taken from Wang and Mandelkow (2016). 
 
 
Another mechanism by which tau aggregation can occur is intermolecular 
disulphide bonding. Tau monomers have one or two cysteine residues, depending 
on the isoform. 3R and 4R isoforms have one and two native cysteine residues 
respectively, at positions 291 and 322 (Bhattacharya et al., 2001; Kim et al., 2015; 
Schweers et al., 1995). Disulphide interactions between tau monomers promote 
aggregation whilst intramolecular bonding is thought to prevent aggregation (Fig. 
1.4). Therefore, 4R tau aggregates faster and more efficiently than 3R tau, due to 
the capacity of 4R tau to form hierarchical chains of disulphide-bonded 
aggregates compared to 3R tau whose cysteine-dependent aggregation is limited 
to dimer formation (Zhong et al., 2012). However, the presence of the pro-
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aggregant hexapeptide structural element 275VQIINK280 in 4R isoforms also likely 
contribute to their higher aggregation rates.  
 
In vitro tau aggregation is thought to follow a nucleation–elongation mechanism 
(Congdon et al., 2008; Friedhoff et al., 1998) where monomers dissociated from 
MTs due to hyperphosphorylation are aggregation-incompetent due to their 
unfolded conformation (Fig. 1.5). Monomer-monomer interactions, involving 
either disulphide bonding or the hexapeptide motifs, lead to a conformational 
change from an unfolded, disordered structure for monomers to a b-sheet-rich 
element that begins to adopt an aggregation-competent, structured conformation. 
This conformational change appears to be triggered by the formation of dimers, 
the minimal forms of aggregated tau (Congdon et al., 2008; Friedhoff et al., 
1998). Dimer formation, thermodynamically disfavoured at physiological 
conditions, promotes further aggregation to form a critical nucleus of aggregated 
tau sufficient to overcome the rate-limiting step. Subsequent steps involve the 
addition of assembly-competent monomers and dimers to form larger oligomers, 
protomers, paired helical or straight filaments (PHFs or SFs respectively) and 
neurofibrillary tangles (NFTs). The neuronal accumulation of NFTs is linked to 
neurologic disorders involving tau, collectively referred to as tauopathies. The 
severity of NFT inclusion is used clinically to diagnose and stage tauopathies 
(Arriagada et al., 1992). Structural phenotypes of NFTs are of two major types: 
PHFs and SFs (Goedert and Jakes, 2005). Notably, both PHFs and SFs can be 
described as two strands wound round each other to form a filament, but perhaps 
the main distinguishing factor is that PHFs have easily recognised crossover 
points whereas SFs do not (Wischik et al., 1985) (Fig. 1.6). While PHFs and SFs 
may have identical protomer composition (made of residues 306 – 378), their 
structural distinction is in the molecular arrangements of protomers (Fitzpatrick et 
al., 2017).  Being a mutation hotspot (Fig.1.7), the protomer core, and therefore 
PHF and SF structures, could be altered in FTD. Because tau filaments assembled 
in vitro from recombinant proteins tend to share close characteristics with AD 
brain-derived filaments (Fig. 1.6), recombinant tau is often used to model the 
mechanistic forms of tauopathies.  
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Tau aggregation can be accelerated in vitro by external agents that help to 
overcome the thermodynamic barrier required for nucleation. An example is 
inducing monomer aggregation with aggregated tau (PHFs or oligomers) used at 
suboptimal concentrations (Falcon et al., 2015; Guo and Lee, 2011). Such 
reactions record aggregation much quicker compared to unseeded controls, as the 
seeds readily overcome the initial rate determining steps of the reaction. Tau 
aggregation in vivo and in cultured cellular models is thought to proceed in a 
mechanism similar to the in vitro seeded aggregation: by the templated 
aggregation of the exogenous tau delivered into the cell by recruiting endogenous 
tau of same or similar conformation (Frost et al., 2009; Stancu et al., 2015). Other 
approaches that can accelerate tau aggregation include the use of metallic 
cofactors (Bader et al., 2011; Du et al., 2014; Nübling et al., 2012; Zhou et al., 
2007) or chemical inducers, including heparin and arachidonic acid (King et al., 
2000; Ramachandran and Udgaonkar, 2011). The mechanism by which these 
agents enhance tau aggregation is not fully understood but a general consensus is 
that they circumvent the rate limiting step, bypassing the need to form a critical 
mass of aggregated tau to enable aggregation. Furthermore, tau aggregation can 
be modulated by specific disease-associated mutations (section 1.4).  
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Figure 1.4. Cysteine-dependent tau aggregation is isoform-specific. 
(A) 4R tau isoforms have two native cysteine residues that can engage in 
intermolecular disulphide bonding to form dimers, trimers and tetramers and 
higher aggregates, as illustrated here. (B) 3R tau isoforms have a single cysteine 
residue each, and can consequently aggregate only through dimer formation. (C) 
putative 4R-3R disulphide bonding mechanisms leading to tau aggregation.  
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Figure 1.5. Schematic illustration of the “nucleation-elongation” mechanism of 
tau aggregation. Hyperphosphorylation causes tau to detach from MTs into a 
pool of free, floating proteins. These aggregation-incompetent tau proteins 
undergo a conformational change, which enable them to make intermolecular 
contacts either through the hexapeptide motifs (red) or by disulphide bonding. 
Successive aggregation results in the formation of a critical nucleus of 
aggregated tau that is sufficient to overcome the thermodynamic barrier and 
promote further aggregation to form filamentous aggregates, and then into NFTs 
(different colours highlight possible structural heterogeneity in tangle 
composition). NFT and oligomer accumulation in affected human brains can lead 
to neurotoxicity through several mechanisms as described in Fig. 1.3.  Specific 
aggregation processes leading to NFT formation may be reversible under defined 
conditions. High concentrations of dimers and/or other small oligomers may be 
able to by-pass the nucleation stage of aggregation. 
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Figure 1.6. Electron micrographs of tau aggregates isolated from AD brains 
(upper panel; three patients – cases 1 – 3) and in vitro polymerised filaments 
from recombinant tau K19, and disease variant forms of K18 and htau40 
(bottom panel). 
The recombinant PHFs, assembled in the presence of the polyanionic cofactor 
heparin, share close features (such as a paired helical characteristic, 10-25 nm 
width and a crossover repeat of ∼80 nm) with the brain-derived PHFs. Figure 
taken from  Barghorn et al., (2004).  
 
1.3 Tauopathies: disease classification, clinical diagnosis, 
progression, and differential roles of tau isoforms  
 
Neurodegeneration in tauopathies is characterised by a gradual dysfunction and 
subsequent loss of affected neurons due to the activities of abnormal tau. 
Notwithstanding the strong similarities, the molecular mechanisms and the 
clinical presentations differ between various tauopathies, and these form the basis 
of their classification (Dickson et al., 2011; Rademakers et al., 2012). Tauopathies 
can be segregated based on multiple pathological factors, including 
histopathological findings, ultrastructure of tau inclusions and the tau isoforms 
mainly affected. The commonest tauopathy is AD, followed by a heterogeneous 
group of tau-positive diseases that have both sporadic and familial causes 
(Rademakers et al., 2012). These include frontotemporal lobar degeneration with 
tau pathology (FTLD-tau; also known as FTD). Common forms of FTD include 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), 
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), Pick's 
disease (PiD) and argyrophilic grain disease (AGD).  
 
 - 14 - 
A major clinical feature of AD is intraneuronal NFT accumulation consisting of 
PHFs and SFs polymerising from both 4R and 3R tau (Wischik et al., 1988). Tau 
filaments in AD are mostly PHFs, with crossover distances of ~80 nm and width 
of 10–20 nm, and SFs 15 nm wide (Wischik et al., 1988). A strong evidence 
supporting a causative role for tau in AD is obtained from amyloid-b processing. 
Amyloid-b is a proteolytic product of the transmembrane protein amyloid 
precursor protein (APP) whose processing occurs by two broad pathways: 
amyloidogenic and non-amyloidogenic, with the former leading to amyloid-b 
production through g-secretase-mediated proteolysis of APP (O’Brien and Wong, 
2011). As a multiprotein complex consisting of, among other proteins, presenilin 
1 (PSEN1) and presenilin 2 (PSEN2), g-secretase activity can influence APP 
proteolysis and hence amyloid-b generation (Bergmans and De Strooper, 2010). 
For example, substituting the aspartyl residues D257 and D385 in PSEN1 to 
Alanine reduces APP cleavage and hence amyloid-b production (De Strooper et 
al., 1998; Wolfe et al., 1999). Since amyloid-b is primarily an extracellular 
protein, its intracellular effects are triggered by activating specific channels and 
receptors (e.g., tyrosine kinase receptors and Ca2+ channels). Extensive 
interactions between candidate protein kinases (phosphatases, serine/threonine 
kinases, and tyrosine kinases) lead to increased tau phosphorylation, which then 
induces NFT formation and subsequent neurodegeneration and neuronal loss 
(Hanger et al., 2009). Based on this pathway, tau toxicity manifests downstream 
of abnormal amyloid-b production. Pathological mutations in APP, PSEN1 and 
PSEN2 would then induce and/or require tau dysfunction to cause disease. For 
example, 87% of a cohort of early-onset AD patients carrying APP or PSEN1, or 
PSEN2 mutations had abnormal cerebrospinal fluid (CSF) levels of total tau, 
phosphorylated tau and amyloid-b (Lanoiselée et al., 2017). Moreover, the V717I 
APP mutation causes increased amounts of amyloid-b by enhancing g-secretase 
cleavage of APP in stem cell-derived neurons, which then leads to increased total 
and phosphorylated tau levels (Muratore et al., 2014). Importantly, total tau 
overproduction was rescued by amyloid-b-specific antibody treatment, suggesting 
a causal link between altered amyloid-b production and tau levels (Muratore et 
al., 2014). Furthermore, altered APP metabolism increases tau production and 
phosphorylation, suggesting APP regulation of tau processing beyond amyloid-b 
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levels (Moore, et al., 2015). This connected pathway of events, referred to as the 
amyloid cascade hypothesis, provides evidence demonstrating that dysfunctional 
tau has a central role in AD pathogenesis, dependent on altered APP metabolism 
and/or amyloid-b levels (Hardy and Allsop, 1991). Another piece of evidence 
supporting this hypothesis is that tau knock-out mice do not develop NFTs, 
suggesting that upstream dysfunctional APP and/or amyloid-b activity is required 
for tau toxicity (Chin et al., 2004, 2005). Indeed, reduction in tau levels is 
neuroprotective due to its obstruction of amyloid-b-induced toxicity (Vossel et 
al., 2015). 
 
NFT accumulation in AD first occurs in the transentorhinal cortex, and tends to 
extend to other brain regions including the neocortex and the hippocampus. This 
gradual development of tau pathology in distinct anatomical brain regions is used 
in staging AD, as first described over two decades ago (Braak and Braak, 1991). 
NFT development in AD often occurs alongside memory and cognitive decline 
(Guillozet et al., 2003; Nelson et al., 2012).  
 
NFT formation in CBD has exclusive phosphorylated 4R tau involvement 
(Ksiezak-Reding et al., 1996). Another feature of CBD is cortical 
neurodegeneration in the superior parietal lobule and the frontal gyrus (Litvan et 
al., 2000). Clinically, CBD may present with apraxia of speech, dystonia and 
asymmetrical limb rigidity (Litvan et al., 2000). CBD diagnosis is not always 
straightforward because patients’ signs and symptoms frequently overlap with 
other diseases such as PSP, usually with no differentiating biomarker. For 
example, cases of symmetrical rigidity and apraxia with dystonia have been 
reported (Boeve et al., 1999; Ling et al., 2010). Due to these challenges, definitive 
diagnosis are usually made only at the post-mortem stage where the NFT 
ultrastructure can be taken into account (Dickson et al., 2011). PSP is another 
tauopathy whose hallmark is selective 4R tau pathology. The disease shares 
several clinical features with CBD and atypical forms of parkinsonism, hence a 
subset of PSP is referred to as PSP-Parkinson’s disease (Williams et al., 2005). 
Brain regions affected in PSP include the substantia nigra, basal ganglia and 
subthalamic region (Hauw et al., 1994) with cortical neurodegeneration 
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sometimes present (Josephs et al., 2008). CBD and PSP both form predominantly 
SFs with few twisted filaments which are often 15-30 nm wide (Ksiezak-Reding 
et al., 1996; Takauchi et al., 1983). However, the crossover periodicity of SFs in 
the two diseases tends to differ, being ∼100 nm and 160 nm for PSP and CBD 
respectively (Ksiezak-Reding et al., 1996; Takauchi et al., 1983). Tau aggregation 
in PiD involves mainly 3R isoforms, and leads primarily to SFs 160 nm in 
periodicity and 15 nm wide (Kato and Nakamura, 1990). As a rare form of frontal 
lobe dementia, PiD mainly affects the cortex and limbic lobe (Barker et al., 2002). 
PiD can be due to sporadic or familial causes, with the latter due to specific tau 
mutations (Hogg et al., 2003; Murrell et al., 1999).  
 
FTDP-17 has several shared clinical features with the other FTDs –  PiD, CBD, 
and PSP – including the affected anatomical regions (cortex, brainstem, and basal 
ganglia), clinical features (dementia, psychosis, and focal cortical syndrome), and 
tau isoforms involved (either 4R only or 4R and 3R jointly) (Dickson et al., 
2011). The majority of familial FTDP-17 are caused by tau mutations (section 
1.4), with the rest often occurring due to mutations in the GRN gene on 
chromosome 17q21 that codes for progranulin (Cruts et al., 2006), and C9orf72 
on chromosome 9p21 (DeJesus-Hernandez et al., 2011; Renton et al., 2011). FTD 
patients with progranulin mutations have TDP-43 pathology, which explains the 
absence of tau-positive inclusions (Cenik et al., 2012; Perry et al., 2013; 
Rademakers et al., 2012). 
1.4 Tau mutations as modulators of familial FTD 
 
Aside from dysfunctions of the wild type (WT) tau, many disease-associated 
mutations in tau have been identified (Coppola et al., 2012; Hogg et al., 2003; 
Murrell et al., 1999; Rosso et al., 2002; Tacik et al., 2015). The Alzforum website 
listed 107 of such mutations as of 8th September, 2017 
(http://www.alzforum.org/mutations/search?genes%5B%5D=492&diseases=&ke
ywords-entry=&keywords=#results). Most mutations are missense mutations 
involving single amino acid changes whilst a few others involve single amino 
acid deletions. While mutations in exons 1, 9, 11, 12 and 13 affect all isoforms, 
mutations in or around exon 10 affect only the 4R isoforms (Andreadis et al., 
1992, 1995). The fact that the majority of the mutations are located in the MT 
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repeat region emphasises the importance of this region not only in tau physiology 
but also pathophysiology. Moreover, because many tau mutations cluster around 
exon 10, they can only be produced through alternative splicing which may alter 
the isoform balance (Fig. 1.7).  
 
Many mutations in MAPT are associated with familial forms of FTD, including 
FTDP-17, CBD, PiD, AGD, and PSP (Goedert and Jakes, 2005) The pathological 
MAPT mutations underlying these tauopathies may confer disease in a number of 
ways: (i) at the mRNA level (through alternative splicing) or (ii) at the protein 
level (by altering MT-binding efficiency or by enhancing/reducing protein 
aggregation). As shown in Table 1.1, familial FTDP-17 exhibits extensive 
heterogeneity in disease characteristics which overlaps with features of other 
FTDs. 
 
Figure 1.7.  Exonic distribution of disease-associated tau mutations. 
Over 100 mutations in the MAPT gene are associated with different brain 
disorders involving dysfunctional tau. Majority of these mutations are single 
point changes or deletions that change the protein’s amino acid composition. 
These alterations can impact physiological functions such as MT stabilisation and 
can lead to disease through reduced MT binding, changes in aggregation 
kinetics, and isoform imbalance. Most mutations cluster around the MT repeat 
region, which spans part of exon 9 through to exon 12. Mutations in exon 10 are 
only evidence in 4R tau isoforms. Figure from Ghetti et al., (2015).  
 
Many mutations found within the MT binding region exert their main effects 
either by reducing MT binding and stabilisation or by altering the aggregation 
rate. For example, P301L and R406W isolated from FTDP-17 brains reduced tau 
 - 18 - 
MT binding whilst V337M and R406W decreased tau’s ability to promote MT 
stabilisation (Hong et al., 1998). Other mutations that reduce MT binding in vitro 
include N279K, G272V and ΔK280 (Barghorn et al., 2000). The ability to alter 
MT binding is not limited to mutations in the MT binding region, as A152T, R5L 
and R5H in the N terminus also cause reduction in MT binding of tau (Coppola et 
al., 2012; Magnani et al., 2007). Since truncation at glutamine 124 in AD brains 
alters tau MT-binding abilities (Derisbourg et al., 2015), the N-terminus 
mutations may have direct functions in tau-MT association  
 
Table 1.1. MT binding effects and clinical phenotypes of some MAPT 
mutations associated with FTDP-17 
Table adapted from Liu and Gong, (2008) 
Exon Mutation  Effect on MT 
binding  
Tau isoforms involved Clinical phenotype  
1 R5H N/A Mostly 4R PSP 
1 R5L N/A 1N3, 4R AD 
9 K257T Reduced  3R>4R PiD 
9 I260V N/A Mostly 4R N/A 
9 L266V N/A 3R PiD 
9 G272V N/A 3R PiD 
10 N279K Variable* 4R PSP 
10 DK280 Reduced   3R>4R FTDP-17 
10 L284L No change  4R maybe AD 
10 N296N No change  Mostly 4R CBD 
10 N296H N/A Mostly 4R FTDP-17 
10 DN296 Reduced N/A PSP 
10 P301L Increased  4R FTDP-17 
10 P301S N/A Mostly 4R FTDP-17 and CBD 
10 G303V N/A Mostly 4R PSP 
10 S305N No change Mostly 4R CBD 
10 S305S N/A Mostly 4R PSP 
11 L315L No change N/A N/A 
11 S320F Reduced  N/A PiD 
11 S320Y N/A N/A PiD 
12 Q336R Increased N/A PiD 
12 V337M Reduced 3R, 4R FTDP-17 
12 E342V N/A Mostly 4R FTDP-17, PiD 
12 S352V N/A 3R, 4R PiD 
13 G389R Reduced 4R>3R PiD 
13 R406W N/A 3R, 4R PSP 
N/A = not available  
Inhibit exon 10 inclusion  
Enable exon 10 inclusion  
*variable MT binding effects reported from different studies 
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Other MAPT mutations have additional suggested mechanisms. Mutations located 
in exon 10 have additional effects in the form of increased 4R isoform production 
which can influence the overall isoform distribution and lead to dysfunction 
through the overproduction of tau. As shown by Hong et al., (1998), insoluble 
human brain-derived tau aggregates from patients with N279K or P301L have 
exclusive involvement of 4R tau contrary to those from V337M and R406W 
brains that separated with both 3R and 4R tau in SDS-PAGE assays. How exon 
10 mutations such as N279K increase 4R production and selectively induce 4R 
tau aggregation is unclear as this appears independent of MT binding effects. This 
could occur by promoting exon 10 splicing at the mRNA level, possibly by 
altering a splicing enhancer element that regulates exon 10 synthesis (Dawson et 
al., 2007; Hong et al., 1998). Although P301L is located in exon 10, it has 
opposite effects on MTs compared to N279K, indicating the two may be acting 
independently. Contrary to N279K, mutations such as G272V ΔK280, and L266V 
all inhibit exon 10 inclusion, thus reducing 4R tau production (Liu and Gong, 
2008).  
 
The aggregation of tau containing specific mutations, irrespective of the isoforms 
involved, can also lead to neurodegeneration via differential aggregation kinetics. 
P301L and DK280 increase thioflavine S-based tau aggregation, independent of 
the presence of the N terminus region (Barghorn et al., 2000). However, V337M, 
R406W, N279K, G272V, P301L and DK280 increase htau40 aggregation whilst 
V337M and G272V reduce K18 aggregation, suggesting that effects on 
aggregation kinetics are mutation-specific (Barghorn et al., 2000). A152T reduces 
tau aggregation, promoting oligomer but not PHF formation (Coppola et al., 
2012). Using arachidonic acid as an inducer, htau40 aggregation was reduced by 
K369I and L315R but was increased in the presence of G272V, P301L, V337M 
and S320F (Combs and Gamblin, 2012). Importantly, tau mutations do not 
change the natively unfolded structure of monomers, and the b-sheet ordered 
conformation associated with aggregation (Barghorn et al., 2000). This suggests 
that the mutations do change the rate but perhaps not the overall mechanism of 
aggregation.  
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1.5 Theories of tau pathology: aggregation and conformational 
change 
 
As discussed (section 1.2.2), a well-known route to tau dysfunction is 
hyperphosphorylation, which disrupts the protein’s MT stabilisation function. 
This therefore suggests that gain-of-function effects of tau that occur downstream 
of MT destabilisation, such as aggregation, will be dependent on the protein’s 
phosphorylation status. Motivated by this hypothesis, the tau research field has 
conducted intensive research aimed at identifying critical tau phosphorylation 
sites and kinases that may regulate aggregation (Šimić et al., 2016). It has 
however been found that tau aggregation can occur independently of 
phosphorylation, indicating that hyperphosphorylation may not be the sole route 
to disease-related aggregation (Tepper et al., 2014). Although there are 
disagreements as to which stage of tau aggregation (e.g., oligomers and PHFs; 
section 1.7) best correlates with disease, it is generally accepted that tau 
aggregation can lead to disease (Goedert, 2016; Goedert and Spillantini, 2017). If 
WT tau aggregation can cause disease, how then do FTD mutations affect this 
mechanism and therefore clinical outcomes? As specific mutations can alter tau’s 
MT-stabilisation and aggregation functions (Table 1.1; section 1.2), it can be 
hypothesised that they do so by modifying tau’s mechanism of disease. This 
could occur through multiple means, including: (i) by inducing conformational 
changes that make the mutated protein a more preferred substrate for aggregation 
(Jicha et al., 1999); (ii) by influencing the aggregation rate, as illustrated by 
significant lag time changes in kinetic aggregation assays (Combs and Gamblin, 
2012); and (iii) by reducing the protein’s affinity for MTs (which may also occur 
due to conformational change)  (Table 1.1). 
 
The effects of FTD mutations can therefore be broadly grouped into two: 
aggregation and conformational change, although the two are interconnected 
because reduced binding of mutant tau to MTs increases the amount of free, 
cytoplasmic tau capable of forming aggregates (Hong et al., 1998; Vogelsberg-
Ragaglia et al., 2000). Aggregation changes are likely to occur in the nucleation-
elongation mechanism (Fig. 1.5), where specific mutations would influence the 
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rate of nucleation and/or elongation, as shown previously (Barghorn et al., 2000; 
Combs and Gamblin, 2012) . However, these induced effects are likely to act 
downstream of the initial conformational change that tends to enable or enhance 
aggregation competence. For example, a “correct turn” conformational change in 
the third repeat region is essential to induce aggregation even in the presence of 
the 306VQIVYK311 hexapeptide motif, as tracked by time-dependent NMR assays 
(Jiji et al., 2016). Such a conformational change which influences initiation of 
aggregation should perhaps occur before the nucleation stage (Fig. 1.5). Another 
form of conformational change could occur at the elongation stage of tau 
aggregation. In early stage AD (Braak stages I and II) brains: the monoclonal 
antibody MC1 recognises soluble forms of aggregated tau that appear before PHF 
and NFT formation in vulnerable brain areas, indicating that the MC1 epitope is 
an early pathological signal (Weaver et al., 2000). The conformational 
significance of the MC1 epitope may be the reason why the S320F FTD mutation 
causes reduced MT binding (Rosso et al., 2002).  
 
1.5.1 Biochemical and biophysical tools for studying tau aggregation 
and conformation 
 
Much of the insights into tau conformation and aggregation have been obtained 
from in vitro experiments on recombinant or brain-derived proteins using 
biochemical and biophysical tools. Those used in this thesis are introduced here. 
 
Kinetic assays – using fluorescent dyes 
 
Tau aggregation is rate-dependent: there are different reaction phases that can be 
monitored kinetically. As tau on its own does not give measurable chemical 
signals during aggregation (Sahara et al., 2007; Sui et al., 2015), fluorescence 
changes in the presence of specific chemicals that bind tau are used to estimate 
the protein’s aggregation. Probably the most widely used is the benzothiazole salt 
thioflavin T (ThT) or its alternative thioflavine S (ThS), which is a mixture of 
several sulphonated compounds. When bound to tau monomers, ThT-tau and 
ThS-tau interactions lead to spectroscopic changes that alter the reported 
fluorescence signal. Following a brief lag phase, an exponential increase in 
fluorescence is recorded which is believed to indicate cumulative aggregation 
until filament formation when the curve reaches a plateau (Biancalana and Koide, 
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2010). Nonetheless, this property is dependent on the forms of tau used, buffer 
conditions, spectrophotometer and the tau-ThT/S ratio (Xue et al., 2017). The 
principle of ThT/S binding to tau filaments has been applied in clinical 
histopathology to diagnose tauopathies (Bussière et al., 2004; Rajamohamedsait 
and Sigurdsson, 2012). The mechanism of ThT/S binding to tau is not fully 
understood: one model suggests that ThT binds to amino acid side surface chains 
that are arranged in parallel to the b-sheet axis of tau filaments (Biancalana and 
Koide, 2010). Binding to proteinopathic aggregates can drastically increase the 
fluorescence intensities of both ThT and ThS, but the main difference is that a 
corresponding forward shift in emission spectrum is observed for ThT but not 
ThS for which no change in the excitation or the emission spectra is recorded 
(Groenning, 2010; LeVine, 1999). This results in a consistently high background 
fluorescence in the case of ThS, making it unsuitable for quantitative analysis 
(LeVine, 1999).  
 
Secondary structure determination: circular dichroism (CD)  
 
 
CD spectroscopy is routinely used to ascertain the structural transition of tau from 
its random coiled conformation to b-sheet formation. A CD spectrum is obtained 
due to a sample’s differential absorption of left and right circularly polarised light. 
The extent to which a test molecule absorbs the two light waves which are 
arranged 90 O out of phase leads to the generation of an electrical field signal. The 
resultant differences in the electric field generated by the clockwise- and anti-
clockwise-facing lights is calculated to give the CD readout at each wavelength. 
Signature CD spectra measured in the far UV range differ for given proteins 
depending on their predominant secondary structure content (Fig. 1.8). Unfolded 
proteins, such as monomeric tau, have negative peaks at 198 – 200 nm, b-sheet-
enriched proteins like PHFs have negative peaks at ~220 nm, whilst soluble 
aggregated tau (e.g., oligomers) have an intermediate negative peak between 200 
and 220 nm. Other proteins with majority a-helix content have two negative 
peaks at ~210 nm and ~220 nm (Whitmore and Wallace, 2008). CD-resolved 
secondary structure content can be analysed by comparing spectral signals to 
those in given databases (Greenfield, 2006; Kelly et al., 2005).  
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Ultrastructure of aggregated species: atomic force microscopy (AFM) and 
transmission electron microscopy (TEM) 
 
AFM and TEM are similar techniques used to probe the ultrastructural properties 
of aggregated tau. AFM involves three-dimensional scanning of a sample surface 
with a cantilever-suspended flexible probe. Deflection of the cantilever occurs in 
response to probe-sample surface contacts on a piezoelectric scanner, leading to 
parallel images formed along the probe tracks. These images are then projected by 
laser signals onto photodiode detectors and processed with specific algorithms. 
There are three main AFM modes, depending on probe-sample interactions: 
contact, non-contact and tapping. Tapping mode imaging is often preferred as it 
eliminates the disadvantages of the other methods regarding poor resolution and 
frictional forces that can damage sample surfaces (Carvalho and Santos, 2012; 
Dufrêne, 2002).  
 
In TEM, an electron beam passes through the sample and the micrometer-scale 
image formed based on electron-sample interactions is magnified to enhance 
resolution. As complementary techniques, TEM and AFM compensate for their 
shortcomings. For example, heavy metal staining in TEM can disrupt some 
nanoscale details. This challenge can be addressed by using AFM which does not 
use sample staining and therefore retains samples in their native state. Moreover, 
small aggregated proteins (e.g. oligomers made of <10-20 monomers) whose 
imaging can be problematic with TEM can be easily done with AFM. 
Nonetheless, AFM imaging is extremely slow and gives poor image resolutions. 
On the contrary, TEM images have better resolution and are achievable within 
shorter times (Tinker-Mill et al., 2014).  
 
Dynamic light scattering (DLS) 
 
DLS can be used to measure the sizes of monomeric and aggregated proteins in 
solution and to deduce the approximate number of monomer units that make up a 
given state of aggregation. The principle of DLS is based on measuring Brownian 
motion of proteins (or other macromolecules) when hit by solvent molecules. The 
detected motion is dependent on molecule size: the larger the molecule, the 
slower the motion and vice versa. DLS can therefore be used to efficiently deduce 
the sizes of a mixture of molecules (e.g. a heterogeneous mixture of aggregated 
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tau proteins), using the hydrodynamic radius which relates to the intensity of 
molecule fluctuations (Stetefeld et al., 2016).   
 
 
BA
 
Figure 1.8. Example data from some commonly used biochemical and 
biophysical assays for evaluating tau aggregation and conformation. 
(A) example standard curve from ThT or ThS kinetic assays (Abedini et al., 2016). 
(B) Standard CD spectra for proteins which have predominantly a-helices 
(black), b sheets (red), and unfolded/random coiled (green) conformations. 
Figure taken from http://www.ap-lab.com/circular_dichroism.htm, accessed on 
10th September, 2017. 
 
1.6 Proteinopathies and the prion hypothesis  
 
Proteinopathies is a catch-all term for neurodegenerative diseases characterised by 
specific post translational modifications, involving the disease-related aggregation 
and neuronal accumulation of otherwise unstructured proteins, leading to 
neurodegeneration and eventual neuron loss. The term proteinopathies looks at 
the similarities between the molecular pathogenesis of neurodegenerative diseases 
such as AD, Parkinson’s disease (PD) and Huntington’s disease: the respective 
proteins underlying these diseases are tau/amyloid-b, a-synuclein, huntingtin and 
mutated forms of tau (in familial cases). Several other diseases have also been 
classified as proteinopathies (Golde et al., 2013).  
 
A unifying characteristic of proteinopathies that continues to attract major 
research attention is the prion hypothesis: the mechanism by which aggregated 
and misfolded forms of causative proteins can be transmitted between 
synaptically-connected neurons. Through this strategy, abnormal forms of each 
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protein are gradually distributed throughout the brain, leading to synaptic 
dysfunction and neuron death (Frost and Diamond, 2010; Golde et al., 2013).  
 
1.6.1 Neuronal internalisation and transmission of tau pathology: the 
transneuronal propagation and the selective vulnerability 
hypotheses 
 
Although mounting evidence suggests that tau dysfunction causes 
neurodegeneration, the mechanistic basis for this association is not fully 
understood. Two main mechanisms have been proposed, referred to as the trans-
neuronal propagation and the selective vulnerability spread hypotheses.  
 
Transneuronal propagation  
Against the backdrop that tau pathology in AD is predicted to occur in a defined, 
stereotypical mechanism (Braak and Braak, 1991), many scientists became 
interested in understanding how this may occur in experimental models. The 
hypothesis that misfolded tau may propagate in a transcellular manner, similar to 
the prion protein, was formulated and prompted a series of investigations into the 
cellular internalisation, secretion and propagation of dysfunctional tau. In line 
with this, many studies have reported that exogenously added tau protein can be 
internalised by both neuronal and non-neuronal cells (Clavaguera et al., 2009; de 
Calignon et al., 2012; Lasagna-Reeves et al., 2012a). Whilst in the cell, the 
internalised protein interacts with endogenous tau and propagate intracellular 
toxicity (Lasagna-Reeves et al., 2012; Michel et al., 2014; Usenovic et al., 2015). 
The mechanism of aggregation can therefore be referred to as template misfolding 
since the internalised protein, acting as a “seed” or “template,” induces the 
aggregation or misfolding of endogenous tau (Stancu et al., 2015). Some of the 
internalised tau (perhaps in complex with some endogenous tau) is re-secreted 
into the extracellular environment from where propagation continues to 
neighbouring cells. Remarkably, all the pre-NFT (monomers, oligomers, 
filaments) tau species have been found to be internalised when supplied 
exogenously to cells and can be secreted to initiate the transmission process (Guo 
and Lee, 2011; Jackson et al., 2016; Lasagna-Reeves et al., 2012a; Michel et al., 
2014; Usenovic et al., 2015). Moreover, these observations have been consistently 
made by modelling tauopathies in a range of model systems, including 
physiologically active whole organisms (Clavaguera et al., 2009; 
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Papanikolopoulou and Skoulakis, 2011), neuronal and neuron-like tissues (Michel 
et al., 2014; Usenovic et al., 2015; Wauters et al., 2016), ex vivo brain tissues  (Fá 
et al., 2016) and post-mortem brains (Lasagna-Reeves et al., 2012a). The minimal 
tau peptide sequence required for this propagation behavioural is thought to be a 
31-residue peptide that includes the hexapeptide motif in R3 (Stöhr et al., 2017). 
Neuronal accumulation and propagation of dysfunctional tau causes toxicity by 
impairing neurotransmission through neurite retraction and soma loss (Stancu et 
al., 2015; Usenovic et al., 2015), damaging electrical communication (Fá et al., 
2016; Lasagna-Reeves et al., 2012a), and triggering memory and cognitive 
changes (Fá et al., 2016; Stancu et al., 2015).  
 
Tau propagation is achieved through release and uptake between neighbouring 
neurons, for which several pathways have been reported (Fig. 1.9). In tau 
secretion via exocytosis for example, cytosolic tau is encapsulated in endosomal 
vesicles which undergo endocytic processing and later fuse with the plasma 
membrane to release tau in exosomes (Wang et al., 2017; Saman, et al., 2012) or 
ectosomes (Dujardin, et al., 2014) to the extracellular space. The secretion of tau 
in exosomes has been reported in cellular tauopathy models and in CSF of AD 
patients (Saman, et al., 2012). In the M1C human neuroblastoma cell line, 
exosome secreted 0N4R tau is phosphorylated at specific sites (Saman, et al., 
2012). Differential release of tau isoforms (0N4R>1N4R/1N3R) has also been 
reported in the same cell line (Kim et al., 2010). In human AD CSF, exosome-
associated tau is aggregated and phosphorylated at threonine 181, which is a 
diagnostic marker of AD (Saman, et al., 2012). Other mechanisms of tau secretion 
include tunneling nanotubular release between connected neurons (Tardivel et al., 
2016; Abounit et al., 2016), and the extracellular release of tau in the membrane-
free form (Chai et al., 2012). Tau in the extracellular space can be taken up by 
receiving neurons through several routes, with endocytosis being the commonest. 
Endocytosis has been reported for various forms of tau (monomers, oligomers, 
and fibrils), using cell lines overexpressing specific forms of tau or physiological 
levels of tau. (Frost et al., 2009; Guo and Lee, 2011; Michel et al., 2013; Wu et 
al., 2013). Furthermore, tau in exosomes can be directly transferred between 
neurons (Wang et al., 2017). Another mechanism is heparan sulphate-mediated 
macropinocytosis (Holmes et al., 2013). 
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Selective vulnerability model 
 
A critique of the transneuronal propagation model argues that the physical 
internalisation, release and subsequent propagation proposed may be unrealistic 
because: (i) the model is incapable of explaining cell autonomy in degeneration 
and death; (ii) the Braak staging (Braak and Braak, 1991) used as a premise does 
not support the proposed transmission hypothesis; and (iii) the model does not 
address the patient heterogeneity and the brain regional vulnerability observed in 
proteinopathic protein accumulation. On this basis, an alternative model, referred 
to as the “selective vulnerability” hypothesis has been proposed. This model 
suggests that neuronal vulnerability to toxic insults (e.g., from misfolded tau) is 
selectively dependent on its viability: neurons stressed from the extracellular 
build-up of tau (or due to any other reason) would be easier targets compared to 
healthy ones. Healthy cells may become susceptible over time as the disease 
progresses and/or the levels of the stressor increase (Walsh and Selkoe, 2016). 
There are various mechanisms of transmission reported for the trans-neuronal 
propagation (Fig. 1.9), whilst Fig. 1.10 describes the counter selective 
vulnerability model.  
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Figure 1.9. Mechanisms of misfolded tau transmission in the transneuronal 
propagation model for extracellular tau. 
Misfolded or abnormal tau seeds (could be aggregated or not) accumulate in the 
neuron (1). Some of these are secreted through various routes, such as 
encapsulation and subsequent release by ectocytosis (2) or exocytosis (3). 
Nanotubular transfer between connected neuron is another possibility (4). Uptake 
of secreted tau can occur by naked-form passage through the plasma membrane 
of the receiving neuron (6), endocytosis (7), or macropinocytosis (5).  
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Figure 1.10. The selective vulnerability model of tau toxicity. 
(A) The transneuronal spread model proposes physical transfer of misfolded tau 
between synaptically connected neurons, and thus brain regions, without 
accounting for cell autonomy. (B) The selective vulnerability model suggests that 
neurons of compromised viability will be first affected by possible insult from 
misfolded tau. Vulnerability can be transferred trans-synaptically through 
diffusible metabolic factors, instead of protein internalisation and release (Walsh 
and Selkoe, 2016). 
 
 
1.7 Drug development against misfolded tau protein  
 
The ultimate goal of research into tau-mediated neurodegeneration is to provide a 
knowledge base that enables effective therapy development. As tau dysfunction is 
triggered by phosphorylation, a primary target may be to block abnormal 
phosphorylation with anti-phosphorylation agents that target specific kinases or 
other proteins whose activities promote tau aggregation (option A; Fig. 1.11). 
This strategy appears promising because several candidate drugs have shown 
meaningful anti-phosphorylation activities. For example, the small molecule 
STI571 has been shown to block the activity of c-Abl tyrosine kinase, which 
promotes amyloid b-induced tau phosphorylation at tyrosine 15 (Cancino et al., 
2008, 2011). Moreover, the candidate drug harmine inhibits the activity of dual-
specificity tyrosine phosphorylation-regulating kinase 1A (DYRK1A), which 
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phosphorylates tau serine 202 leading to a pathology-associated conformational 
change (Martin et al., 2013; Seifert et al., 2008). Nonetheless, DYRK1A also 
phosphorylates the cAMP Response Element Binding (CREB) transcription 
factor, which regulates learning and memory (Yang et al., 2001). Hence, CREB 
inhibition is likely to lead to non-specific effects. Glycogen synthase kinase 3 
(GSK3) is a tau protein kinase which has a central role in amyloid b-induced tau 
pathology: exposure to amyloid b increases GSK3 activity, tau phosphorylation, 
memory defects, apoptotic cell death and increased amyloid b expression (Hoshi 
et al., 1996; Takashima et al., 1996). GSK3 phosphorylates tau at multiple sites in 
human AD brains (Hanger et al., 2009; Martin et al., 2013), and its 
overexpression in NFT-forming transgenic mice causes hyperphosphorylation and 
neurodegeneration (Lucas et al., 2001). Lithium treatment rescues both GSK3-
induced hyperphosphorylation and downstream neurodegeneration effects in 
transgenic mice (Klein and Melton, 1996). Other GSK3 inhibitors include specific 
compounds from the anilinomaleimide (Smith et al., 2001), paullone (Leost et al., 
2000), indirubin (Leclerc et al., 2001), and thiadiazolidinone (Martinez et al., 
2002) families. Some of these compounds are non-specific for GSK3 because 
they also inhibit tau kinases from the cyclin-dependent kinase family, including 
CDK2 and CDK5 (Bhat et al., 2004; Leclerc et al., 2001). Since CDK5 inhibition 
activates GSK3, such compounds may not be ideal drug candidates (Hanger et al., 
2009). Whilst tau kinase inhibition may be a promising target, there is a need to 
be cautious in this approach because not all forms of phosphorylation may be 
harmful (Ittner et al., 2016).  
 
A second approach is to prevent the conformational change that makes MT-
detached tau aggregation competent, either by blocking monomer production or 
by immediately degrading monomers on production (option B, Fig. 1.11). Instead, 
preventing oligomer formation, perhaps by targeting cysteine residues and the 
hexapeptide motifs, as well as other forms of post translational modification that 
prevent oligomer formation, as shown for tau and other proteinopathic proteins 
(Hamano et al., 2016; Hayden et al., 2015; Soeda et al., 2015; Wen et al., 2017; 
Yoshitake et al., 2016, Fig. 1.11 Option C) could be an effective approach. 
Alternatively, agents that neutralise or clear formed oligomers, or those that 
prevent the accumulation of protomers may prove useful (options D and E 
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respectively). Formed filamentous aggregates can be otherwise targeted by 
degradation (option F), as explored for amyloid b (Yan et al., 2006). Should PHF 
degradation not prove successful, an alternative strategy will be to inhibit NFT 
accumulation with small molecules or immunotherapeutic agents (option H). 
Importantly, all the approaches proposed here should be feasible in both intra- and 
extra-cellular contexts.  
 
While there are clearly several intervention points being investigated, the 
targeting of the cellular entry and exit of tau, which appears to be the central hub 
of many neurotoxic properties, may be productive in diseases involving tau and 
indeed other proteins (Fig. 1.10).  
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Figure 1.11. Dysfunctional tau-targeted drug development targets and 
approaches. 
Description of each numbered approach has been provided in the text in section 
1.7.  
 
1.8 Aims of this thesis  
 
The evidence for the transneuronal propagation of misfolded tau seems 
compelling. It is however unclear if the described mechanisms are translatable to 
mutant tau associated with FTD. While FTD mutations can cause drastic changes 
in tau aggregation and MT binding, these forms of tau could function through 
other unknown mechanisms. The aims of this thesis are therefore: 
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i. To develop genetic resources and a simple method of expressing and 
purifying tau protein and a selection of its FTD variants;  
ii. To develop a new method of preparing low molecular weight (LMW) tau 
K18 oligomers of enhanced stability for use in biochemical and cell 
biology assays; 
iii.  To study the in vitro conformation and aggregation of tau K18 WT, 
V337M and N279K; and  
iv.  To investigate the cell biological effects of extracellular WT K18 tau 
oligomers and its FTD variants.   
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2| Materials and methods  
2.1 Materials  
BugBuster® 10X protein extraction reagent (70921-4), dimethyl sulfoxide 
(DMSO; K45797112 429) and DNAse I (69182) were purchased from Merck 
Millipore, Watford, Hertfordshire, United Kingdom (UK). 
Acrylamide/bisacrylamide (30 % solution; A3574-100ML), beta mercaptoethanol 
(M6250), bovine serum albumin (BSA; A7906-50G), bromophenol blue (B-
8026), imidazole (12399-500G), retinoic acid (R2625-50MG), SH-SY5Y 
neuroblastoma cells (94030304), sodium chloride (S/3160/60), sodium phosphate 
dibasic (S9763-500G), sodium phosphate monobasic dihydrate (04269-1KG), 
N,N,N’,N’-tetramethylethylenediamine (TEMED; T-7024), thioflavine S 
(T1892), thioflavin T (T3516-5G), Triton X-100 (X100-500ML) and TWEEN 
(P9416–100ML) were procured from Sigma Aldrich (St. Louis, Missouri, USA). 
X1 Amersham Protran 0.45 µm electrochemiluminescence nitrocellulose 
membrane (15259794), Amersham ECL Western blotting analysis system 
(RPN2108) and chelating sepharose fast flow (17-0575-01) were obtained from 
GE Healthcare, Buckinghamshire, UK. Ammonium acetate (CHE1140), 
ammonium persulfate (A/6160/53), glycine (G/0800/60), D-glucose (G/0500/53), 
ethylenediaminetetraacetic acid (EDTA; D/0700/53) and glycerol (G/0650/17) 
were bought from Fisher Scientific, Loughborough, UK. Ethylene glycol-bis(β-
aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA; 437012C), ethanol 
(20821.330) and methanol (20847.307) were purchased from VWR, Lutterworth, 
Leicestershire, UK. Piperazine-N,N′-bis(2-ethanesulfonic acid)(PIPES; A16090) 
was obtained from Alfa Aesar, Heysham, UK.  Cell culture-grade DMSO (P60-
36720100) was obtained from PAN-Biotech GmbH, Aidenbach, Germany. N-
ethyl maleimide (23030) and CL-XPosure Film (34089) were obtained from 
Thermo Scientific, Rockford, Illinois, USA. CellMask® Deep Red plasma 
membrane stain (C10046), Hoechst 33342 (H21492) and Alexa Fluor® 488 C5-
maleimide (A10254) were procured from Molecular Probes, Eugene, Oregon, 
USA. The Q5® site directed mutagenesis (SDM) kit (E0554S) was purchased 
from New England Biolabs, Ipswich, Massachusetts, USA. Lactate 
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dehydrogenase (LDH) cytotoxicity assay kit (88954) was obtained from Pierce 
Biotechnology, Rockford, Illinois, USA). The cOmplete protease inhibitor 
cocktail tablets (11836145001) and DNAse I (11284932001) were obtained from 
Roche Diagnostics GmbH (Mannheim, Germany). Isopropyl β-D-1 
thiogalactopyranoside (IPTG; MB1008) was purchased from Melford 
Laboratories Limited (Ipswich, Suffolk, UK). Tris(2-carboxyethyl)phosphine 
(TCEP; A2233,0001) was procured from Applichem GmbH, Damstadt, Germany. 
SynaptoRedTM C2 (FM4-64; 70021) was obtained from Biotium (Hayward, 
California, USA). The QIAprep Spin Miniprep kit (27104) was obtained from 
QIAGEN GmbH, Hilden, Germany. Marvel dried skimmed milk was obtained 
from Premier Foods Company, UK.  
 
2.2 Cloning of tau proteins into pProEx plasmids 
Three plasmids were used for recombinant expression of the WT K18 and htau40 
tau proteins and four FTDP-17 variants of theirs (Fig. 2.1). For the K18 and 
htau40-FLAG plasmids, the protein sequences were preceded by the Tobacco 
Etch Virus (TEV) protease-recognition sequence ENLYFQG fused at the N-
terminus to a hexa-histidine tag and a c-Myc tag. In the case of c-Myc-htau40, the 
c-Myc tag was placed downstream of the protein sequence. The coding sequences 
of the WT tau proteins were generated by polymerase chain reaction (PCR) using 
pCMV-FLAG-tau as template (a gift from Dr. Calum Sutherland, University of 
Dundee, UK) and cloned between the EheI and EcoRI sites of the pProEx-HTa 
plasmid (Invitrogen) containing ampicillin-resistance and lacI-encoding genes 
(courtesy of Dr. David Nagel, Aston University). Protein expression was 
controlled by a trc promoter, and initiated with the addition of IPTG. Plasmid 
sequences were confirmed by deoxyribonucleic acid (DNA) sequencing 
performed externally at GATC Biotech AG, Konstanz, Germany. Primers were 
synthesised using the standard desalting method and later diluted in 50 µl of 10 
mM Tris HCl, pH 8.5 to give 500 mM stock solutions from which working 
solutions of 10 µM were prepared. Working solutions were diluted 1:10 with 
double distilled water (ddH2O) in 10 µl sequencing reaction mixtures, in the 
presence of 80 ng/µl template DNA.  
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Figure 2.1. Bacterial expression plasmids used in this study. 
 (A-C) The pProEx-HTa-Myc-K18, pProEx-HTa-Flag-htau40 and pProEx-HTa-
htau40-Myc plasmids for expressing the K18 and htau40 proteins. (D) Essential 
elements common to all the plasmids are shown, including a trc promoter, a 
hexa-histidine tag, a TEV cleavage site and a c-Myc or Flag tag followed by the 
tau coding sequence (note that for the plasmid in (C), the tau gene precedes the c-
Myc tag).  
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2.3 SDM 
The Q5® SDM kit was utilised to create the N279K, V337M, P301L and C291R 
mutations in the WT tau constructs, according to the manufacturer’s instructions, 
using primers listed in Table 2.1 (designed using the NEBaseChangerTM 
programme http://nebasechanger.neb.com, version 1.2.3).  
 
Table 2.1. Primers used in SDM to generate FTD variants of tau.  
Codon changes are underlined.   
Primer  Sequence (5’ to 3’) 
N279K _Forward GCAGATAATTAAAAAGAAGCTGGATCTT  
N279K_Reverse ACCTTCCCGCCTCCCGGC  
V337M_Forward AGGTGGCCAGATGGAAGTAAAATC  
V337M_Reverse CCTGGTTTATGATGGATGTTG  
P301L_Forward CAAACACGTCCTGGGAGGCGGCA 
P301L_Reverse ATATTATCCTTTGAGCCACACTTGGACTGG 
C291R_Forward CCAGTCCAAGCGTGGCTCAAAGG 
 
C291R_Reverse ACGTTGCTAAGATCCAGC 
 
DNA samples (20 ng/µl) were exponentially amplified in the presence of 1X Q5 
Hot Start 2X High Fidelity Mastermix and 0.5 µM each of the forward and 
reverse primers as indicated in Table 2.2. PCR was performed in an Eppendorf 
Mastercycler Gradient thermal cycler according to the following protocol: 
i. Initial denaturation: 98 oC, 30 s 
ii. Denaturation: 98 oC, 10 s 
iii. Primer annealing: Ta* oC, 30 s 
iv. Elongation: 72 oC, 2.5 min for K18 and 3 min for htau40 
v. Final extension: 72 oC, 2 min 
vi. Repeat steps ii – v for 24 times  
vii. Hold at 4 oC 
*Primer annealing temperatures varied for the different primer pairs: 72 oC for 
N279K, 62 oC for V337M, 72 oC for P301L and 63 oC for C291R. 
 
Subsequently, 1 µl of the PCR product was treated with 1X final concentration 
each of the Kinase, Ligase and DpnI reaction buffer and enzyme mix and kept at 
room temperature (RT) for 5 min. Following the mutagenesis, 5 µl plasmid DNA 
was transformed into 50 µl competent NEB-5α Escherichia coli cells (a DH5α 
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derivative; genotype = fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17), incubated on ice for 30 min, heat 
shocked at 42 oC for 30 s, incubated on ice for a further 5 min, and 950 µl super 
optimal broth with catabolite repressor added and shaken at 37 oC for 1 h before 
overnight growth in Luria-Bertani (LB) broth containing 100 µg/ml ampicillin in 
a shaking incubator with agitation (180 rpm) at 37 0C. Plasmid DNA was isolated 
using the QIAprep Spin Miniprep kit according to the manufacturer’s 
instructions.  
 
Table 2.2. Details of PCR settings used in SDM to create FTD tau variants. 
Constituent  25 µl mix 
Volume (µl) Final concentration 
2X Q5 Hot Start 2X High 
Fidelity Mastermix 
12.5 1X 
10 µM forward primer 1.25 0.5 µM 
10 µM reverse primer 1.25 0.5 µM 
Template DNA 20 ng/µl 1 20 ng 
Nuclease-free water 9 - 
 
Next, the SDM process described above was utilised to modify the native cysteine 
residues in the tau protein constructs to alanine (C291A and C322A) and 
introduce a new cysteine at amino acid position 260 (I260C). Primers used in this 
process are provided in Table 2.3, and the annealing temperatures were: 60 oC for 
C291A, 61 oC for C322A and 58 oC for I260C.  
 
The presence of the desired mutations was confirmed by DNA sequencing as 
described previously, using the primers listed in Table 2.4, following which 
plasmid DNA was transformed into BL21(DE3)*pRosetta E. coli cells, plated 
overnight on selective LB agar plates. Single colonies were then grown overnight 
in selective LB agar, and aliquots stored at -80 oC in 40 % glycerol until use. 
Primers were designed with Clone Manager Professional (Scientific and 
Educational Software, Denver, Colorado, USA) and synthesised by Integrated 
DNA Technologies (Leuven, Belgium). 
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Table 2.3 Primers used in SDM to introduce cysteine modifications in the 
WT tau constructs. 
Codon changes are underlined. 
Primer Sequence (5’ to 3’) 
C291A_Forward CCAGTCCAAGGCTGGCTCAAAGGATAATATC 
C291A_Reverse ACGTTGCTAAGATCCAGC 
C322A_Forward GACCTCCAAGGCTGGCTCATTAGGCAAC 
C322A_Reverse ACCTTGCTCAGGTCAACTG 
I260C_Forward CAAGTCCAAGTGTGGCTCCACTGAGAACC 
I260C_Reverse ACATTCTTCAGGTCTGGC 
 
  Table 2.4. DNA sequencing primers designed and used in this study. 
Tau construct Primer  Sequence (5’ to 3’) 
K18 Sequencing primer 1 ACAGACCATGTCGTACTACC  
Sequencing primer 2 AGGCGGCAGTGTGCAAATAG  
Flag-htau40 Sequencing primer 1 GTGGCTCATTAGGCAACATC 
 Sequencing primer 2 CAACGCCACCAGGATTCCAG 
 Sequencing primer 3 CACGGCATCTCAGCAATGTC 
htau40-myc Sequencing primer 1 CAACGCCACCAGGATTCCAG 
 Sequencing primer 2 TGGCTCATTAGGCAACATCC 
 Sequencing primer 3 CACGGCATCTCAGCAATGTC 
 
2.4 Transformation of E. coli BL21*(DE3) cells with tau-encoding 
plasmids 
Five nanograms of plasmid DNA was added to 50 µl competent 
BL21(DE3)*pRosetta cells and incubated on ice for 30 min. Cells were heat-
shocked at 42 oC for 30 s in a Clifton unstirred water bath, followed by 2 min 
incubation on ice. 950 µl LB broth was added and the mixture incubated at 37 oC 
for 1 h. Forty microlitres of the mixture was plated on LB agar supplemented with 
ampicillin (100 µg/ml) and chloramphenicol (35 µg/ml) and incubated overnight 
at 37 oC.  
 
Genotype of BL21(DE3) = fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ∆nin5 
 
2.5 Expression of tau proteins 
Single colonies of BL21(DE3)*pRosetta cells expressing specific tau proteins 
were inoculated into 10 ml selective LB broth and grown overnight at 37 oC. The 
following morning, 1 ml of the overnight culture was inoculated into 50 ml 
selective LB broth and grown at 37 oC with 180 rpm agitation. Cultures were 
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grown until reaching OD600 = 0.6 – 0.7, induced with 0.5 mM IPTG and grown 
for a further 3 h. Aliquots (1.5 ml) were centrifuged at ~ 11,000 xg for 1 min, the 
pellet re-suspended in 100 µl phosphate buffered saline (PBS) and sonicated for 5 
s at 10 % power and re-centrifuged at ~11,000 xg for 5 min. All sonication was 
done in a Bandelin Sonopuls 2070 sonicator. The soluble (supernatant) fraction 
was pipetted into an Eppendorf tube for gel electrophoresis. The pellet was re-
suspended in 500 µl PBS, sonicated (10% power, 5 s) and centrifuged (~11,000 
xg for 5 min). The resultant pellet was re-suspended in 150 µl PBS, producing the 
insoluble fraction. Tau expression in the soluble and insoluble fractions was 
analysed by SDS-PAGE and Western blotting (WB) as described below. 
 
2.6 SDS-PAGE and WB  
Protein samples were separated on precast 4-20 % NuSep Tris-glycine gels or 
standard handcast 15 % Tris-glycine gels with (reducing gels) or without (non-
reducing gels) β-mercaptoethanol and 5 min heating at 95 oC (gel and buffer 
preparation protocols in Table 2.5). Samples were analysed against protein ladder 
(#P7712 or #P7712S from New England BioLabs, size range = 11 – 245 kDa, or 
Precision Plus standard (#161-0374 from Biorad; size range = 10 – 250 kDa) for 
35 min at 200 V in a Biorad Mini-PROTEAN Tetra system (BioRad Laboratories, 
California, USA) and stained with Instant Blue (Coomassie-based stain from 
Expedeon, Cambridge, UK) for 1 h at RT with no washing steps required and 
imaged using a SynGene G-Box imaging system. MagicMarkTM XP Western 
standard (#LC5602, Invitrogen) was used as a loading marker for WB. To 
identify tau-positive bands, WB was performed prior to antibody detection as 
described below.  
 
Gels were transferred overnight at 4 oC or 2 hr at RT onto Amersham Hybond 
electrochemiluminescence nitrocellulose membrane and blocked for 15 min (in 5 
% w/v non-fat dried milk in TBS-Tween) prior to 2 h incubation with the primary 
antibody. Unbound antibody was removed by 5 x 5 min washes with 10 % TBS-
Tween in ddH2O before 2 h incubation at RT with the secondary antibody and the 
membrane washed as previously. Antibodies used are indicated in Table 2.6. 
Antibody detection was performed using the Amersham 
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electrochemiluminescence detection reagents according to the manufacturer’s 
instruction and bands visualised by exposure to X-ray film (Fuji Medical X-ray 
Film Super RX or CL-XPosure Film) and developed in an AGFA Curix 60 
processor (Agfa Healthcare, Greenville, SC, USA). On a few occasions, WB 
detection was performed using the ImageQuant™ LAS4000 biomolecular 
imaging system (GE Healthcare). Densitometry analysis of protein bands was 
performed using ImageJ (Schneider et al., 2012), and statistically analysed with 
Prism 6 (GraphPad Inc., CA, USA) at the 5 % significance level. 
 
Table 2.5. Preparation of hand-cast gels and buffers for SDS-PAGE and WB 
Solution  Recipe 
Loading buffer 
(2X Laemmli 
buffer) 
25 mM Tris HCl pH 6.8, 25 % v/v glycerol, 2 % SDS, 0.01 
% w/v bromophenol blue. Diluent = ddH2O. For reducing 
gels, β-mercaptoethanol was added to 5 % final concentration 
in loading buffer aliquots.  
Running buffer 
(10X) 
25 mM Tris, 190 mM glycine, 0.1 % SDS.  
Transfer buffer 25 mM Tris, 190 mM glycine, 20 % methanol. 
15 % protein gel Resolving gel: 50 % acrylamide/bisacrylamide, 390 mM Tris 
HCl pH 8.8, 0.1 % SDS, 0.1 % ammonium persulfate, 0.01 % 
TEMED.  
Stacking gel: 125 mM Tris HCl pH 6.8, 0.1 % SDS, 13.4 % 
acrylamide/bisacrylamide, 0.1 % ammonium persulfate, 0.1 
% TEMED 
 
2.7 Large-scale expression of tau constructs 
Large cultures were produced by inoculating 500 ml selective LB broth with 10 
ml overnight cultures using the expression parameters described above. Cultures 
were subsequently centrifuged at 4 oC for 10 min at 9800 xg. The resulting pellet 
was resuspended in 50 mM Na2PO4 pH 7.5 and frozen until use. Prior to 
purification, the lysate was boiled at 70 oC for 10 min to thaw, and protease 
inhibitor cocktail (1 tablet/~ 50 ml lysate), DNAse I and 5 ml of 1X BugBuster® 
protein extraction reagent added. The mixture was left to stand at RT for 1 h, 
sonicated at 70 % power for 1 min and centrifuged at 4 oC for 30 min at 48,000 
xg. The supernatant containing the soluble fraction (crude extract) was decanted, 
filtered through a 0.2 µm filter and purified as below.  
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Table 2.6. Primary and secondary antibodies used in this study. 
Antibody Epitope Host  
species 
Vendor Dilution 
Polyclonal rabbit 
anti-human tau 
(#A0024) 
C-terminus 
(amino acids 
243 – 441) of 
the four-repeat 
isoforms of tau  
 
Rabbit Dako 1:1000 
or 
1:5000 
Goat anti-rabbit 
IgG (#31460) 
-  Goat Thermo Scientific 1:1000 
or 
1:5000 
Anti-His antibody 
(#27-4710-01) 
6xHis tag Mouse GE Healthcare 1:2500 
Rabbit anti-mouse 
IgG (#31450) 
-  Rabbit  Thermofisher 1:5000 
T22 oligomeric tau 
antibody 
(#ABN454) 
Tau MT binding 
domain 
Rabbit Merck 1:1000 
Anti-c-Myc 
(#C3956-100UG) 
The Myc 
oncogene  
Rabbit  Thermo Scientific 1:1000 
HT7 anti-human 
tau (#MN1000) 
Amino acid 
sequence 
159PPGQK163 of 
full length 
human tau 
2N4R 
Mouse  Thermo Scientific 1:100 
Alexa Fluor® 594-
cojugated 
AffiniPure goat 
anti-mouse 
-  Goat  Jackson 
ImmunoResearch 
1:100 
Alexa Fluor® 647-
conjugated anti-
nucleolin 
(#ab198580) 
Human 
nucleolin 
Mouse  Abcam 1:500 
 
2.8 Tau protein purification by immobilised metal affinity 
chromatography (IMAC)  
Ni-NTA column (Econo-Pac, Biorad) was used for protein purification. Chelating 
sepharose resin was charged with 10 mM NiCl2/CH3COONa pH 4.0 and 
equilibrated with buffer A (50 mM Na2PO4 pH 7.0, 500 mM NaCl, 10 mM 
imidazole) before addition of the crude extract. The column was re-washed with 
buffer A, followed by buffer B (50 mM Na2PO4 pH 7.0, 500 mM NaCl, 25 mM 
imidazole) and the protein eluted with buffer C (50 mM Na2PO4 pH 7.0, 500 mM 
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NaCl, 500 mM imidazole) followed by overnight dialysis in the presence of 25 
µg/ml TEV protease, against dialysis buffer (50 mM Tris HCl pH 7.5, 100 mM 
NaCl) to cleave the polyhistidine-TEV tag. The dialysed tau was re-purified to 
isolate the TEV protease-cleaved tau. Briefly, the column was equilibrated with 
buffer A, the cleaved protein collected as the flow-through upon elution and 
concentrated using Vivaspin 20 (Sartorius; 5 kDa and 10 kDa cut off for K18 and 
htau40 respectively) where necessary. At each step of the purification process, 
aliquots were taken for SDS-PAGE and WB analysis. Protein concentration and 
purity were estimated using the Bicinchoninic acid (BCA) assay and SDS-PAGE 
respectively. 
 
2.9 Expression and purification of TEV protease 
A maltose binding protein-His-TEV protease construct (kind gift of Dr. Deborah 
Brotherton, University of Warwick) was expressed, purified and used to cleave the 
polyhistidine tag on the tau proteins constructs where necessary. The MBP-His-
TEV construct transformed into BL21(DE3)plus (for rare Arginine tRNA) was 
grown in LB broth containing 100 µg/ml carbenicllin until reaching OD600 = 0.6, 
induced with 0.4 mM IPTG and grown at 25 oC overnight. Cells were harvested by 
centrifugation at 9800 xg, 4 oC for 10 min and re-suspended in cell resuspension 
buffer (PBS, 0.3 M NaCl) at the ratio of 5 ml buffer to 1 g wet cell weight. 
Thereafter, the cells were lysed by 30 min boiling at 100 oC and sonication (1 min, 
70 % power), and centrifuged at 150,000 xg for 30 min, 4 oC.  Final concentration 
of 20 mM imidazole was added to the supernatant (after 0.2 µm filtering) and 
purified with a Ni-NTA column pre-equilibrated with purification buffer (20 mM 
Tris-HCl pH 7.5, 0.3 M NaCl, 3 mM dithiothreitol (DTT), 20 % glycerol) +20 mM 
imidazole. The washing step was done with purification buffer containing 50 mM 
imidazole for 20 column volumes and the purified protein eluted with purification 
buffer + 250 mM imidazole and dialysed overnight against 3 l of dialysis buffer 
(20 mM Tris-HCl pH 7.5, 0.3 M NaCl, 5 mM DTT, 30 % glycerol) at 4 oC. On the 
next day, the dialysed sample was further purified on a column pre-equilibrated 
with dialysis buffer with 20 mM imidazole and purified same as on the previous 
day. The eluted protein was stored at -80 oC in storage buffer (20 mM Tris-HCl pH 
7.5, 0.3 M NaCl, 5 mM DTT, 50 % glycerol) with 60 % glycerol.  
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2.10 Protein quantification using the BCA assay 
The concentrations of purified proteins were estimated using the BCA colorimetric 
assay (G-Biosciences, Missouri, USA). First, a linear plot was generated by 
monitoring the 562 nm absorbance of serial dilutions of manufacturer-provided 
bovine serum albumin (BSA) as the standard protein. Nine 1:2 serial dilutions of a 
stock 2 mg/ml BSA were prepared, thoroughly mixed and 50 µl aliquots added to 1 
ml working solution (10 ml BCA reagent + 200 µl copper solution). The 
absorbance of each mixture was measured with an Ultrospec 2100 
spectrophotometer after 30 min incubation at 37 oC. To identify the absolute 
protein concentration per dilution, the absorbance value for the working solution 
alone (the last tube in the dilution series with no protein present) was deducted 
from all collected absorbance values. The normalised absorbance readings were 
subsequently plotted against protein concentration to generate a standard curve 
(Fig. 2.2), which was used to estimate the concentration of purified proteins used 
in this work.  
 
Concentrations in mg/ml were converted to molarity using each protein’s molar 
mass calculated from Expasy (http://web.expasy.org/compute_pi/). For example, 1 
mg/ml of purified His-tagged K18 equals 55 µΜ whilst 1 mg/ml of the untagged 
K18 is 66 µΜ. Indicated concentrations of tau proteins throughout this thesis refer 
to monomer equivalents.  
 
2.11 Preparation of Alzheimer-like PHFs  
 
Experiments shown in Chapter 4 (characterisation of purified tau): a method 
adapted from (Barghorn et al., 2005) was used. Briefly, 200 µl reaction mixtures 
containing 12 µM monomeric tau, 10 mM Na2PO4 pH 7.4, 50 mM ammonium 
acetate, 1 mM DTT and 6 µM heparin (MW 6000) were prepared and incubated at 
37 °C for 7 days to promote filament formation.  
 
Influence of disease mutations on tau aggregation (Chapter 6): 0.7 mg/ml (38.5 
µM) of freshly-purified tau K18 or its pathologic variants were mixed with 0.75 
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mg/ml (125 µM) heparin and incubated for 4 days or 45 days at 37 °C before 
negative-stain transmission electron microscopy (TEM) analysis.   
 
 
Figure 2.2. BCA assay standard plot for estimating protein concentration. 
Manufacturer-supplied BSA was used to generate this standard plot for 
estimating the concentrations of purified tau proteins. 
 
2.12 CD spectroscopy 
 
Chapter 4: following dialysis of the purified tau protein in Thermo Scientific™ 
Slide-A-Lyzer™ MINI Dialysis Device (10K MWCO) in excess of 10 mM 
Na2PO4 pH 7.4 buffer as per the manufacturer’s instructions, 10 µM samples were 
diluted in the same buffer and CD spectra collected using a Jasco J-815 CD 
spectropolarimeter in a 1 mm path length cell. The response time was 1 s with a 
data pitch of 0.1 nm and the scan speed was 100 nm/min. 32 spectra 
accumulations were obtained for each sample at wavelengths ranging from 190 
nm to 280 nm and averaged. The high-tension voltage was ≤ 550 V throughout.  
 
PHF samples were centrifuged at 100,000 xg for 1 h at 4 °C, supernatant removed 
and the pellet re-suspended in 200 µl of 10 mM Na2PO4 pH 7.4. CD analysis on 
PHF samples was conducted as described above. Secondary structure elements 
were estimated using the DichroWeb Contin-LL (Provencher and Glockner 
method) reference dataset 4 (Sreerama and Woody, 2000; Whitmore and Wallace, 
2008, 2004).  
 
CD assays on tau oligomers (Chapter 6): readings were taken on 0.1 mg/ml (5.5 
µM) of RT overnight-incubated samples using the above-stated conditions. For 
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each CD assay, three independent experiments using different batches of protein 
preparations were conducted. 
 
2.13 ThT kinetic assay of tau aggregation  
 
Freshly-prepared samples were diluted to 0.2 mg/ml (11 µM) in 10 mM Na2PO4 
pH 7.4 and seeded at 100 µl per well (heparin-free aggregation studies) in 96-well 
plates (Greiner Bio-One #655077). In heparin-induced aggregation studies, 10 µl 
each of ThT (20 µM final concentration) and heparin (0.15 mg/ml = 25 µM final 
concentration) were added to 80 µl tau 0.16 mg/ml (8.85 µM; final concentration) 
per well of a FLUOTRACTM 96-well plate (Greiner Bio-One #655077). Tau 
aggregation was monitored for up to 40 h by measuring ThT fluorescence at 440 
nm excitation and 510 nm emission in a CLARIOstar microplate reader (BMG 
Lab Tech). Sensitivity was set to 20 % to prevent signal saturation. Fluorescence 
readings were taken with the top optic setting every 5 min after 200 rpm shaking 
for 30 s. Data analysis was done with Prism 7 (GraphPad Inc.).  
 
2.14 TEM analysis of tau filament formation  
 
Formvar/carbon-coated 300-mesh copper grids (Agar scientific, UK, #S162) were 
glow-discharged and 5 µl of sample preparations (samples in Chapter 4 were 
diluted 1:2) pipetted onto the grid and allowed to bind for 1 min. Excess sample 
was removed and 5 µl of 2% uranyl acetate added for 1 min and excess removed. 
The grids were imaged using a JEOL-2100F transmission electron microscope.  
 
2.15 Dot blot assay of tau aggregation  
 
Dot blotting without heparin (Chapter 6): freshly-purified tau proteins at 1 mg/ml 
(55 µM) were incubated in standard PCR tubes and heated at 37 oC to promote 
aggregation in quiescent conditions. Unless otherwise stated, all incubation was 
done in an Eppendorf Mastercycler gradient thermocycler. Aliquots taken at each 
time point were immediately snap-frozen and kept at -80 oC until use. Samples 
were diluted to 0.5 mg/ml with 10 mM Na2PO4 pH 7.4 before dot blotting. 
 
Dot blotting for oligomers prepared by overnight incubation of monomers at RT 
(Chapter 6): Freshly-prepared tau proteins (0.1 mg/ml; 5.5 µM) were incubated at 
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RT overnight (~ 15 h), and used immediately for dot blot and CD or snap-frozen 
and kept at -80 oC until use.  
 
Dot blotting for Alexa Fluor®-488-maleimide (AF-maleimide) and N-
ethylmaleimide (NEM) labelled tau proteins (Chapter 5): The labelled and 
unlabelled control samples (prepared as in section 2.18 below) were each mixed 
with 0.75 mg/ml (125 µM) heparin, incubated at 37 oC for 48 h and aliquots taken 
and snap-frozen for dot blotting. Samples were diluted in half before dot blotting. 
 
Two microlitres of the tau samples collected at the given time points were spotted 
onto a nitrocellulose membrane, air dried, blocked with 10 % non-fat milk in PBS 
overnight at 4 °C overnight or 30 min at RT, and washed five times with 10 % 
TBS-Tween. The nitrocellulose membrane was incubated at RT for 2 h in the 
primary antibody (total tau antibody #A0024 or oligomeric antibody #T22; Table 
2.6), washed five times with 10 % TBS containing 0.05% Tween-20, and 
incubated with the secondary antibody (horse radish peroxidase-conjugated anti-
rabbit IgG; Table 2.6) for a further 2 h at RT. Thereafter, the nitrocellulose paper 
was washed five times as previously, developed with the ECL chemiluminiscent 
kit, and imaged.  
 
2.16 AFM analysis of tau aggregation 
 
ThT end-point samples: As a complementary method to ThT analysis of tau 
aggregation, aliquots of tau samples after the ThT assay were taken, snap-frozen 
and examined by AFM.  
 
Time-dependent aggregation of tau: to closely monitor the structural 
transformation of tau during aggregation, 0.7 mg/ml (38.5 µM) tau was mixed 
with 0.75 mg/ml (125 µM) heparin and incubated at 37 oC. Samples were taken at 
the indicated time points, snap-frozen and stored at -80 oC until use. 
 
For AFM analysis, tau protein samples were adsorbed onto freshly-cleaved mica 
surface (Agar Scientific, #G250-3) for 15 min and unbound protein removed by 
washing with excess ddH2O. Random positions on the mica surface were chosen 
for the collection of 1 µm2 height images using a cantilever. The scan rate was 0.5 
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– 2.0 Hz, in AC Air Topography mode using an MFP3D AFM (Asylum Research, 
UK). Data processing was done using the “Flatten” function of the Igor Pro 6.37 
software. Sample sizes were determined using Image J as previously described 
(Tepper et al., 2014).  
 
2.17 Preparation of tau oligomers  
Tau oligomers were prepared by diluting each given monomer sample to 0.1 
mg/ml (5.5 µM) in 10 mM Na2PO4 pH 7.4 and incubating at RT overnight under 
quiescent conditions. Oligomerisation was confirmed by SDS-PAGE, WB, AFM 
or TEM.  
 
2.18 AF-maleimide and NEM labelling of tau protein and the 
characterisation of labelled proteins 
 
Optimisation of AF-maleimide labelling: Tau proteins were first labelled using 
two adapted protocols that differed in their pre-treatment with reducing agents. 
Following the method of Michel et al., (2014), protein samples were treated for 
30 min at RT with 4X molar excess of TCEP whilst the protocol adapted from 
Bader et al., (2011) omitted this step. The tau proteins were treated with 4X molar 
excess of AF-maleimide in 10 mM Na2PO4 pH 7.4 or 1X BRB buffer (1 mM 
KCl, 80 mM PIPES, and 1 mM EGTA pH 6.8) and incubated in the dark at RT 
for 3 h. The reaction time was later extended to overnight to enable 
oligomerisation of the labelled monomers. Free fluorophore and TCEP were 
removed using NAP-5 chromatography column from GE Healthcare or by 
extensive dialysis against dialysis buffer (section 2.8) in the Thermo Scientific™ 
Slide-A-Lyzer™ MINI Dialysis Device (10K MWCO) perforated to increase 
buffer volume to about 2 l. Protein labelling and unbound fluorophore removal 
were confirmed with SDS PAGE. The concentration of labelled protein was 
routinely determined spectrophotometrically using Beer’s law and molar 
extinction coefficient of 72000/cm/M for AF-maleimide.  
 
Preparation of NEM-labelled tau oligomers: freshly-prepared tau (1 mg/ml) was 
treated with 5X molar excess of TCEP for 2 h. Subsequently, 5X molar excess of 
NEM was added and the reaction mix incubated at RT overnight. Oligomer 
formation was confirmed by dot blot and negative-stain TEM. In both cases of tau 
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labelling, unlabelled control samples were prepared identically except that equal 
volume of 10 mM Na2PO4 pH 7.4 was added in place of the maleimide label. 
 
 
DLS: AF-maleimide labelled tau K18 oligomers at 1 mg/ml (55 µM) 
concentrations (100 µl) were aliquoted into a clean ZEN 040 cuvette, transferred 
into a Zetasizer Nano-series spectrometer (Malvern Instruments, UK) and 
equilibrated for 5 min at 20 OC. Eleven measurements were taken and analysed 
with the Zetasizer software to estimate the hydrodynamic radius of the protein.  
 
2.19 Neuroblastoma cell culture  
 
SH-SY5Y cells were purchased from Sigma Aldrich UK (#94030304) and 
maintained on 1:1 minimal essential medium (MEM)/F12 Ham medium 
containing 1 % L-Glutamine, 15 % foetal bovine serum, and 1 % antibiotic 
antimycotic acid. The cells were seeded at 200,000 cells/ml in CellViewTM 
Advanced Tissue Culture dishes (Greiner Bio-One, #627975) in the presence of 
100 nM – 10 µM AF-maleimide labelled tau oligomers dissolved in the culture 
medium, and incubated for 24 h at 37 oC, 5 % CO2. Thereafter, the extracellular 
medium was removed, the cells washed with PBS and fresh tau-free medium 
containing 2 µM nuclear marker Hoechst and 1:1000 dilution of the plasma 
membrane marker Deep Red, both added 30 min before confocal microscopy. 
Cells between passages two and ten were used for all experiments.  
 
2.20 Differentiated neuroblastoma cell culture 
 
Tissue culture plates were treated with 0.01 % poly-l-ornithine followed by 5 
µg/ml laminin, and washed with PBS. Cells were seeded at same density as above 
in MEM-FI2 medium supplemented with 10 µg/ml retinoic acid and grown for 5 
days. The media was changed to serum-free MEM-FI2 supplemented with 10 
µg/ml retinoic acid and 25 ng/ml brain derived neurotrophic factor, and the 
differentiated cells used within 10 days.  
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2.21 Human induced pluripotent stem cell (hiPSC)-derived cerebral 
cortical neural stem cells  
Neural precursors (differentiated by the supplier following a 21-day protocol) 
obtained from cord blood CD34+ cells of a healthy, newborn female donor were 
purchased from Axol Bioscience (#ax0016, Cambridge, UK). Tissue culture 
grade 12-well plates (Corning, USA) were each pre-coated with 250 µl/cm2 
ReadySet reagent (Axol) and incubated at 37 oC, 5 % CO2 for 45 min and rinsed 
four times with ddH2O. Thereafter, Surebond reagent (Axol) was diluted in 
Dulbecco’s PBS (DPBS) and used at 200 µl/cm2 and incubated at 37 oC, 5 % CO2 
to equilibrate for 1 h. Next, stem cells were seeded at 25,000 cells/cm2 on plasma-
cleaned 13 mm glass coverslips, incubated at 37 C oC, 5 % CO2 and media 
changed every other day with Axol Neural Maintenance Medium kit (ax0031 
a&b). Neuronal differentiation was monitored using phase contrast images 
obtained periodically with an EVOS XL Core Imaging System (Life 
Technologies). Neurons were used for experiments after 14 – 16 days in vitro. 
WT and FTD tau K18 oligomers were diluted to 5 µM in Legacy medium and 
added to neurons and incubated at 37 C oC, 5 % CO2 for 24 h or 48 h, after which 
the spent medium was carefully removed, neurons washed with DPBS, and new 
tau-free medium added.  
 
2.22 Immunohistochemistry  
SH-SY5Y live cell assays: cells were treated with the appropriate antibodies 
(Table 2.6) or dyes and imaged without fixing. In examining the mechanism of 
tau internalisation, the FM4-64 endocytic marker was added to tau-free medium 
containing Hoechst and transferred to cells after PBS wash as described above. 
Confocal microscopy imaging was performed following 30 min incubation at 37 
oC, 5 % CO2. The nucleolin colocalisation test was conducted similarly using a 
conjugated anti human nucleolin antibody (Table 2.6) and imaged after 2 h 
incubation. For endogenous tau colocalisation, the HT7 antibody recognising the 
159PPGQK163 motif of full length tau but falls outside the K18 domain was added 
to tau-treated cultures at 22 h of incubation. The spent medium containing the 
HT7 antibody was removed at 24 h, washed with PBS, and new tau-free medium 
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with Hoechst and the Alexa Fluor® 594-cojugated AffiniPure secondary 
antibody. Cells were imaged after 2 h incubation. Antibody dilutions are given in 
Table 2.6. 
 
hiPSC fixed tissue assays: Spent medium was removed and neurons washed with 
PBS after 24 h or 48 h of seeding with 5 µM tau. Neurons were then fixed with 4 
% paraformaldehyde for 30 min, washed twice with DPBS and rinsed with 
permeabilising solution (0.2 % Triton in DPBS). Afterwards, the fixed neurons 
were incubated in blocking buffer (DPBS containing 0.2 % Triton and 2 % BSA) 
for 1 h and then primary antibody with Hoechst for another 1 h. Excess primary 
antibody was removed by washing thrice with blocking buffer only for 5 min 
each time, followed by secondary antibody incubation for 1 h and a repeat of the 
blocking buffer wash steps. Both antibodies were diluted in the blocking buffer. 
Next, the slides were rinsed with distilled water and dropped into ProLong Gold 
antifade mounting medium (#P36934, ThermoFisher Scientific). Neurons were 
observed by confocal microscopy imaging at least 24 h after curing.    
 
2.23 Confocal microscopy 
Live neuroblastoma cell imaging: 12-bit images were obtained at RT using a C-
Apochromat 63x/1.20 W Korr M27 water immersion objective lens on an LSM 
710 confocal microscope (Leica). hiPSC neurons were imaged using a Leica STP 
6000 microscope. Images were analysed with Image J. Internalisation data were 
analysed as shown in the Appendix, and expressed as integrated density (area x 
mean fluorescent intensity).  
 
2.24 Lactate dehydrogenase (LDH) assay of tau oligomer toxicity 
The Pierce LDH Cytotoxicity assay kit was used. SH-SY5Y neuroblastoma cells 
were seeded at 20,000 cells/well in Falcon 96-well plates and varying 
concentrations of tau oligomers added. Controls included spontaneous 
cytotoxicity (cells + 10 µl sterile water), media only (no cells) and maximum 
control (membrane lysed with a manufacturer-supplied reagent). The cells were 
incubated for 72 h at 37 oC 5 % CO2. After 72 h, lysis buffer was added to the 
maximum control wells and the plates incubated for a further 45 min. Then, 50 µl 
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of the sample mix in each well was transferred to a new 96-well plate and 50 µl 
reaction mix added to each well and incubated at RT in the dark for 30 min. Stop 
solution (50 µl) was added and absorbance measured at 490 nm and 680 nm with 
a CLARIOstar microplate reader (BMG Lab Tech). The background readings at 
680 nm were subtracted from corresponding 490 nm readings and LDH release 
measured using the following equation:  
 
% cytotoxicity = Tau-treated LDH activity – Spontaneous LDH activity x 100 % 
                               Maximum LDH activity – Spontaneous LDH activity 
 
 
2.25 Statistical analysis 
 
Statistical analyses were conducted with Prism 6 or 7 (GraphPad Inc., CA, USA) 
at the 5 % significance level. Data sets were first tested for normality using the 
D’Agostino and Pearson test in Prism. If appropriate, parametric analyses were 
performed with the Student’s t-test (two variables) or one-way ANOVA (three 
variables). Otherwise, non-parametric analyses were performed using the Mann 
Whitney test (two data variables) or Kruskal Wallis test followed by Dunn’s 
multiple comparison test. All statistics data are expressed as mean ± standard 
deviation.  
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3| A plasmid library for expressing full-
length and truncated tau proteins, and 
their pathologic and cysteine-modified 
variants  
 
3.1 Introduction 
Understanding the structural, biochemical and molecular basis of tau aggregation 
is essential for structure-activity studies and therapy development (Cisek et al., 
2014). This however requires high-yield production of tau proteins in sustainable 
supply. Although it is feasible to isolate reasonable amounts of tau proteins from 
human brain tissues, this process has many disadvantages including: (i) the need 
for specialised purification equipment and expertise; (ii) unsustainable supply for 
research purposes due to the need to process several brain tissues; (iii) potential 
inconsistent properties of proteins obtained from patients of diverse disease 
aetiologies e.g. whether genetic or sporadic. For these reasons, recombinant 
approaches are often used to produce homogenous tau proteins in a renewable way. 
Recombinant and AD brain-derived tau aggregate through the same mechanism 
(i.e, shift of monomers from an unfolded state towards beta sheet structures) and 
form filaments of the same ultrastructural properties (Barghorn et al., 2004). When 
recombinant tau monomers are induced with AD brain-derived tau filaments, the 
former aggregates into PHF of identical structural properties as the AD tau, 
indicating shared structural properties between the two (Morozova et al., 2013). 
Consistent with these findings, PHF prepared from recombinant tau closely shares 
structural properties of AD tau (Barghorn et al., 2004). Hence, recombinant tau will 
be used throughout this thesis as a validated model for studying native tau.  
 
This thesis aims to characterise the structural, conformational and aggregation 
properties of different disease-linked tau proteins and to apply the insights obtained 
to support investigations into how extracellular tau is internalised. As a starting 
point in this pursuit, it was essential to obtain plasmids expressing all the tau 
proteins of interest. It was however realised that no such comprehensive library of 
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tau-expressing plasmids existed, hence one was created. In this Chapter, the 
rational design of a large library of plasmids for expressing a variety of full-length 
and truncated tau proteins is described. This collection of ~50 unique molecular 
clones provides a vital resource for preparing a wide variety of tau proteins for in 
vitro and in vivo studies.  
 
3.2 Results  
3.2.1 Creation of a library of plasmids for expressing pathologic 
variants of tau  
Four pathologic mutations in the MAPT gene identified in familial cases of 
tauopathies (Table 3.1) were created in the htau40 and K18 tau constructs (plasmid 
templates in Fig. 2.1) using SDM. Protein and amino acid sequence alignments 
confirmed induction of the V337M, N279K, P301L and C291R mutations in the 
WT tau constructs are shown in Fig. 3.1 – 3.3, with a schematic illustration of this 
process given in Fig. 3.4. In addition to plasmids for expressing Myc-tagged 
pathologic tau mutants, FLAG-tagged versions of the htau40 plasmids were created 
to provide flexibility in plasmid selection.   
 
Table 3.1 Details of pathological mutations created in the htau40 isoform and 
the K18 fragment of tau. 
Note that amino acids are numbered according to the full-length brain isoform of 
tau (htau40).   
Amino acid 
change 
DNA codon change 
N279K AAT to AAA 
V337M GTG to ATG 
P301L CCG to CTG 
C291R TGT to CGT 
 
 
 
 
 
 
 
 
 
 
 - 53 - 
 
 
 
Figure 3.1. Clustal Omega sequence alignments confirming the creation of the 
FTD mutations N279K, V337M, P301L and C291R in the WT K18 tau 
construct. 
(A), (B), (C), and (D) show sequence alignments demonstrating the N279K, 
V337M, P301L and C291R point mutations respectively. Mutation sites are 
highlighted in blue.  
 
 
Figure 3.2. Clustal Omega sequence alignments confirming the creation of the 
N279K, V337M and P301L pathological mutations in the FLAG-tagged htau40 
plasmid. 
 (A), (B) and (C) indicate the N279K, V337M and P301L mutations respectively.  
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Figure 3.3. Clustal Omega sequence alignments confirming creation of the 
N279K and V337M mutations (A and B respectively) in the Myc-tagged htau40 
plasmid. 
 
 
Figure 3.4. Schematic illustration of the creation of four disease-associated 
exonic mutations in the K18 and htau40 tau proteins.  
 
 
3.2.2 Introduction of cysteine modifications into the tau proteins 
A major aim of this thesis was to study the cellular internalisation of extracellular 
tau protein. In this regard, there was a need to use fluorescently labelled tau proteins 
to enable live tracking of their internalisation. A method of choice was to covalently 
label a single cysteine residue with a chemical fluorophore e.g., maleimide-
conjugated Alexa Fluor® 488. However, the native full-length and truncated four-
repeat tau proteins contain two cysteine residues, one each in the second and third 
repeat region. To complicate issues further, these cysteine residues are located in 
the protein’s region believed to be required for MT binding and stabilisation (Lee 
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et al., 1989). To label a single cysteine residue outside of this region, the two native 
cysteine residues at amino acid positions 291 and C322 were modified to the 
nonpolar amino acid alanine and a new cysteine introduced at position 260, which 
is further away from the central core of the repeat region (Fig. 3.5). DNA codon 
changes made are shown in Table 3.2, and sequence alignments demonstrating 
these modifications are given in Figs. 3.6 – 3.16. For the K18-C291R construct, 
only two cysteine modifications (i.e., C322A and I260C) were induced due to the 
presence of a putative pathological mutation of unknown pathogenicity at position 
291 (Marshall et al., 2015). This method of labelling tau for functional studies has 
previously been reported, and is believed to have no adverse effects on the protein’s 
ability to form fibrils (Kumar et al., 2014; Michel et al., 2014; Shammas et al., 
2015).  
 
An alternative chemical labelling approach would be to directly label the two native 
cysteine residues without cysteine alterations, as done previously by Tepper et al., 
(2014). Obviously, this method would save time and avoid the potential risk of 
altering the protein’s biochemical and structural characteristics through cysteine 
modification. However, the high tendency of double-cysteine tau proteins, 
especially the K18 truncation fragment, to form both intra- and inter-molecular 
disulphide bonds even in reducing conditions and at low temperatures (Barghorn 
and Mandelkow, 2002) presents the possible danger of “false positive labelling” 
i.e., not labelling cysteine residues locked up in disulphide bonding. Unfortunately, 
it would be difficult to remove such unlabelled proteins in post-labelling treatment 
steps, and may lead to irreproducible results due to the inability to quantify the 
contribution of unlabelled proteins to experimental outcomes. 
 
Table 3.2. Codon changes made in the cysteine modifications induced in the 
tau proteins to enable chemical labelling with maleimide. 
Note that these changes were made in all the tau protein constructs except the K18-
C91R construct for which the C291A modification was omitted due to a pathogenic 
mutation at the same amino acid position. 
Amino acid 
change 
DNA codon 
change 
C291A TGT to GCT 
C322A  TGT to GCT 
I260C  ATC to TGT 
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Figure 3.5. Schematic illustration of cysteine modifications induced in the tau 
protein-expression library hitherto created. 
The DNA sequences that code for the native cysteine residues in each plasmid was 
modified to alanine (C291A and C322A), and a new cysteine residue introduced 
nearer to the N-terminus end of the MT binding domain (I260C; numbered 
according to the full-length tau) where it was believed not to affect tau-MT binding 
dynamics. The resultant plasmids will be later expressed, purified, and 
fluorescently labelled on the novel cysteine residue introduced at the amino acid 
position 260.  
 
  
 
Figure 3.6. Cysteine modifications in the WT K18 sequence. 
(A) and (B) refer to the modification of C291 and C322 to alanine. (C) shows the 
introduction of a novel cysteine residue to replace isoleucine at position 260. 
Nucleotide changes are highlighted in blue.  
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Figure 3.7. Evidence of cysteine modifications in the Myc-K18-N279K 
construct. 
The modification of C291 and C322 to alanine is shown in (A) and (B) respectively. 
(C) shows the introduction of a new cysteine residue to replace isoleucine at 
position 260. Nucleotide changes are highlighted in blue.  
 
 
 
Figure 3.8. Modification of native cysteine residues in the Myc-K18-V337M 
construct. 
(A), (B) and (C) show the generation of the C291A, C322A and I260C amino acid 
modifications respectively.  
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Figure 3.9. Evidence of native cysteine modification in the Myc-K18-P301L 
construct. 
 (A), (B) and (C) show the creation of the C291A, C322A and I260C amino acid 
modifications respectively.  
 
 
 
Figure 3.10. Modification of native cysteine residues in the Myc-K18-C291R 
construct. 
 (A) and (B) provide evidence of induction of the C322A and I260C amino acid 
modifications respectively. Note that the C291A cysteine modification was not 
induced for this construct due to the presence of the C291R disease-associated 
mutation at the same amino acid position. 
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Figure 3.11. Modification of native cysteine residues in the WT Myc-htau40 
construct. 
The C291A, C322A and I260C amino acid changes are shown in (A), (B) and (C) 
respectively.  
 
 
 
 
Figure 3.12. Native cysteine residue modification in the Myc-htau40-N279K 
construct. 
The two cysteine residues in this tau construct at positions C291 and C322 were 
each modified to alanine, a nonpolar amino acid that does not confer an extra 
charge on the protein (shown in (A) and (B) respectively). (C) A new cysteine 
residue was introduced upstream, replacing isoleucine at position 260. 
 
 
 
 - 60 - 
 
Figure 3.13. Modification of the native cysteine residues in the Myc-htau40-
V337M construct. 
The C291A, C322A and I260C amino acid changes created in this construct are 
shown in (A), (B) and (C) respectively.  
 
 
Figure 3.14. Evidence of the creation of amino acid modifications in the WT 
htau40-Flag construct. 
(A) and (B) The native cysteine residues (C291 and C322) were each substituted 
with alanine. (C) A novel cysteine residue was introduced at position I260C, 
outside of the core of the microtubule binding region.  
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Figure 3.15. Cysteine modification in the htau40-Flag-N279K construct, 
showing the C291A, C322A and I260C amino acid modifications in (A), (B) 
and (C) respectively. 
 
 
Figure 3.16. Modification of the native cysteine residues C291 and C322 to 
alanine (A and B respectively) and the introduction of a new cysteine residue at 
position 260 (C) in the htau40-FLAG-V337M construct. 
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Figure 3.17. Schematic illustration of cysteine-modified tau plasmids created. 
Using plasmids encoding genetic constructs for expressing WT K18 (A) and htau40 
(B and C) as templates, tau constructs carrying specific disease-associated 
mutations and cysteine modifications were generated.  
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Figure 3.18. Disease-specific mutations and cysteine modifications made in the 
primary sequence of tau. 
(A) Schematic illustration of the location of amino acid changes made in the WT 
tau-expressing cDNA clones (disease mutations in black and cysteine modifications 
in red). (B) The complete amino acid sequence of htau40, showing the K18 region 
(residues 241 – 372 in blue; same as regions R1 to R4 in Fig. 3.18A). Pathological 
mutations are shown in black and underlined. Sites for cysteine modification are 
given in red and are underlined. Note that residue 291 doubles as a putative 
pathological mutation site.  
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A
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Table 3.3. A comprehensive collection of plasmids created in this study for the 
recombinant expression of human tau proteins, described according to the 
encoded genetic construct. 
The tau genetic construct in each plasmid is preceded by a hexahistidine motif.   
 
No. Plasmid 
name 
Tau genetic 
construct 
encoded  
Description of expressed protein 
 Plasmids encoding WT tau or its fragment  
1 pProEx-HTa-
Myc-K18 
K18  Myc-tagged fragment of the MT repeat 
region (amino acids 244 – 372) of the 
full-length human tau brain isoform  
2 pProEx-HTa-
FLAG-htau40 
htau40  The 441-amino acid full-length human 
brain isoform of tau, tagged with 
FLAG 
3 pProEx-HTa-
htau40-Myc 
htau40 The 441-amino acid full-length human 
brain isoform of tau, tagged with c-
Myc 
  
Plasmids encoding pathological mutant versions of K18  
4 pProEx-HTa-
Myc-K18-
N279K 
K18 
incorporating the 
N279K mutation  
Myc-tagged K18 tau fragment 
containing the FTD-associated N279K 
mutation  
5 pProEx-HTa-
Myc-K18-
V337M 
K18 carrying the 
V337M mutation  
Myc-tagged K18 tau fragment 
containing the FTD-associated V337M 
mutation 
6 pProEx-HTa-
Myc-K18-
C291R 
K18 containing 
the C291R 
mutation 
Myc-tagged K18 tau fragment 
consisting of the putative corticobasal 
degeneration-associated C291R 
mutation 
7 pProEx-HTa-
Myc-K18-
P301L 
K18 containing 
the P301L 
mutation 
Myc-tagged K18 tau fragment 
containing the P301L FTD-associated 
mutation 
  
Plasmids encoding pathological mutant versions of htau40  
8 pProEx-HTa-
FLAG-
htau40-
N279K 
htau40 with the 
N279K mutation 
FLAG-tagged full-length human tau 
isoform containing the N279K 
pathological mutation 
9 pProEx-HTa-
FLAG-
htau40-
V337M 
htau40 with the 
V337M mutation 
FLAG-tagged full-length human tau 
isoform containing the V337M 
pathological mutation 
10 pProEx-HTa-
FLAG-
htau40-P301L 
htau40 
incorporating the 
P301L mutation 
FLAG-tagged full-length human tau 
isoform containing the P301L 
pathological mutation 
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11 pProEx-HTa-
htau40-Myc-
N279K 
htau40 with the 
N279K mutation 
Myc-tagged full-length human tau 
incorporating the N279K mutation 
12 pProEx-HTa-
htau40-Myc-
V337M 
htau40 with the 
V337M mutation 
Myc-tagged full-length human tau 
incorporating the V337M mutation 
  
Plasmids encoding cysteine-modified versions of WT K18  
13 pProEx-HTa-
Myc-K18-
C291A 
K18 with C291A 
mutation 
K18 tau fragment with one of two 
native cysteines (at position 291) 
modified to the non-polar amino acid 
alanine 
14 pProEx-HTa-
Myc-K18-
C291A-
C322A 
K18 with C291A 
and C322A 
mutations 
K18 tau fragment with both native 
cysteine residues modified to alanine 
15 pProEx-HTa-
Myc-K18-
C291A-
C322A-I260C 
K18 with C291A, 
C322A and 
I260C mutations 
K18 tau fragment with the two native 
cysteine residues modified to alanine, 
and a new cysteine introduced at 
position 260  
  
Plasmids encoding cysteine-modified versions of WT htau40  
16 pProEx-HTa-
FLAG-
htau40-
C291A 
htau40 carrying 
the C291A 
modification 
FLAG-tagged full-length human tau 
isoform with a native cysteine replaced 
with alanine  
17 pProEx-HTa-
FLAG-
htau40-
C291A-
C322A 
htau40 carrying 
the C291A and 
C322A amino 
acid substitutions 
FLAG-tagged full-length human tau 
with no cysteine residue 
18 pProEx-HTa-
FLAG-
htau40-
C291A-
C322A-I260C 
htau40 carrying 
the C291A, 
C322A and 
I260C 
modifications 
FLAG-tagged full-length human tau 
with both native cysteines removed and 
a novel cysteine introduced at position 
260 
19 pProEx-HTa-
htau40-Myc-
C291A 
htau40 carrying 
the C291A 
modification 
Myc-tagged full-length human tau with 
a single cysteine removed 
20 pProEx-HTa-
htau40-Myc-
C291A-
C322A 
htau40 carrying 
the C291A and 
C322A amino 
acid substitutions 
Myc-tagged full-length human tau with 
both cysteine residues removed 
21 pProEx-HTa-
htau40-Myc-
C291A-
C322A-I260C 
htau40 carrying 
the C291A, 
C322A and 
I260C 
“Cysteineless” Myc-tagged full-length 
human tau with a new cysteine residue 
introduced at position 260C in the first 
repeat region 
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Plasmids encoding cysteine-modified versions of pathological variants of 
K18  
22 pProEx-
HTa-Myc-
K18-N279K-
C291A 
K18 with 
N279K and 
C291A 
mutations  
A single-cysteine variant of the K18 
fragment with the N279K pathological 
mutation  
23 pProEx-
HTa-Myc-
K18-N279K-
C291A-
C322A 
K18 with 
N279K, C291A 
and C322A 
mutations 
Cysteine-free variant of the K18 
fragment with the N279K pathological 
mutation 
24 pProEx-
HTa-Myc-
K18-N279K-
C291A-
C322A-
I260C 
K18 with 
N279K, C291A, 
C322A, and 
I260C mutations 
The K18-N279K protein lacking native 
cysteine residues but has a novel 
cysteine at position 260 
25 pProEx-
HTa-Myc-
K18-
V337M-
C291A 
K18 with 
V337M and 
C291A 
mutations 
The V337M pathological variant of tau 
K18 with a native cysteine residue 
removed 
26 pProEx-
HTa-Myc-
K18-
V337M-
C291A-
C322A 
K18 with 
V337M, C291A 
and C322A 
mutations 
The V337M pathological variant of tau 
K18 lacking both native cysteines 
27 pProEx-
HTa-Myc-
K18-
V337M-
C291A-
C322A-
I260C 
K18 with 
V337M, C291A, 
C322A and 
I260C mutations  
The V337M pathological variant of tau 
K18 with both native cysteine residue 
removed and a new cysteine introduced 
in the first repeat region 
28 pProEx-
HTa-Myc-
K18-P301L-
C291A-
C322A 
K18 with 
P301L, C291A 
and C322A 
mutations 
The P301L variant of tau K18 with no 
cysteine residue present 
29 pProEx-
HTa-Myc-
K18-P301L-
C291A-
C322A-
I260C 
K18 with 
P301L, C291A, 
C322A and 
I260C mutations 
The P301L variant of tau K18 with 
both native cysteine residues removed, 
and a novel cysteine introduced outside 
the MT binding region 
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30 pProEx-
HTa-Myc-
K18-C291R-
C322A 
K18 with 
C291R, and 
C322A 
mutations 
A cysteine-free version of the C291R 
pathological variant of tau K18 
31 pProEx-
HTa-Myc-
K18-C291R- 
C322A-
I260C 
K18 with 
C291R, C322A 
and I260C 
mutations 
Tau K18-C291R with a new cysteine 
introduced at position 260 
 Plasmids encoding cysteine-modified versions of pathological variants of 
htau40 
32 pProEx-HTa-
FLAG-
htau40-
N279K-
C291A 
htau40 with 
N279K and 
C291A mutations 
FLAG-tagged single cysteine-
containing full-length tau with the 
N279K familial mutation  
33 pProEx-HTa-
FLAG-
htau40-
N279K-
C291A-
C322A 
htau40 with 
N279K, C291A 
and C322A 
mutations 
FLAG-tagged N279K variant of full-
length tau, with no cysteine residue 
present 
34 pProEx-HTa-
FLAG-
htau40-
N279K-
C291A-
C322A-I260C 
htau40 with 
N279K, C291A, 
C322A and 
I260C mutations 
FLAG-tagged htau40-N279K 
containing a novel cysteine at position 
260, but no native cysteine 
35 pProEx-HTa-
FLAG-
htau40-
V337M-
C291A 
htau40 with 
V337M and 
C291A mutations 
FLAG-tagged single cysteine-
containing full-length tau with the 
V337M familial mutation 
36 pProEx-HTa-
FLAG-
htau40-
V337M-
C291A-
C322A 
htau40 with 
V337M, C291A 
and C332A 
mutations 
The V337M variant of tau FLAG-
tagged htau40 with both cysteine 
residues removed 
37 pProEx-HTa-
FLAG-
htau40-
V337M-
C291A-
C322A-I260C 
htau40 with 
V337M, C291A 
and C332A 
mutations 
FLAG-tagged htau40-V337M with 
native cysteine residues removed, and a 
novel cysteine introduced outside the 
MT binding core 
38 pProEx-HTa-
htau40-Myc-
N279K-
C291A 
htau40 with 
N279K and 
C291A mutations  
A single-cysteine variant of Myc-
tagged htau40 with the N279K 
pathological mutation 
 - 68 - 
39 pProEx-HTa-
htau40-Myc-
N279K-
C291A-
C322A 
htau40 with 
N279K, C291A 
and C322A 
mutations 
Cysteine-free variant of Myc-tagged 
htau40-N279K 
40 pProEx-HTa-
htau40-Myc-
N279K-
C291A-
C322A-I260C 
htau40 with 
N279K, C291A, 
C322A, and 
I260C mutations 
Myc-tagged htau40-N279K with native 
cysteine residues removed, and a novel 
cysteine introduced outside the 
microtubule binding core 
41 pProEx-HTa-
htau40-Myc-
V337M-
C291A 
htau40 with 
V337M and 
C291A mutations 
A single-cysteine variant of Myc-
tagged htau40 with the V337M 
pathological mutation 
42 pProEx-HTa-
htau40-Myc-
V337M-
C291A-
C322A 
htau40 with 
V337M, C291A 
and C322A 
mutations 
Cysteine-free variant of Myc-tagged 
htau40-V337M 
43 pProEx-HTa-
htau40-Myc-
V337M-
C291A-
C322A-I260C 
htau40 with 
V337M, C291A, 
C322A and 
I260C mutations 
Myc-tagged htau40-V337M with native 
cysteine residues removed, and a novel 
cysteine introduced outside the MT 
binding core 
 
 
3.3 Discussion  
This chapter describes the generation of a large library of plasmid clones for 
expressing WT tau (both full-length and truncated) and their disease-associated and 
cysteine-modified variants. Protein expression, purification and initial biochemical 
characterisation of selected constructs will be described in Chapter 4.  
 
As the first large scale collection of molecular clones for expressing any 
neurodegenerative protein, this library provides a rich collection of tau proteins that 
will be beneficial for future studies into different aspects of the protein’s 
physiological and toxic functions, including the influence of specific MAPT 
mutations in cellular physiology and diseases, as well as the contribution of 
cysteine residues/bonding to tau aggregation and its inhibition. Moreover, the 
library will serve as a useful resource for studying the structure-activity 
relationships between the different tau variants created.  Furthermore, it will serve 
as a resourceful drug-screening platform, for instance, to investigate drug potency 
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against full-length tau, C-terminal truncated tau, and their respective disease 
variants. This library is serving members of our laboratory and collaborators, and 
is already being shared with colleague scientists in the neurodegenerative disease 
research community. Plans are advanced to share these clones in an open access 
repository to ensure wider, unrestricted access.  
 
In creating these plasmids, the small molecular weights of the tau proteins 
(approximately 15.1 kDa for K18 and 70 kDa for htau40) ruled out the use of 
popular fluorescent tags such as the green and red fluorescent proteins (both ~ 27 
kDa) for the intended biochemical assays of tau aggregation, and tracking of 
cellular internalisation of extracellular tau. These fluorescent tags, which are about 
twice the size of K18 and half that of htau40, have also been shown to influence 
protein internalisation and secretion (Baens et al., 2006), and may therefore have 
adverse effects on the uptake and release of tau. Another set of tags that were 
considered is the c-Myc and FLAG tags on the tau plasmids used (Fig. 2.1). Since 
these tags would require immunocytochemistry that takes several hours to days to 
complete, they were deemed un-ideal for quick, real-time assessment of protein 
spread in living cells but as secondary, confirmatory assays in cell imaging and 
immunoblotting. Both challenges were avoided through proposed chemical 
labelling with an Alexa®-Fluor 488-tagged maleimide (97.07 g/mol), which binds 
covalently to cysteine residues in tau.  
 
In conclusion, a large library of molecular clones has been constructed for the 
recombinant expression of full-length and truncated tau proteins. Additionally, 
variations of these plasmids bearing specific FTD-relevant mutations as well as 
those with cysteine modifications have been generated. These clones are being 
prepared for sharing through the open access plasmid repository, Addgene, to 
facilitate storage, maintenance and unrestricted distribution of these ready-to-use 
resources for the tau research community.  
 
Further studies in subsequent chapters will focus on the WT K18 and its N279K 
and V337M variants. These mutations have been selected for the following reasons: 
(i) The N279K is a component of the PHF6* hexapeptide motif (275VQIINK280) 
whilst the V337M is located within PHF6** (337VEVKSE342), and also close to the 
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PHF6 motif (306VQIVYK311). These motifs are critical for tau aggregation and 
seeding hence mutation in the constituent or nearby amino acids may change these 
pathways (Bergen et al., 2000, 2001; Falcon et al., 2015; Li and Lee, 2006). (ii) 
The N279K and V337M mutations fall within the second and fourth repeat regions 
respectively. Hence, their characterisation should offer insights into the 
consequences of amino acid changes in alternatively- and constitutively-spliced 
regions of tau. (iii) The two mutations lead to divergent pathological consequences 
in affected human brains (Hong et al., 1998), suggestive of differing effects on 
protein structure and aggregation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - 71 - 
 
4| Expression and purification of tau and 
its FTD variants using a cleavable 
histidine tag 
 
This chapter has been published as:  
Karikari TK, Turner A, Stass R, Lee LCY, Wilson B, Nagel DA, Hill EJ, Moffat 
KG (2017) Expression and purification of tau protein and its frontotemporal 
dementia variants using a cleavable histidine tag. Protein Expression and 
Purification 130:44–54. doi: 10.1016/j.pep.2016.09.009  
 
4.1 Introduction 
Tauopathies are a major neurodegenerative health concern worldwide. These 
include AD, FTDP-17, PiD, PSP and CBD (Spillantini and Goedert, 1998). A 
common feature shared by these diseases is the abundance of tau-positive NFTs 
that define neuropathology (Mandelkow and Mandelkow, 2012; Spillantini and 
Goedert, 1998). While tau is involved in MT assembly and stabilisation in 
physiological conditions, dysfunctional tau has been implicated in tauopathy-
associated NFTs resulting from the accumulation of insoluble toxic aggregates 
(Arriagada et al., 1992).  
 
Recombinant tau closely mimics important properties of the naturally-occurring 
human protein. To this end, recombinant tau has been used extensively to study the 
molecular, biochemical and cellular aspects of the protein’s functions, including (i) 
binding to MTs in physiological and pathological conditions (ii) tau-tau 
interactions leading to their aggregation into toxic PHFs that are similar to those 
isolated from the brains of AD patients, and (iii) the transcellular spread of this 
toxicity in affected organisms (Barghorn et al., 2000, 2004; Hasegawa et al., 1998; 
Hong et al., 1998; Michel et al., 2014; Usenovic et al., 2015; Yao et al., 2003). The 
binding of tau to MTs is disrupted in disease and also by the presence of specific 
FTDP-17 mutations some of which can enhance the protein’s aggregation into 
PHFs (Barghorn et al., 2000; Combs and Gamblin, 2012; Hasegawa et al., 1998; 
Hong et al., 1998). Furthermore, truncated tau constructs such as the repeat domains 
are aggregation-prone and demonstrate enhanced aggregation kinetics compared 
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to the full-length isoforms (Barghorn et al., 2005; Friedhoff et al., 1998). The K18 
construct, for example, is sufficient for the protein’s polymerisation into PHFs 
(Barghorn et al., 2000). When exogenously supplied, this tau fragment can be 
internalised by cells, engaging endogenous proteins to form toxic aggregates which 
spread in prion-like cell-to-cell transmission (Frost et al., 2009; Guo and Lee, 2011; 
Michel et al., 2014; Usenovic et al., 2015).  
 
High-yield expression of pure tau is critical for in vitro tauopathy studies. However, 
the protein’s expression and purification are complicated by its high aggregation 
and truncation tendencies, and time-consuming and expensive methodologies 
(Csokova et al., 2004). Here, we sought to identify parameters that would ensure 
optimal expression of tau K18 and its FTDP-17 variants V337M and N279K. The 
following expression conditions were investigated: the choice of E. coli host strain, 
induction temperature, duration of induction, and the presence of glucose in the 
culture medium. Subsequently, the newly established conditions were utilised for 
the large-scale protein expression and purification. The purified proteins were 
characterised through circular dichroism analysis of secondary structures and the 
assembly of Alzheimer-like PHFs.  
 
4.2 Results  
 
4.2.1 Preparation of tau pathogenic mutants  
 
The K18 WT construct (Fig. 4.1A) was used as a platform for the creation of tau 
constructs carrying the N279K and the V337M FTDP-17 mutations. Both 
mutations were single point: N279K = AAT (Asn) à AAA (Lys) and V337M = 
GTG (Val) à ATG (Met), and were confirmed by DNA sequencing and 
subsequent multiple sequence alignments to the original K18 WT construct (Fig. 
4.1).  
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Figure 4.1. The WT K18 expression plasmid used in this study. 
 (A) A schematic representation of the pProEx-HTa plasmid into which the K18 tau 
construct was cloned. The EheI and EcoRI restriction sites between which K18 was 
cloned are shown, as well as the genes encoding the LacI repressor (lacI), 
ampicillin resistance (AmpR), and origins of replication (f1Ori and pBR322 
Ori). (B) Essential elements of the pProEx-HTa-Myc-K18 plasmid are indicated. 
These include a trc promoter, a hexa-histidine tag, a TEV site, and a c-Myc tag 
followed by K18.  
 
 
4.2.2 Comparison of tau expression in two different E. coli strains  
Tau expression in two E. coli strains – BL21(DE3)*pRosetta and NEB-5α – was 
compared (Fig. 4.2). The intention was to compare expression in the former strain, 
which is adapted for the expression of eukaryotic proteins with the latter strain 
lacking this property. After IPTG induction, expressed tau proteins were positively 
identified with the anti-tau antibody used (Fig. 4.2A). SDS-resistant K18 WT 
monomers and dimers were approximately 22 kDa and 44 kDa in size respectively, 
with shorter fragments most likely indicating truncation products. The resistance 
of tau to denaturation by SDS has been previously reported (Goedert and Jakes, 
1990; Schafer et al., 2013). Note that the presence of the c-Myc, poly-histidine and 
TEV tags, and the anomalous SDS-binding property of tau influenced the observed 
size of expressed tau. Higher amounts of soluble monomeric tau were recorded in 
the BL21(DE3)*pRosetta strain compared to NEB-5α, although this difference was 
not significant (two-tailed Mann Whitney test, p = 0.60; Fig. 4.2B). While 
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comparable levels of monomeric tau were observed in the soluble and insoluble 
(pellet) fractions of BL21(DE3)*pRosetta (41±18 and 42±19 respectively), 
expression in NEB-5α resulted in higher levels of monomeric tau in the insoluble 
fraction compared to the soluble fraction (42±22 and 31±4 respectively; Fig. 4.2A 
and B), suggesting a higher proportion of inclusion body formation in this host. For 
this reason, all subsequent experiments were conducted using tau transformed into 
BL21(DE3)*pRosetta. Note that the densitometry analysis was focused on 
monomers as the most abundant and primary tau protein species but due to the high 
tendency of the protein to form aggregation and truncation products, this may not 
represent overall tau production in some cases.  
 
 
Figure 4.2. Representative WB analysis of K18 tau expression in the NEB-5α 
and BL21(DE3)*pRosetta E. coli strains. 
 (A) Dimerisation and truncation of expressed tau protein were noticeable in both 
strains. (B) Densitometry analysis of soluble monomeric tau levels in the 
BL21(DE3)*pRosetta strain and NEB-5α. Two-tailed Mann Whitney test, p = 0.6. 
Data shown as mean ± SD of three independent experiments. (C) Evaluation of K18 
WT and K18 V337M expression in the BL21(DE3)*pRosetta strain. S, soluble 
fraction; P, pellet (insoluble) fraction; IPTG, isopropyl β-D-1 
thiogalactopyranoside. 
 
 
The effect of the V337M disease mutation on protein expression was also 
measured, since this point mutation is sufficient to reduce the MT-binding ability 
of tau in vitro (Hasegawa et al., 1998). In this experiment, similar levels of 
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monomeric tau expression were observed for both K18 WT and the V337M variant, 
suggesting that the pathogenic mutation did not affect expression levels (Fig. 4.2C). 
Furthermore, both proteins shared tendencies to form aggregates and truncation 
products, indicating that the spontaneous aggregation and truncation properties of 
tau were independent of this mutation (Fig. 4.2C). 
 
4.2.3 Temperature optimisation for tau expression  
Subsequently, conditions for protein expression in the BL21(DE3)*pRosetta strain 
were investigated. The following parameters were studied: post-induction 
expression temperature, length of induction, and media supplementation with 
glucose. 
 
To identify an ideal expression temperature for K18 production, an initial culture 
of K18 WT-expressing cells was divided into three equal aliquots immediately after 
induction and grown for a further 3 h at 25 oC, 30 oC and 37 oC. WB analysis 
showed that all three temperatures were suitable for tau expression. 37 oC was 
found to be the best for soluble tau production, as the expression of full-length 
monomeric K18 WT was highest at this temperature (Fig. 4.3). However, 
increasing temperature appeared to favour protein aggregation and truncation.  
 
 
Figure 4.3. Representative WB analysis showing the influence of induction 
temperature on expression levels of K18 WT tau. 
Cultures of tau-encoding BL21(DE3)*pRosetta cells were grown at 37 oC until 
reaching OD600 = 0.6. After IPTG induction, the cultures were immediately split 
into three aliquots and grown at 25 oC, 30 oC or 37 oC for 3 h.  
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4.2.4 Induction length for optimum tau expression  
Optimal incubation time can vary depending on the target protein and the choice of 
expression system. To establish an optimum induction length for K18 WT 
expression, aliquots of induced cultures were taken at regular intervals post-
induction and analysed by WB. Although no marked difference in monomeric tau 
levels was recorded at the different time points, truncation products and aggregates 
were least evident at 1 h (Fig. 4.4A). 
 
 
Figure 4.4. Time-course evaluation of K18 WT expression in E. coli using 
optical density measurement and WB. 
Cultures of tau K18 WT-expressing cells were grown at 37 oC until reaching OD600 
= 0.6. The cultures were divided into two halves, and one portion induced with 0.5 
mM IPTG. Both cultures were subsequently incubated at 37 oC, and OD600 readings 
and aliquots for WB taken periodically. (A) Soluble cell fractions showing the 
expression of K18 WT over time. Truncation products were least evident at 1 h 
post-induction but increased after this time point. (B) Growth curves of IPTG-
induced and un-induced cultures of tau, showing the same pattern of growth for 
both cultures. Arrow indicates point of induction.  
 
Next, the growth curves of un-induced and induced cultures were monitored to 
ascertain whether prolonged expression resulted in accumulating toxicity. 
Although the un-induced culture grew at a slightly faster rate post-induction, this 
difference appeared minimal, suggesting that tau expression did not pose 
significant cellular toxicity to the bacterial system (Fig. 4.4B).  
 - 77 - 
 
4.2.5 Media supplementation with 0.2 %w/v glucose  
Glucose regulates the lac operon and may reduce  promoter “leakiness” (detectable 
expression without induction) (Rosano and Ceccarelli, 2014). Glucose may 
therefore be provided as an extra carbon source to enhance growth of E. coli 
expressing a protein of interest. Addition of up to 1% glucose has been shown to 
enhance protein yield (Sivashanmugam et al., 2009). For this reason, the effect of 
media supplementation with 0.2 % glucose prior to IPTG induction of tau 
expression was investigated. The level of monomeric K18 WT was not 
significantly enhanced by glucose supplementation (p = 0.6667; Fig. 4.5A and 
4.5C). Similar findings were also recorded for K18 with the two FTDP-17 variants 
(Fig. 4.5B). 
 
 
Figure 4.5. Media supplementation with 0.2% glucose did not significantly 
enhance tau expression. 
BL21(DE3)*pRosetta cells expressing tau were grown in selective LB media in the 
presence or absence of glucose. (A) Representative WB analysis of soluble cell 
fractions showing the expression of K18 WT in the absence and presence of 0.2% 
glucose. (B) WB analysis of induced protein expression in K18 WT and its FTDP-
17 variants (V337M and N279K). (C) Densitometry analysis of monomeric K18 
WT expression in LB media with or without glucose (two-tailed Mann Whitney test, 
p = 0.6667, n = 3).  
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4.2.6 Purification of tau constructs  
 
After identifying optimum conditions for expressing K18, these conditions were 
used in growing larger cultures of tau that were subsequently purified using IMAC. 
All three protein constructs (K18 WT, K18 V337M and K18 N279K) were 
successfully purified using this system, followed by overnight dialysis and TEV 
site cleavage. Tau expression and purification were confirmed by SDS-PAGE and 
WB (Fig. 4.6). As expected, the crude extracts contained tau in addition to 
contaminating cellular proteins (lanes labelled CE in Fig. 4.6). After initial 
separation of the crude extracts, the tau component was bound to the Ni2+ resin, 
leaving unbound proteins to filter through (UPFT lanes in Fig. 4.6). Washing the 
column with buffer B removed residual contaminants and loosely-bound protein 
(lanes B1-B3 in Fig. 4.6). Proteins were eluted with buffer C containing 500 mM 
imidazole (C1-C3 lanes in Fig. 4.6). and subsequently dialysed overnight with TEV 
protease and the purification process repeated to isolate tau proteins with the TEV 
site cleaved. Complete cleavage of the His tag was confirmed in WB using an anti-
His antibody (Fig. 4.7). While the total tau antibody recognised K18 WT with or 
without the His tag (Fig. 4.7A, lanes 2 and 1 respectively), the anti-His antibody 
had no recognition for K18 WT and K18 N279K with the His tags cleaved (Fig. 
4.7B, lanes 3 and 4 respectively) but for K18 WT with the His tag intact (Fig. 4.7B, 
lanes 5). Protein yield was up to ~5.5 mg/ml per 500 ml culture (Table 1). WB 
showed that the tau constructs were purified both in the monomeric and dimeric 
forms (and sometimes in higher oligomeric forms; Fig. 4.6), emphasising the 
characteristic tendency of the protein to readily form aggregates. Contrary to the 
expression experiments, truncation products were rarely observed in purified 
proteins. Gel electrophoresis confirmation of TEV protease purification is shown 
in the Appendix.  
 
4.2.7 CD assessment of secondary structure properties of the 
purified tau  
 
Following successful purification of the tau proteins, K18 WT and K18 V337M 
were characterised to compare their biochemical properties to those previously 
reported (von Bergen et al., 2005; Yao et al., 2003). Firstly, CD spectroscopy was 
used to investigate secondary structure conformation of the purified tau. To assess 
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the secondary structures of the tau proteins in solution, their CD spectra were 
measured in the far-ultraviolet spectral region (wavelength 190 – 280 nm) using 
proteins dissolved in 10 mM phosphate buffer (pH 7.4) at RT. Previous studies 
have reported that tau, in the mostly-monomeric state, is inherently unfolded, with 
predominantly random-coil conformation (Barghorn et al., 2004, 2000a; 
Mizushima et al., 2006; von Bergen et al., 2005; Yao et al., 2003). The analysis 
confirmed this observation for the purified proteins; CD spectra for both K18 WT 
and K18 V337M showed minimum peaks around 200 nm (Fig. 4.8A and 4.8B), 
characteristic of predominantly random coil structures (von Bergen et al., 2005; 
Yao et al., 2003). Moreover, the depth of the negative peaks were similar for both 
the WT and mutant constructs, suggesting that the disease-associated mutation did 
not cause obvious changes in secondary structure of tau as previously reported 
(Barghorn et al., 2000). To estimate the relative contribution of different secondary 
structure elements, the CD spectra were analysed with the CONTIN algorithm in 
DichroWeb, which showed that the secondary structures were dominated by 
random coils, with traces of α-helices and β-sheets (Fig. 4.8C and 4.8D). 
 
4.2.8 Preparation of Alzheimer-like PHF and subsequent imaging 
using negative-stain TEM 
 
In order to validate their authenticity, Alzheimer-like filaments were prepared from 
the recombinant proteins and visualised by TEM. PHFs were prepared in the 
presence of the reducing agent DTT and the polyanion inducer heparin. The 
reaction was carried out in 10 mM Na2PO4 pH 7.4 buffer. The use of a non-chlorine-
containing buffer enabled subsequent CD investigations on the prepared PHF 
without having to change buffers as was previously done (Yao et al., 2003). TEM-
based structural examination suggested that the filaments consisted of distinct 
features including two strands wound round each other, with crossover points every 
few nanometers (Fig. 4.9) in line with previous observations (Barghorn et al., 2004; 
Wischik et al., 1985).  
 
Subsequently, the filamented tau samples were analysed by CD to assess whether 
PHF assembly induced a shift in secondary structure composition as suggested (von 
Bergen et al., 2005). The CD spectra for filamented tau showed a shift in peak to 
approximately 220 nm, which is indicative of β-sheet formation (Fig. 4.8). While 
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the soluble fractions in the PHF preparation samples consisted of monomers and 
low molecular weight oligomers, the insoluble PHF was predominantly made up of 
higher molecular weight species that were not noticeable by WB (Fig. 4.9F), 
consistent with previous observations (Huvent et al., 2014).  
 
 
Figure 4.6. Analysis of IMAC-based tau purification using SDS-PAGE 
followed by WB. 
Cultures were grown until reaching OD600 = 0.6, IPTG-induced and grown for a 
further 1 h after which the expressed tau protein was recovered and purified. 
Aliquots taken at each step of the purification process were analysed on 15% Tris-
glycine SDS-PAGE gels. (A), (D) and (F) show SDS-PAGE analysis of the 
purification of K18 WT, K18 V337M and K18 N279K respectively. (B) and (C) are 
WB of K18 WT purification. (E) and (G) WB analysis of the purification of K18 
V337M and K18 N279K respectively. Arrows indicate monomeric tau; black 
arrows point to uncleaved His-tagged tau while open arrows refer to tag-free tau. 
M = marker protein; CE = crude extract; UPFT = unbound protein flow-through; 
B1, B2 and B3 = wash fractions; C1, C2 and C3 = eluted fractions; DOT = pooled 
eluted fractions dialysed overnight in the presence of TEV protease, against 
dialysis buffer; TR = eluent after TEV cleavage. C = K18 WT control protein from 
a previous preparation after the removal of breakdown products and aggregates, 
leaving homogenous monomeric tau.  
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Figure 4.7. Confirmation of cleavage of the polyhistidine tag. 
 (A) WB using the total tau antibody (#A0024 from Dako) confirmed the presence 
of tau in purified K18 WT with and without the His tag cleaved (lanes 1 and 2 
respectively). (B) WB using the anti-His antibody however recognised the His 
tagged K18 WT (lane 5) but not equal concentrations of K18 WT and K18 N279K 
with the His tags cleaved (lanes 3 and 4 respectively).  
 
 
Table 4.1. Summary of studies on expression and purification of recombinant 
tau.  
Study Tau 
isoform or 
construct 
studied 
Purification 
method used 
Yield  Purity  
This work Wild type 
K18 and its 
N279K and 
V337M 
FTD 
variants  
Ni2+ affinity 
chromatography 
 Up to ~5.5 
mg/ml, 4.0 mg/ml 
and 3.5 mg/ml 
protein per 500 
ml culture for 
K18 WT, K18 
V337M and K18 
N279K 
respectively 
Up to 99 % 
purity for 
monomer 
only and 95 
% for 
monomer-
oligomer 
mix 
Tepper et 
al. (2014)  
2N4R 
(longest tau 
isoform in 
the adult 
human 
brain) 
Tau expressed in 
Sf9 cells was 
purified by size 
exclusion and 
anion exchange 
chromatography 
5 – 10 µM 
(subsequently 
concentrated to 
~50 µM) 
Not 
indicated 
Geodert 
and Jakes 
(1990)  
The six 
human tau 
isoforms 
Ammonium 
sulphate 
precipitation and 
ion exchange 
chromatography 
30 – 60 µg/ml 
culture 
Up to 95 % 
purity 
Barghorn 
et al 
(2005)  
Tau 
isoforms 
and 
constructs 
Gel permeation 
and cation 
exchange 
chromatography  
10 – 100 mg 
protein/10 L  
culture (specific 
concentration for 
95 % for 
monomer-
oligomer 
mixtures 
and 99 % 
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including 
K18  
K18 not 
indicated) 
for 
monomer 
only 
Csokova 
et al 
(2004)  
221-441 
fragment of 
tau 
Cation exchange, 
anion exchange 
and size 
exclusion 
chromatography 
4 – 8 mg 
protein/500 ml 
culture 
Up to 98 % 
purity 
 
 
Figure 4.8. Characterisation of purified tau proteins using CD spectroscopy 
and the preparation of Alzheimer-like PHFs. 
 (A) and (B) CD spectra within the far-UV region for K18 WT and K18 V337M 
monomers (blue curves) and insoluble filaments (red curves). (C) and (D) 
Computational analysis of secondary structure content from the CD data using the 
CONTIN algorithm in the DichroWeb database. 
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Figure 4.9. Representative electron micrographs showing negative-stained 
Alzheimer-like filaments of distinct morphologies prepared from the purified 
tau proteins. 
Panels (A), (B) and (C) are from K18 WT, (D) and (E) are from K18 V337M, whilst 
(F) and (G) are from K18 N279K. Panel A shows PHFs of varying width. Panels B 
and D contain SFs with no obvious periodicity. Panels C and E display spiral-like 
PHFs.	Panels F and G are PHFs of distinct morphological phenotypes in terms of 
width, crossover pattern and periodicity. Arrowheads indicate possible peak-to-
peak crossover points. (H) Following heparin-induced tau aggregation, filament 
samples were ultra-centrifuged to isolate soluble species from insoluble PHFs. WB 
analysis suggested that the soluble fraction consisted of a heterogeneous mix of 
monomers and oligomers while the insoluble aggregates consisted mostly of higher 
molecular weight filaments that were not separated by gel electrophoresis.  
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4.3 Discussion 
 
Tau protein has been the subject of intensive research because of its physiological 
importance in stabilising MTs, supporting axonal transport, neurite outgrowth and 
other processes involved in neuronal cell biology (Lee et al., 2012; Mandelkow and 
Mandelkow, 2012; Rodríguez-Martín et al., 2016). In addition, toxic aggregation 
of WT tau and its FTDP-17 variants is the primary hallmark of Alzheimer's disease 
and other tauopathies (Mandelkow and Mandelkow, 2012). Efficient production of 
recombinant tau is a pre-requisite for the in vitro and some in vivo modelling of 
these diseases. Insufficient yield of this target protein can result in several 
experimental pitfalls. In this study, we investigated parameters that can affect the 
expression and purification of WT and FTDP-17 pathogenic tau, in an attempt to 
identify ways to increase the yield of pure tau for downstream applications. It was 
shown that the presence of the V337M and N279K pathogenic mutations appeared 
not to affect monomeric tau expression, which was greatest at 37 oC induction 
temperature compared to 25 oC and 30 oC. Build-up of truncation products and 
aggregates was least evident at 1 h post-induction, compared to up to 13 h post-
induction. Supplementing the growth medium with 0.2 % glucose did not 
significantly affect the percentage of monomeric tau present. The expressed protein 
was purified using IMAC and characterised by CD and PHF analysis. Our findings 
show that the described method led to the production of authentic tau proteins, 
which followed the known biochemical and biophysical properties. This report 
provides a reliable method for efficient expression and purification of tau that 
would be useful for further studies. 
 
The BL21(DE3)*pRosetta strain used in this study was deficient in RNAseE, and 
genetically modified to be Lon and OmpT protease-deficient, making it suitable for 
high-yield expression of foreign genes in bacteria. WB showed that using this strain 
did not significantly enhance the amount of monomeric tau compared to NEB-5α 
(Fig. 4.2). This was possibly due to the high propensity of tau to aggregate and form 
truncated peptides, thus preventing efficient evaluation of monomeric tau yield. 
Whilst 37 oC appeared optimal for expression of monomeric tau, aggregation 
seemed to increase with temperature (Fig. 4.3). This corroborates previous reports 
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that tau polymerisation is most efficient at high temperatures (Friedhoff et al., 
1998). A relatively short induction time of 1 h was optimal for the amount of 
monomeric protein yields achieved and a concentration of 0.1 mM – 1mM IPTG 
was sufficient to induce expression (data not shown). Media supplementation with 
glucose did not significantly enhance expression yield, suggesting that the strain 
can be used for tau production without glucose (Fig. 4.5). A common observation 
throughout the expression-optimisation experiments was the high tendency of the 
tau constructs to form truncation products, in both strains studied (Fig. 4.2 – 4.5). 
This possibly could have been reduced by the addition of protease inhibitors to the 
growth medium or lysis buffer, notwithstanding the reported protease resistance of 
the tau repeat domain (Novak et al., 1993). However, this step was omitted to allow 
the proteins to be observed in a native-like state. It was also observed that a 
considerable portion of the protein existed in the pellet fraction, which could not be 
recovered by additional sonication (Fig. 4.2). This was likely as a result of the 
formation of inclusion bodies or insoluble aggregates and not due to insufficient 
cell lysis, as reported for another protein (An et al., 2015).  
 
The purified tau proteins were characterised using CD spectroscopy, PHF 
preparation and TEM visualisation of PHFs (Fig. 4.7). The CD data revealed that 
the purified tau proteins were inherently unfolded, showing negative peaks at 
approximately 200 nm. For direct evidence of filament formation, samples were 
negative-stained and imaged by TEM, which indicated that the purified tau proteins 
were capable of forming filaments. Filament formation was induced with the 
addition of heparin; the role of heparin as an inducer of PHF formation has been 
characterised (Ramachandran and Udgaonkar, 2011). Filament formation is 
promoted by hexapeptide motifs at the beginning of the second and third tau repeats 
(Bergen et al., 2000), both of which were intact in the 4R tau constructs used 
(Mizushima et al., 2006). Figs 4.8 and 4.9 indicate that the tau proteins produced 
were able to form filaments as expected, and that the filaments consisted of high 
molecular weight oligomers compared to pre-filament species. The observed 
structural shift in CD spectra following tau aggregation can also be achieved by 
incubating tau at physiological temperatures with or without heparin, although 
incubation times are lengthened in the absence of heparin (Kumar et al., 2014; 
Mizushima et al., 2006).			 
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An advantage of the method reported here is that it enables the production of tau 
oligomers and monomers (the toxicity of both of which is currently under intense 
investigation) through one- or two-step purification protocols. The first purification 
step produces polyhistidine-tagged tau; the tag can be removed following TEV 
protease treatment during dialysis. We have confirmed that both His-tagged and 
tag-free tau proteins prepared using the described protocol are fully functional in 
terms of their aggregation tendency, ability to form Alzheimer-like filaments, and 
secondary structure features. These findings are in agreement with earlier studies 
that reported the use of untagged and His-tagged tau for in vitro and cell culture 
investigations (Kim et al., 2015; Kumar et al., 2014; Puri et al., 2009; Tepper et al., 
2014), further confirming the authenticity of the proteins produced using our 
simplified protocol.  
 
Whether or not the purified tau should undergo further processing before utilisation 
for functional studies would depend on the intended use. The preparation of 
monomer-oligomer mixtures, described in this report, could be used for many 
studies. However, if exclusively monomeric tau is required (as in Fig. 4.6C lane 
C), then it is possible to remove truncation products and aggregates by size 
exclusion chromatography. It is important to be certain about the nature of purified 
tau being used for downstream applications (whether consisting exclusively of 
monomers, oligomers or a heterogenous mixture of the two) since seemingly 
conflicting results have been reported for the toxicity-seeding potential of 
monomeric and oligomeric tau (Lasagna-Reeves et al., 2012; Michel et al., 2014; 
Usenovic et al., 2015).  
 
Historically, there has been a debate as to which tau protein species is the most 
toxic to cells – whether monomers, oligomers, PHF or NFT (Huang et al., 2015; 
Krüger and Mandelkow, 2016). Recent attempts to address this question have also 
sought to understand if tau toxicity and pathology spread in a prion-like manner. In 
such studies, recombinant forms of the various protein species are injected into the 
brains of living experimental animals or extracellularly added to neuronal or 
neuron-like cells, and their ability to be internalised, secreted and co-aggregate with 
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endogenous proteins monitored in real time (Mohamed et al., 2013). Converging 
evidence has mostly suggested that oligomeric tau are the early-stage species 
required to initiate the trans-cellular spread, toxicity and associated learning and 
memory impairments (Lasagna-Reeves et al., 2012a, 2011; Usenovic et al., 2015), 
although others have reported that tau monomers are the fundamental toxic species 
(Michel et al., 2014). Although the transcellular spread of tau pathology has 
become a well-known, experimentally-confirmed phenomenon, the mechanisms 
through which this process occurs have however remained elusive. It was recently 
reported that the internalisation of tau K18 fibrils occurs via binding with heparan 
sulphate proteoglycans (Holmes et al., 2013) whilst the extracellular release of 
4R0N tau occurs by exocytosis mediated by interaction with the DnaJC/Hsc70 
molecular chaperone complex (Fontaine et al., 2016). It however remains unknown 
as to whether all tau isoforms and fragments and their FTD variants are internalised 
and secreted through these same processes. As the scope of research in this area 
grows, the importance of recombinant tau will undoubtedly increase. Certainly, 
recombinant tau proteins of the highest purity and yield will be essential to produce 
reliable and reproducible data in future studies investigating the cellular 
mechanisms involved in the spread of tau toxicity as well as the in vitro structural, 
biochemical and biophysical aspects of the protein’s ability to cause disease. The 
present study has demonstrated a simple protocol for the preparation of tau K18 
proteins for such investigations. This is the first report that focuses specifically on 
the expression and purification characteristics of K18 tau. Although Barghorn et 
al., (2005) earlier described a method that combines gel permeation and size 
exclusion chromatography for the purification of tau isoforms and constructs, a 
general protein yield range was provided (10-100 mg/10 L culture), with no specific 
value given for K18 tau. Protein yields for the tau constructs and isoforms vary 
(Barghorn et al., 2005), possibly due to the different structural and functional 
characteristics exhibited by these proteins. For this reason, studies dedicated to 
documenting expression and purification approaches for each tau protein is 
necessary to inform future research. Such reports are available for the adult human 
brain tau isoforms and some truncation constructs (Table 4.1), although the 
procedures described mostly depend on methodologies that are unavailable in many 
labs. In contrast, the protocol described in the present study makes use of a simple, 
inexpensive approach to purify both WT and mutant K18 tau proteins in high yield, 
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without compromising on the purity. This protocol can be adapted for the 
preparation of the other tau proteins. In fact, we have successfully used this protocol 
in our laboratory to express and purify several other tau proteins, including K18 
and the full-length isoform carrying FTDP-17 mutations not described here, with 
similar protein quality and yield (data not shown).  
 
 
4.5 Conclusion  
We have investigated specific parameters affecting the production of the 
recombinant tau protein, reporting on conditions that may ensure optimal 
expression. Using these parameters, the tau MT repeat domain (K18) and two FTD 
variants were expressed and purified, leading to pure proteins of high 
concentrations. The purified proteins were natively unfolded and followed the 
classical fibrillisation pathway to form mature PHFs. The formation of filaments 
initiated a shift in secondary structure re-organisation from mostly random coils 
towards β-sheet formation. As such, this report demonstrates efficient methods for 
the production of tau protein that can be used in in vitro and in vivo studies.  
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5| Preparation of stable tau oligomers for 
cellular and biochemical studies 
 
5.1 Introduction  
 
The gradual intracellular accumulation of tau aggregates into NFTs is a clinical 
hallmark for diagnosing and staging AD (Braak and Braak, 1991). Nonetheless, tau 
pathology likely develops several years prior to symptom onset (Bateman et al., 
2012). Indeed, cell death and synaptic lesions have been observed independent of 
NFT formation (Andorfer et al., 2005; Polydoro et al., 2009), prompting a need for 
tau biomarkers that better correlate with disease onset and progression (Beason-
Held et al., 2013). Increasing evidence suggests that the activities of LMW 
oligomers, formed during the early nucleation stages of tau aggregation, likely 
associate with neurotoxicity that leads to AD pathology (Lasagna-Reeves et al., 
2012a, 2012b, 2011). For example, tau oligomers induce mitochondrial, synaptic 
and memory defects (Lasagna-Reeves et al., 2011). Conversely, insoluble filaments 
have been postulated to provide neuroprotective functions since they sequester 
toxic oligomers into inert filaments (Gendron and Petrucelli, 2009). Many studies 
of tau oligomer neurotoxicity use recombinant proteins, due to the close properties 
they share with Alzheimer brain-derived tau (Fá et al., 2016; Frost et al., 2009; 
Usenovic et al., 2015). However, the transient formation and further aggregation of 
LMW tau oligomers presents a daunting challenge for their preparation and 
characterisation. Several tau oligomer preparation protocols that seek to address 
these difficulties have therefore been described (Bader et al., 2011; Lasagna-
Reeves et al., 2010; Nübling et al., 2012b; Ren and Sahara, 2013). Nonetheless, a 
critical persisting challenge is the stability of the resulting oligomers. For example, 
htau40 oligomers prepared by seeding monomer aggregation with preformed a-
synuclein or amyloid b oligomers lose their stability and aggregate completely into 
filaments within 48 h of incubation incubation (Lasagna-Reeves et al., 2010). This 
suggests that oligomers prepared in vitro are unstable and are prone to further 
aggregation, which may affect experimental outcomes and reproducibility due to 
the distinct conformations that tau adopts during aggregation (Combs et al., 2016; 
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Kumar et al., 2014). This instability has previously been demonstrated for amyloid 
b, another AD-linked protein, which is capable of undergoing detectable 
aggregation even when stored at an ultralow temperature (-80 oC) for long periods 
(O’Nuallain et al., 2011).  
 
Tau aggregation occurs by two known mechanisms: (i) cysteine-dependent, 
whereby polymerisation occurs by intermolecular disulphide bonding 
(Bhattacharya et al., 2001; Schweers et al., 1995), and (ii) cysteine-independent, 
which occurs through the hexapeptide motifs (275VQIINK280 and 306VQIXXK311) 
and non-covalent bonding between monomer molecules (Bergen et al., 2000; Goux 
et al., 2004; Li and Lee, 2006). Although either mechanism is sufficient, 
aggregation efficiency is increased in the presence of both (Sahara et al., 2007). It 
was therefore predicted that labelling cysteine residues in tau monomers would 
extend the stability of oligomers formed by blocking cysteine-dependent 
aggregation. Since maleimide binds strongly to cysteine residues, it was 
hypothesised that this conjugation would generate stable tau oligomers. In this 
chapter, a simple approach of preparing stable, LMW tau K18 oligomers by 
labelling cysteine residues with commercially available derivatives of maleimide, 
namely AF-maleimide and NEM is described. For efficient fluorescent labelling, 
and consistency between labelled and unlabelled proteins, cysteine modified K18 
(C291A/C322A/I260C) will be used in this and the subsequent results chapter.  
 
5.2 Results  
 
5.2.1 Preparation of tau oligomers from monomers  
 
Existing methods for tau oligomer preparation differ substantially in reaction 
constituents, as discussed above in section 5.1. Particularly, the addition of 
polyanion inducers to accelerate aggregation may therefore adversely affect the 
structure and stability of oligomer species (Ramachandran and Udgaonkar, 2011; 
Ren and Sahara, 2013). To circumvent these challenges, tau oligomers were 
prepared by overnight incubation of freshly-prepared monomers in quiescent 
conditions at RT, by diluting samples in 10 mM Na2PO4 buffer pH 7.4. The choice 
of Na2PO4 buffer was informed by its crucial role in maintaining phosphate 
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homeostasis in physiological conditions (Penido and Alon, 2012) and non-
interference in biophysical assays including CD (Kelly et al., 2005). Overnight 
incubation of low starting protein concentrations of 100 µg/ml (5.5 µM) was 
sufficient to induce small oligomer formation, as characterised by dot blot assays 
confirming the presence of both total and oligomeric tau (Fig. 6.1). The total tau 
blot intensity was almost identical for WT and the two FTD-causing mutations, 
indicating equal starting concentrations (Fig. 5.1A and B). Oligomer formation was 
observed by immunoreactivity to the T22 antibody which is believed to react 
exclusively with tau oligomers (Lasagna-Reeves et al., 2012a, 2012b). By visual 
inspection, WT tau and N279K tau gave noticeable T22 dot blot intensities whilst 
V337M tau had a peculiarly poor output (Fig. 5.1). The observed V337M-T22 poor 
reactivity may have occurred due to one of two possibilities: (i) the T22 epitope on 
tau falls within the region of V337, the mutation of which to methionine may have 
reduced the protein-antibody interaction (the exact T22 epitope is unknown); or (ii) 
the V337M mutation reduces initial steps of K18 oligomerisation, hence an 
inadequate population of oligomers was produced. This issue will be resolved by 
direct monitoring of oligomer formation with AFM (section 5.2.2).  
 
Figure 5.1. Characterisation of oligomer formation by WT and pathologic tau 
K18 using an oligomer-specific antibody. 
(A) Dot blotting analysis of immuno-reactivity of WT K18 and its V337M and 
N279K pathologic variants to the A0024 total tau antibody. (B) K18 WT and K18 
N279K samples, but not K18 V337M, were strongly reactive to the T22 
conformation-specific antibody. Arrow points to K18 V337M dot blot.  
 
5.2.2 Structural characterisation of tau oligomers 
 
Having identified a viable method of oligomer preparation, the next step was to 
directly visualise and structurally characterise the oligomers formed. For this, AFM 
was used as it allows direct observation of small oligomers and preserves their 
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nano-structural features (shapes and sizes) akin to their native state (Tinker-Mill et 
al., 2014). AFM imaging revealed that overnight incubation at RT induced 
monomers of tau K18 WT, V337M and N279K to aggregate into a heterogeneous 
assembly of LMW granular oligomers (Fig. 5.2A-C). This indicates that the 
variable immunoreactivity of the oligomers to the T22 antibody in Fig. 5.1 was 
likely due to altered conformations that changed their immunoreactivity.  
 
 
Figure 5.2. Structural characterisation of tau K18 oligomers using AFM.  
Oligomers were prepared as described in section 2.17, and their structural features 
analysed using AFM. Granular structures were observed for each K18 variant. 
Scale bars = 200 nm. 
 
5.2.3 Oligomer preparation with regards to the aggregation pathway 
 
One way to demonstrate authenticity of the recombinant tau monomers from which 
the oligomers were prepared was to investigate their capacity to undergo the 
Alzheimer-like aggregation process. To do this, the K18 WT protein which is 
known to self-polymerise from monomers into insoluble filaments was used. 
Freshly-purified samples were induced with heparin and their ability to undergo the 
tau aggregation process characterised with negative-stain TEM incubation at 37 oC. 
Sample aliquots were imaged without ultracentrifugation in order to identify the 
co-existence of different tau aggregates. As anticipated, monomers aggregated first 
into oligomers and subsequently into protomers and then to mature filaments (Fig. 
6.3). This confirms the authenticity of the recombinant proteins used in this study. 
 
5.2.4 The K18 tau repeat domain construct forms filaments of diverse 
structural morphology 
 
WT tau K18 forms two major forms of filaments: paired helical and straight 
filaments (PHF and SF respectively) (Barghorn and Mandelkow, 2002). A means 
to characterise the authenticity of recombinant preparations of this construct is 
therefore to carefully observe the structural details of mature filaments and make 
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comparisons with the literature. Most filamentous structures (~90 %) were paired 
helical in appearance, with the rest being SFs (Fig. 5.4). In addition to the general 
PHF previously reported, it was found that these structures can further interact to 
form more complex aggregates through crosslinking, intertwining or by forming a 
“meshwork” of aggregates. Taken together, this data further confirms the 
authenticity of the tau proteins used in this study.  
 
 
Figure 5.3. The tau monomer preparations from which the oligomers were 
produced were capable of recapitulating the tau aggregation pathway in vitro. 
(A) Tau K18 WT monomers grow into granular oligomers. (B) The oligomers 
aggregate into protomers. (C) to (H) are filamentous aggregates of increasing 
maturity (both in terms of length and diameter) are formed. Scale bars = 100 nm. 
 
 
 
 
Figure 5.4. WT tau K18 forms mature filaments of diverse morphology. 
The majority of filaments were PHFs, with a few others presenting as SFs and 
rarely a “meshwork” of filaments. Scale bars = 100 nm.  
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5.2.5 Preparation of fluorescently-labelled tau oligomers 
 
The pro-aggregant MT repeat domain of tau (the K18 fragment) was used in all 
experiments because demonstrating oligomer stability for this aggregation-prone 
functional tau domain would in principle make the method applicable to the full-
length isoforms which are less aggregation-prone.  
 
Two methods of fluorescent labelling of tau with AF-maleimide were compared in 
an attempt to identify a more suitable option: Bader et al., (2011) and Michel et al., 
(2014). The main difference between these protocols is the provision of a reducing 
environment to hydrolyse apparent cysteine-dependent oligomers to monomers to 
ensure accessibility of sulfhydryl groups to fluorophores. Whilst the former method 
labels tau proteins irrespective of their aggregation state, the latter ensures that the 
proteins are initially treated with the reducing agent TCEP. Using the Bader et al., 
(2011) method, labelled proteins existed as a multimer of a distinct size (Fig. 5.5A). 
On the other hand, the Michel et al., (2014) method reduced the samples to 
monomers before maleimide treatment. This protocol was modified to enable 
oligomer preparation by overnight incubation of labelled monomers at RT without 
heparin. This approach was found sufficient for the preparation of small oligomers 
of multiple variants of tau, including: (i) WT and N279K tau K18; and (ii) His-
tagged and tag-free WT K18 (Fig. 5.5 A).  
 
The modified Michel et al., (2014) method was adopted for further use because it: 
(i) uses a simple “one-pot” approach for fluorescent labelling and oligomer 
preparation; (ii) had better labelling efficiency than the alternative method; (iii) the 
labelled oligomers were a heterogeneous mixture of monomers, dimers and trimers, 
which likely resembles the human AD brain state (Lasagna-Reeves et al., 2012a).  
 
5.2.6 Fluorescently-labelled tau oligomers exist principally as trimers  
 
The established method of preparing fluorescent tau oligomers was extended to 
prepare WT and two FTD tau K18 oligomers for application in cell culture studies. 
Oligomers were prepared by initially treating freshly-purified proteins with the 
reducing agent TCEP for 1 h to completely monomerise apparent oligomers to 
ensure exposure of cysteine residues. Thereafter, the exposed sulfhydryl groups 
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were labelled with 4x molar excess of AF-maleimide and the reaction allowed to 
proceed at 4 oC overnight (~ 15 h) following by extensive dialysis to remove excess 
dye and TCEP. Oligomerisation at low temperatures tended to increase labelling 
efficiency thereby reducing the likelihood of unlabelled contaminants. 
 
 
Figure 5.5. Comparison of two methods of fluorophore labelling of tau 
oligomers. (A) Non-denaturing SDS-PAGE analysis of tau K18 labelling according 
to the protocol of Michel et al., (2013) J Biol Chem 289: 956–967. (B) Non-
denaturing SDS-PAGE analysis of the AF-maleimide labelling of tau K18 proteins 
following the method of Bader et al., (2011) Biochem Biophys Res Commun 
411:190-196.	 
 
The labelled proteins aggregated into granular, LMW oligomers akin to those 
reported from other recombinant expression protocols (Lasagna-Reeves et al., 
2010) (Fig. 5.6A and B). Unlabelled control proteins were prepared same way as 
the labelled proteins but supplied with identical volumes of buffer (10 mM Na2PO4 
pH 7.4) instead of AF-maleimide. No detectable difference in oligomerisation 
patterns was observed between the labelled and unlabelled proteins (Figs. 5.6A) 
because unlike dimer-forming crosslinking techniques which restrict 
oligomerisation mainly to even ordered species, AF-maleimide does not appear to 
limit the polymerisation flexibility of target proteins. 
 
5.2.7 Cysteine-specific labelling with maleimide derivatives stabilises 
tau oligomers 
 
To test the hypothesis that cysteine labelling interferes with tau aggregation, the 
AF-maleimide labelled oligomers and unlabelled controls were challenged with the 
aggregation inducer heparin and heated at 37 oC under quiescent conditions for 48 
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h. Afterwards, aliquots were taken from each reaction solution after quick mixing 
and analysed by TEM. The labelled proteins existed mostly as granular oligomers 
(Fig. 5.7A), and were of similar structure as those imaged prior to heparin and heat 
treatment (Fig. 5.6Bii). On the contrary, the unlabelled protein underwent the 
complete aggregation process to form mature insoluble filaments, via intermediate 
protomers and early-stage filaments (Fig. 5.7B). These results indicate that AF-
maleimide labelling stabilises tau oligomers and prevents their aggregation and 
conformational change into PHFs.  
 
As a further test of tau oligomer stabilisation, conformations of the labelled and 
unlabelled proteins were studied by probing their immunoreactivity with a total tau 
antibody (A0024, Dako) and an oligomer-specific antibody (T22, Merck 
Millipore). Based on the above TEM findings for heparin-treated tau, it was 
hypothesised that the labelled proteins will be less immuno-reactive to the 
oligomer-specific antibody (because it formed a heterogeneous mix of monomers 
and LMW oligomers compared to the unlabelled protein which was additionally 
abundant in large oligomers and protomers which may be T22 reactive) whilst both 
proteins will be similarly reactive to the total tau antibody (since equimolar 
concentrations of monomeric tau were used). In the dot blotting experiments, the 
labelled and the unlabelled proteins gave near-identical reactivity to the total tau 
antibody (Fig. 5.7C and D). No significant difference was recorded in semi-
quantitative analysis of immuno-reactivity to the A0024 antibody (based on 
normalised intensities to the unlabelled; Mann Whitney test, p = 0.3429). The 
situation was rather different when the proteins were probed with the T22 antibody, 
with immunoreactivity being significantly less for the labelled protein (Mann 
Whitney test, p < 0.0286; Fig. 5.7C and D). This corroborates earlier TEM findings 
that AF-maleimide labelling prevents filament formation (Fig. 5.7A). It can 
therefore be concluded that AF-maleimide labelling stabilises LMW tau K18 
oligomers.  
 
 - 97 - 
 
Figure 5.6. Preparation of tau K18 oligomers stabilised by crosslinking with 
maleimide derivatives.  
(A) Non-denaturing SDS-PAGE analysis of oligomers prepared without 
crosslinking (Unlabelled; lane 1) or by labelling tau K18 with AF-maleimide (MAL 
labelled; lane 2) or NEM (NEM labelled; lane 3). (B) Negative stain TEM 
micrographs of oligomers prepared with or without crosslinking. Scale bars = 50 
nm.   
 
Next, the question was asked if the observed oligomer-stabilising property of AF-
maleimide was shared by other maleimide derivatives. For this, the alkylating agent 
NEM which reacts in a similar mechanism as AF-maleimide with sulfhydryls to 
form stable thioesters was tested. NEM labelling of tau K18 was performed as 
described above, and the labelled oligomers were mainly dimeric and trimeric in 
distribution, same as for AF-maleimide labelled (Fig. 5.6A). To test their stability, 
the formed oligomers were treated with heat and heparin for 48 h and characterised 
by TEM and dot blotting. It was observed that, like AF-maleimide, NEM labelling 
stabilised tau oligomers and blocked further aggregation into filaments (Fig. 5.8A 
and B). Moreover, the immuno-reactivity pattern between the labelled and the 
unlabelled proteins was similar to what was observed earlier for AF-maleimide, 
with the labelled oligomers being significantly less reactive to the T22 antibody 
(Mann Whitney test, p < 0.0286) but similarly reactive to the A0024 antibody (p = 
0.6857; Fig. 5.8C and D). Altogether, cysteine-specific labelling of the tau repeat 
domain with AF-maleimide and NEM appears to enhance the stability of 
oligomers.  
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Figure 5.7. Crosslinking with AF-maleimide stabilises tau K18 WT oligomers 
and prevents their aggregation into Alzheimer-like filaments. 
 (A) Representative TEM micrographs of tau K18 oligomers labelled with AF-
maleimide. (B) Representative TEM micrographs of unlabelled control aggregates. 
Scale bars = 100 nm. (C) Representative dot blot data for the reactivity of labelled 
and unlabelled tau K18 to two tau antibodies (A0024, top panel) and T22 (bottom). 
(D) Semi-quantitative analysis of dot blot intensity using Image J. Mann Whitney 
test, * = p<0.05, ns = not significant.  
 
A model by which AD pathology propagates in the human brain is through the 
transmission of toxic tau proteins between neurons in some specific brain areas 
(Guo and Lee, 2014). A critical step in this interneuronal transmission model is the 
uptake of extracellular tau into neighbouring neurons, followed by their interaction 
with endogenous proteins and subsequence release of tau aggregates to template 
new internalisation cycles (Guo and Lee, 2014). For better understanding of the 
molecular cascade of events occurring in this process, real-time microscopic 
visualisation of live cells will be necessary. As oligomers are thought to be the most 
crucial species regulating the interneuronal transmission of tau pathology (Gerson 
and Kayed, 2013), the molecular fluorescence of AF-maleimide was used to study 
the real-time internalisation of stabilised extracellular tau K18 oligomers into the 
neuron-like cell line SH-SY5Y human neuroblastoma cells. Labelled tau was 
diluted in extracellular medium bringing the final concentration to 5 µM and 
supplied exogenously to cultured cells and incubated for 24 h. Thereafter, the spent 
medium was removed, the cells washed with warm PBS to remove non-internalised 
tau and the internalised fluorescent proteins visualised by confocal microscopy 
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after new tau-free medium containing nuclear and cell membrane markers had been 
added. The internalised proteins exhibited diverse morphological phenotypes, with 
some appearing as diffused whilst others were speckled (Fig. 5.9A). These 
phenotypes were similar to those reported for labelled K18 tau internalised in the 
same neuroblastoma cell line (Michel et al., 2014), as well as other mammalian cell 
lines (Sanders et al., 2014). To extend the applicability of fluorescent stabilised 
oligomers in cellular assays to neurons, hiPSC cortical neurons were prepared and 
seeded with extracellular tau prepared identically as the above. Maximum 
projection of z-stack confocal images revealed that tau oligomer internalisation 
occurred by endocytosis (since they were encapsulated by the vesicular marker 
FM4-64®) and that the inclusions accumulated both in the soma and neurites, 
hence providing insights into the subcellular localisation of tau oligomer inclusions 
and their morphological phenotypes (Fig. 5.9B). Altogether, these findings 
demonstrate that maleimide stabilisation offers a unique strategy for the 
characterisation of cellular internalisation of tau oligomers.  
 
 
Figure 5.8. NEM labelling stabilises tau K18 oligomers in their granular 
conformation. 
 (A) Representative TEM micrographs of NEM-labelled tau K18 oligomers. (B) 
Representative TEM micrographs of unlabelled control aggregates. (C) 
Representative dot blot data for the reactivity of labelled and unlabelled tau K18 
to two tau antibodies (A0024, top panel) and T22 (bottom panel). (D) Semi-
quantitative analysis of dot blot intensity using Image J. Mann Whitney test, * = 
p<0.05, ns = not significant. Scale bars = 100 nm. 
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Figure 5.9. Extracellularly-applied stabilised tau K18 oligomers are 
internalised by human neuroblastoma cells and cortical neurons. 
(A) Uptake of AF-maleimide-labelled K18 WT oligomers by SH-SY5Y cells, 
observed by confocal microscopy. Internalised proteins appeared localised both in 
the cytoplasm and nucleus. (B) Internalisation of extracellular oligomers was 
studied in hiPSC-derived neurons, revealing their localisation in neurites and 
soma. Scale bars = 10 µm in (A) and 50 µm in (B). 
 
 
5.3 Discussion  
 
Labelling with AF-maleimide or NEM provides the rare advantage of stabilising 
oligomers of the rather aggregation-prone tau K18. The proposed simple strategy 
herein described (Figs. 5.10 and 5.11) ensures that preformed tau oligomers remain 
in their desired authentic oligomeric state for extended periods of time, offering an 
exceptional opportunity to advance downstream investigations into the 
biochemical, biophysical and neurobiological aspects of the elusive association 
between tau aggregation and neurodegeneration. Important advantages of this 
strategy are that: (i) maleimide labelling of tau is irreversible, making oligomer 
hydrolysis difficult, (ii) it does not appear to directly influence the hierarchical 
order of aggregation. Moreover, the method is simple, time efficient and does not 
require expensive pre- and post-treatment stages. The proposed approach is 
potentially applicable to brain derived tau oligomers, and will support studies of 
mechanistic and conformational changes in tau oligomers that may alter the 
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protein’s neurotoxicity and drug-reactivity profiles. Additionally, the method can 
be extended to other proteinopathic proteins such as huntingtin, and amyloid b 
containing cysteine residues. This approach has been applied to obtain novel 
insights into the subcellular internalisation and neuronal transmission of exogenous 
wild type tau K18 and several of its FTD variants (data not shown). The results 
indicate that this method provides a quick and reliable approach of monitoring 
cellular internalisation of exogenous proteins in real time, and therefore offers an 
advantage over fluorescent tags especially for small proteins like tau K18. 
 
 
 
 
 
Figure 5.10. Schematic illustration of the tau oligomer stabilisation method 
described in this study.	 
Provision of a reducing environment minimises tau protein aggregation. 
Monomers are then labelled with AF-maleimide or NEM, and oligomer formation 
and stabilisation probed by heparin-induced aggregation.  
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Figure 5.11. Schematic illustration of the chemical reaction involved in 
labelling of tau protein with maleimide derivatives. 
(A) Molecular structure of AF-maleimide. (B) Reactivity of the maleimide 
functional group with a sulfhydryl group on tau protein to produce a stable 
thioether conjugate.  
 
 
Furthermore, the neuronal internalisation and release of extracellular tau oligomers 
are regulated by protein-cell membrane interactions details about which is unclear. 
This oligomer stabilisation strategy offers a straightforward approach to study 
conformational and aggregation dynamics of protein-membrane interactions both 
at the single and bulk molecule levels using fluorescent spectroscopic and cell 
biology techniques. Additionally, stabilised oligomers are ideal immunogen 
candidates for antibody production against tau oligomer-targeted immunotherapy.  
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6| Distinct conformations, aggregation and 
neuronal internalisation of different tau strains   
 
6.1 Introduction  
A characteristic feature of tauopathies is the intracellular accumulation of NFTs 
composed of aggregated misfolded tau (Spillantini and Goedert, 2013). These misfolded 
proteins can be formed when tau loses its ability to bind to and support MT assembly, 
but rather forms insoluble aggregates that eventually develop into NFTs (Alonso et al., 
1994; Barghorn et al., 2000a; Vogelsberg-Ragaglia et al., 2000). Whilst the monomeric, 
physiological form of tau is natively unfolded, the protein becomes increasingly 
enriched in b-sheets as it aggregates into soluble, granular oligomers and subsequently 
into protomers and then PHFs that make up the NFTs (von Bergen et al., 2005). 
Although mounting evidence suggests that tau dysfunction causes neurodegeneration, 
the mechanistic basis for this association is not fully understood, several recent studies 
have suggested that the characteristic stereotypical temporospatial development of tau 
inclusions across specific brain regions observed in AD may arise due to transmission 
of misfolded tau between synaptically connected neurons (section 1.6). This 
interneuronal propagation of misfolded tau, often referred to as “spread,” is thought to 
initiate the functional and the structural impairments recorded in affected neurons and 
brain regions (Boluda et al., 2015; Usenovic et al., 2015). Therefore, the development 
of effective therapies for AD and other tauopathies would significantly benefit from 
improved understanding of the developmental pathway of this disease.   
 
Efficiency of the interneuronal transmission of pathological tau is dependent on the 
conformations of the seed protein (the internalised) and the seeded (the recipient 
endogenous protein) (Alonso et al., 2016; Goedert et al., 2014; Scott et al., 1993). This 
has consequently given rise to the tau strain hypothesis, which suggests that misfolded 
tau proteins of different conformations (distinct strains) will vary in their ability to 
induce pathology due to variability in their interaction with endogenous proteins 
(Gerson et al., 2016; Narasimhan et al., 2017). By injecting human brain isolates from 
clinically confirmed tauopathy cases into non-tangle-forming transgenic mice brains, 
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Clavaguera et al., (2013) observed differential induction of tau inclusions depending on 
the diagnosis of the source of homogenate. Whilst tau inclusions that were formed after 
the intracerebral injection of isolates from human AD, PSP, AGD, tangle-only dementia, 
and CBD were propagated between connected brain regions, the aggregates formed in 
the case of PiD were limited to the inoculation site. Importantly, similar outcomes were 
obtained upon seeding WT mice with the same human tauopathy brain extracts, 
signifying that the ability of tau seeds to corrupt endogenous tau into forming aggregates 
was independent of the background of mice used (Clavaguera et al., 2013). Furthermore, 
intracerebral inoculation of human AD and CBD brain extracts into young PS19 
transgenic mice led to cell type specificity in the formation and propagation of tau 
inclusions and induction of neuron loss (Boluda et al., 2015). Whilst tau inclusions were 
limited to oligodendrocytes of the fimbria and white matter around the site of injection 
after introducing tau from CBD patients, the tau inclusions formed after injecting AD 
tau were found in neuronal perikaya without evident oligodendrocyte involvement 
(Boluda et al., 2015). Recombinant full length and truncated tau (e.g. K18) have also 
been shown to propagate tauopathies by inducing endogenous tau to aggregate (Guo and 
Lee, 2011; Iba et al., 2013; Michel et al., 2014; Usenovic et al., 2015). This seeding 
capacity may be due to conformational similarity between the recombinant and 
endogenous tau used since the recombinant forms took on the conformation of 
endogenous tau from mice (Falcon et al., 2015). 
 
It is unclear if misfolded tau conformers from FTD with tau mutations are distinct from 
those in AD, and also if they differ in their ability to seed endogenous tau aggregation. 
Whilst there is strong evidence supporting the interneuronal propagation of misfolded 
WT tau, little is known about same for tau-positive FTD. Answering this question will 
be critical to understanding the mechanisms by which AD and non-AD tauopathies 
develop, and to establish whether or not selectivity is required in drug development for 
tauopathies. In this chapter, the conformation and aggregation of tau K18 and two of its 
FTD tau variants, namely V337M and N279K, were studied using complementary 
biochemical and biophysical assays to ascertain if these mutations alter the 
conformation and the aggregation of the WT.  
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Modelling the tau interneuronal transmission process in cellular systems is challenging 
partly because endogenous tau is highly soluble and resists spontaneous aggregation in 
many cell lines, even in the presence of known pro-aggregant tau mutations such as 
P301L and R406W (Guo and Lee, 2011; Vogelsberg-Ragaglia et al., 2000). 
Additionally, genetic overexpression of tau poorly recapitulates the disease process due 
to its inhibition of cell division and proliferation, and compromise of MT stabilisation 
(Kanai et al., 1989; Vogelsberg-Ragaglia et al., 2000). To overcome these challenges, 
WT SH-SY5Y neuroblastoma cells and hiPSC neurons (dividing and non-dividing cells 
respectively) were exogenously supplied with WT and FTD tau K18 oligomers to study 
the biological consequences of the conformational differences (Chapter 5), as well as to 
investigate if these would influence their ability to be taken up by cells and to interact 
with endogenous tau. Since some forms of secreted tau are cleaved at the C-terminus 
(Plouffe et al., 2012), and the repeat region-containing forms of tau are more likely 
released by unhealthy neurons (Kanmert et al., 2015), focusing on the K18 fragment 
may provide disease-relevant understanding in the structural and neurobiological basis 
of tau transmission.  
6.2 Results  
6.2.1 FTD mutations alter tau K18 binding to ThT 
The V337M and N279K mutations in the MAPT gene result in distinct forms of familial 
FTD, which reflect in differential pathology compared to tau-positive AD (Ghetti et al., 
2015). The pathological consequences of the V337M and N279K tau mutations have 
been summarised (Table 6.1 and Fig. 6.1). To study the structural and functional 
biochemistry of WT and FTD K18, the ThT assay of aggregation kinetics and beta sheet 
formation was used. Using freshly-purified tau K18 WT, V337M and N279K samples 
treated with or without the polyanion inducer heparin, ThT fluorescence readings were 
taken every 5 min for 15 h. Analysis of pooled data from three independent experiments 
showed no detectable changes in fluorescence in experiments lacking heparin (data not 
shown). In heparin-induced aggregation, however, distinct ThT-binding behaviours 
were observed for each sample (Fig. 6.2). K18 WT displayed a lag time of ~5 h, 
following which fluorescence readings increased until 15 h (Fig. 6.2A). It is worth 
noting that the single-cysteine tau K18 WT (with a cysteine at positon 260) used in this 
study has a reduced aggregation rate but same b-sheet-enrichment mechanism of 
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aggregation compared to the native double-cysteine protein which was not used due to 
anticipated adverse effects of fluorescent labelling of cysteines located within the core 
of the repeat regions on MT dynamics in cell biology experiments (data not shown; 
Shammas et al., 2015 supplementary data). The reverse was the case for tau K18 V337M 
for which initial fluorescence readings at ~5000 a.u. decreased to ~3000 a.u. about 
halfway through the assay. No increase in fluorescence values was observed over 15 h 
for K18 N279K (Fig. 6.2C). These results suggest that tau K18 WT and the two variants 
formed aggregates of distinct conformations that were differentially recognised by ThT, 
consistent with findings that ThT binding to proteins of distinct b-sheet features is based 
on protein cavity size accommodation of ThT ions (Groenning et al., 2007). Similarly, 
protein aggregates of distinct morphologies have their bona fide characteristic ThT 
binding profiles due to differences in quantum yields that affect their inherent brightness 
and hence fluorescence (Lindberg et al., 2015). The increased ThT binding for WT K18 
after the lag phase may be indicate of a shift from a conformation of low ThT binding 
to a new conformation of enhanced ThT binding during its aggregation. For K18 
V337M, the conformational switch seems to have occurred from one of high ThT 
affinity to another of reduced ThT affinity due to the reduction in fluorescence observed 
in Fig. 6.2B. The conformation of N279K either did not change during the assay or the 
change did not reflect in altered ThT binding, hence the unchanged fluorescence 
measurements.  
 
Figure 6.1. Schematic illustration of the molecular arrangement of the N279K and 
V337M tau mutations. Tau K18 was constructed based on the htau40 sequence. The 
N279K mutation is located in the first hexapeptide motif (red) located at the start of the 
alternatively-spliced R2 region (green). V337M is located at the beginning of the fourth 
repeat region, and is a few amino acids away from the second hexapeptide motif (second 
red region).  
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Table 6.1. Previously-reported pathological consequences of the V337M and N279K familial mutations and their impacts on 
aggregation and filament morphology of tau protein.  
 
Familial 
mutation 
Influence on tau aggregation and MT binding Pathological consequences  References 
 Aggregation 
kinetics and 
dynamics 
Dominant 
filament 
morphological 
phenotypes 
MT binding   
V337M Aggregation rate and 
aggregate structures 
similar to the WT;  
increased 3R 
aggregation  
Mostly PHFs  Reduces MT 
binding and 
stabilisation  
Diffuse neuronal loss, astrogliosis, 
hippocampal and cortical tau deposition; 
delayed symptom onset; no insoluble 
aggregates in over-expressing cell lines; 
similar 4R tau levels in hiPSCs compared 
to WT.  
(Barghorn et al., 2000; 
Combs and Gamblin, 2012; 
Domoto-Reilly et al., 2017; 
Ehrlich et al., 2015; Hong et 
al., 1998; Tanemura et al., 
2002; Vogelsberg-Ragaglia 
et al., 2000) 
N279K Selective 
aggregation of 4R 
tau  
Mostly SFs  Similar MT 
binding and 
assembly as the 
WT  
Enhanced exon 10 splicing; tau accumulation 
in neurons and tufted astrocytes; higher 4R tau 
levels in hiPSCs compared to WT 
(Barghorn et al., 2000; 
Dawson et al., 2007; Ehrlich 
et al., 2015; Hasegawa et al., 
1999; Hong et al., 1998) 
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Figure 6.2. FTD mutations alter tau K18 binding to ThT. (A), (B), and (C) Normalised 
ThT fluorescence readings for K18 WT, V337M, and N279K respectively (n = 3 each). (D), 
(E), and (F) AFM analysis of representative endpoint ThT assay samples for K18 WT, 
V337M, and N279K respectively (n = 3 each). Scale bars = 200 nm. 
 
 
6.2.2 AFM analysis of endpoint ThT assay samples provides insights into 
the aberrant binding of the tau K18 variants to ThT   
Based on the unusual ThT binding characteristics of the variant tau K18 proteins, it was 
hypothesised that the FTD-associated proteins might be of different conformations 
compared to the WT. If this is true, the endpoint samples from the ThT assay should exhibit 
different structural features since they displayed variable ThT fluorescence at 15 h (Fig. 
6.2A-C). To test this hypothesis, endpoint samples were subjected to AFM analysis to 
ascertain their structural properties. Distinct granular oligomers were recorded for K18 WT 
whilst V337M gave a mix of small and large oligomers. N279K had a combination of 
granular oligomers and filament-like structures. Altogether, the structural features and the 
stages of aggregation of endpoint WT and variant tau K18 samples appear distinct, which 
may explain their variable ThT binding characteristics.  
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6.2.3 The FTD familial mutations alter the ultrastructure of tau aggregates 
 
Notwithstanding the importance of the ThT assay in providing insights into the stages of 
aggregation and folding of the tau K18 proteins, it fell short of describing the filamentous 
structures formed. Negative-stain TEM was therefore used to study the influence of the 
V337M and N279K mutations on tau K18 aggregate structures; each sample was induced 
with heparin and incubated at 37 °C for 4 days before being analysed. The WT protein 
predominantly formed PHFs and to a less extent SFs similar to those previously reported 
(Barghorn and Mandelkow, 2002). The PHFs structures varied in their degree of twisting, 
which was up to ~ 45o (Fig. 6.3Ai –vii). On the other hand, SFs had no observable periodic 
twisting (Fig. 6.3Aviii). Tau K18 V337M formed two types of aggregates: large 
amorphous aggregates (Fig. 6.3Bi-iii) and short filamentous aggregates (Fig. 6.3Biv-v) 
whilst K18 N279K formed thick bundles of filaments of different width and length (Fig. 
6.3Ci-vi).  
 
Figure 6.3. The V337M and N279K FTD mutations induce changes in the structural 
properties of tau K18 filaments. (A), (B), and (C) Representative TEM micrographs for 
K18 WT, K18 V337M and K18 N279K aggregates respectively. Scale bars = 100 nm. (D) 
Boxplot of filament lengths. Kruskal Wallis test with Dunn’s posthoc test, **** p<0.0001, 
ns = not significant. (E) Boxplot of filament widths. Kruskal Wallis test with Dunn’s 
posthoc test, **** p<0.0001, ns = not significant.  
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Quantitative information about filament structure was obtained by statistically comparing 
filament length and width identified from three independent experiments using Kruskal 
Wallis test with the Dunn’s post hoc analysis. Mean filament lengths for K18 WT, V337M 
and N279K were 510 ± 361 nm, 106 ± 161 nm, and 534 ± 290 nm respectively. Significant 
difference was recorded between the mean filament lengths (p<0.0001). The WT formed 
significantly longer filaments than the V337M (p<0.0001) but not the N279K (p>0.9999). 
N279K filaments were also significantly longer than those of V337M (p<0.0001; Fig 
6.3D). Moreover, filament widths for the three tau proteins were significantly different 
(mean filament width = 27± 64 nm for WT, 21± 7 nm for V337M and 52 ± 84 nm for 
N279K; p<0.0001), with those of the WT and V337M being comparable (p=0.6698; Fig. 
6.3E). However, N279K filament width was significantly higher than the WT and V337M 
(p<0.0001 for both; Fig. 6.3E). Altogether, the two FTD mutations alter the morphology 
of tau K18 aggregates, causing a shift from PHF and SF for the WT to amorphous 
aggregates and significantly shorter but similarly wide filamentous aggregates for the 
V337M, and bundles of filaments of comparable length to the WT but increased thickness 
for the N279K.  
 
6.2.4 Structural features of WT and FTD tau K18 aggregates are unchanged 
following prolonged incubation  
 
Since aggregation and fracture are opposing forces in tau K18 aggregation (Meyer et al., 
2016), it was investigated if the structural properties identified after 4-day incubation will 
be maintained on prolonged incubation. This was necessary because filament conformation 
is determined by the recruitment of soluble monomers and oligomers onto template 
conformers (Guo and Lee, 2014). It is conceivable that over extended reaction times, 
repeated cycles of breakdown and growth may result in the amplification of minor 
aggregate conformers which may not be identified in short incubation assays (Meyer et al., 
2014b, 2016). Following the same experimental procedure as in Fig. 6.3, the incubation 
time was extended to 45 days, after which sample aliquots were analysed by TEM. The 
morphological phenotypes of tau aggregates formed by each protein were similar to those 
observed at 4 days: K18 WT formed PHF and SF whilst V337M formed both amorphous 
aggregates and short filaments, with N279K forming thick bundles of filament networks 
(Fig. 6.4). This data, combined with that in Fig. 6.3, indicate that the conformations of WT 
tau K18 aggregates are altered by the two FTD mutations, and that the new conformations 
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are stable and can withstand possible biochemical pressures when the reaction time is 
extended.   
 
 
 Figure 6.4. The structural distinctions between WT and FTD tau K18 aggregates are 
maintained following extended aggregation reactions. (A), (B), and (C) Representative 
TEM micrographs for K18 WT, K18 V337M and K18 N27K aggregates respectively. Scale 
bars =100 nm. 
 
6.2.5 FTD mutations alter the dynamics of tau aggregation   
Although the ThT binding data and associated AFM images (Fig 6.2) and mature filaments 
(Fig. 6.3 and 6.4) provided novel insights into the conformational and aggregational 
variability of WT and FTD tau K18, these experiments were unable to provide an 
understanding into the stepwise formation of aggregates. AFM was therefore used to probe 
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the stages of aggregation of each tau protein. To ensure consistency, the experimental setup 
followed that of the 4-day aggregation assay described above.  
 
For K18 WT, samples at 0 h predominantly consisted of monomers and small oligomers 
of sizes 1 – 3 nm (Fig. 6.5A, green arrow) and to a limited extent small oligomers 5 – 10 
nm in size (Fig. 6.5A, blue arrow). By 5.5 h, more 5 – 10 nm small oligomers had formed 
alongside larger oligomers 10 – 30 nm in size (red arrows) and polymers (> 30 nm). At 24 
h, the polymers had shifted from the granular morphology to “stretched” structures of 
increased vertical length but reduced diameter. This stage likely signifies the transition to 
protomers. Small oligomers were still observable at this stage, indicating a gradual 
polymerisation process. At 72 h, short filaments of up to 100 nm could be identified (yellow 
arrows), which were further polymerised into complex filamentous aggregates by 96 h, 
similar to those observed in Fig. 6.3A.  
 
In addition to monomers and small oligomers (1 – 3 nm), larger oligomers (5 – 30 nm) 
were observable for V337M at 0 h (Fig. 6.5 B). A high proportion of polymers were 
recognisable at 5.5 h, the diameters of which increased up to 200 nm by 24 h. Protomers 
and/or short filaments were also visible at 24 h (yellow arrow), with amorphous aggregates 
together with short filaments evident at 72 h. By 96 h, larger amorphous aggregates >1 µm 
(inset) were recorded in addition to short filaments. Morphologies of aggregates formed by 
tau K18 encoding the V337M mutation were similar to those recorded in Fig. 6.3B, 
providing strong evidence that the V337M mutation alters the aggregation of tau K18.  
 
For tau K18 N279K, monomers and small oligomers were recognised at 0 h along with a 
few large oligomers (10–30 nm) and a few polymers (>30 nm; Fig. 6.5C). By 5.5 h, more 
large oligomers (red arrow) had been formed either from the amplification of small 
oligomers or breakdown of the polymeric aggregates observed at 0 h (orange arrow). 
Furthermore, globular aggregates, several of which were seen fusing together (orange 
arrow), were observed at 5.5 h and subsequently at 24 h (see inset). More globular 
aggregates were formed at 72 h through 96 h. These structures formed the “tracks” for 
dense networks of thick filaments (series of orange arrows at 72 h) which were more 
evident at lower magnification (inset at 96 h; Fig. 6.5C). Similar to the WT and V337M, 
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the endpoint aggregates formed by the N279K K18 tau recapitulate those recorded from 
earlier independent assays (Fig. 6.3C).  
 
In summary, AFM allowed the characterisation of incipient aggregation of the three tau 
K18 proteins, with the results strongly corroborating initial findings from the TEM analysis 
of endpoint aggregation reactions. It can therefore be concluded that the V337M and 
N279K familial FTD mutations alter the aggregation features of tau K18, which may 
contribute to the phenotypic diversity observed in neurodegeneration involving WT tau 
and either familial mutation.  
 
 
Figure 6.5. AFM imaging provides insights into the stages of tau K18 aggregation in the 
presence of FTD mutations. Representative AFM images for 4-day aggregation of K18-
WT, K18-V337M and K18-N279K are given in was (A), (B) and (C) respectively. Scale 
bars = 1µm for the 96 h insets, and 200 nm for all other images.  
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6.2.6 FTD mutations alter the immunoreactivity of aggregating tau K18 
The distinctive ThT binding, structural and aggregation features of tau K18 carrying FTD 
alterations (Figs. 6.2 – 6.5), is consistent with the hypothesis that they alter the 
conformation of tau K18.  Because conformational distinctions between variants of the 
same proteinopathic protein can lead to differential immunoreactivity profiles (Hatami et 
al., 2017), binding of tau K18 to specific antibodies was used to explore any further 
evidence of protein conformational differences. Each sample (1 mg/ml) was dissolved in 
10 mM Na2PO4 pH 7.4 and incubated at 37 oC to promote polymerisation. Aliquots were 
taken at the specified intervals, diluted in half and then probed with the total tau antibody 
A0024 (Dako) or the oligomer-specific antibody T22 (Merck; (Lasagna-Reeves et al., 
2012a)). Since oligomer formation is an important yet dynamic stage of tau aggregation 
(Fig. 6. 5), the rationale here was to probe the conformation of evolving oligomers during 
aggregation and as to whether aggregation induces changes in the proteins’ 
immunoreactivity to the total tau antibody.  
 
The WT was most reactive to the total tau antibody at 0 h when aggregation was at a 
minimum (Fig. 6.6 A and B, upper panels). Immuno-reactivity however quickly and 
consistently decreased with time, with the least intensity observed at 314 h (Fig. 6.6 A and 
B, upper panels). Immunoreactivity for K18 V337M was the poorest; dot blot intensity at 
0 h was the highest throughout its time course, being comparable to the worst for the WT 
(Fig. 6.6 A and B, upper panels). Reactivity also decreased steadily from 0 h until 314 h. 
For K18 N279K, immuno-reactivity was similar to the WT, with high intensities in the 
early stages of aggregation which gradually weakened over time (Fig. 6.6 A and B, upper 
panels).  
 
Next, reactivity to the oligomer-specific antibody was analysed by dot blotting and semi-
quantified by densitometry. Similar to its reactivity to the total tau antibody, the WT K18 
recorded higher immunoreactivity to T22 at the early stages of aggregation. This however 
dropped sharply from 168 h onwards, compared to the anti-total tau reactivity for the same 
protein (Fig. 6.6 A and B). For K18 V337M, reactivity was poor throughout the assay 
except at 24 h where the highest signal was recorded (Fig. 6.6 A and B; lower panels). 
Contrary to its reactivity to anti-total tau, K18 N279K had the least intensity to T22 which 
remained barely visible throughout the time course (Fig. 6.6 A and B; lower panels).  
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Figure 6.6. The V337M and N279K familial FTD mutations alter the immunoreactivity 
of tau K18. (A) The conformations of tau K18 WT and its FTD variants aggregating 
without heparin were probed with the A0024 and T22 antibodies using dot blotting. (B) 
Semi-quantification of dot blot intensity using Image J. (C) AFM analysis of the 314 h dot 
blot samples.  Arrow points to filaments. Scale bars =200 nm. 
 
6.2.7 AFM structural evidence support the variable immunological reactivity 
for the tau K18 proteins  
 
As a further independent test of conformational variability, structural features of endpoint 
samples from the time course immunoreactivity experiments (Fig. 6.6 A and B) were 
analysed by AFM (Fig. 6.6C). Whilst the WT formed filamentous aggregates similar to 
those recorded in Figs. 6.3 – 6.5, the K18 encoding either V337M or N279K formed 
aggregates of distinct shapes and sizes (Fig. 6.6C). The V337M formed amorphous 
aggregates akin to those observed earlier whilst the N279K aggregates appeared similar to 
components of the dense filament networks described above (Figs. 6.3 – 6.5). Altogether, 
the WT and FTD K18 tau form aggregates of distinct morphologies, which in addition to 
the immunoreactivity data above, demonstrate that the V337M and N279K mutations 
modify the conformation and aggregation of tau K18.  
 
6.2.8 WT and FTD tau K18 oligomers have distinct conformations  
 
LMW oligomers are thought to be the seminal species responsible for tau-mediated 
neurodegeneration partly because they induce mitochondrial and synaptic defects 
independent of higher-order aggregates (Lasagna-Reeves et al., 2011). To exclude the 
possibility that the observed conformational diversity was limited to endpoint aggregates 
(Figs. 6.3 – 6.5) and aggregates in transition (Fig. 6.6), tau K18 oligomers were prepared 
and their conformation and structural properties characterised. After exploring several 
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protocols, overnight incubation of monomers at RT in the absence of inducers proved to 
be a viable strategy (Chapter 5). The oligomers had granular appearances, but the structural 
features appeared somewhat different between the WT and FTD variants (Fig. 6.7 A-C). 
Oligomer conformations, as measured by reactivity to the A0024 and T22 antibodies, were 
different (Fig. 6.7D). K18 WT and N279K had comparable reactivity to the total tau 
antibody whilst K18 V337M had reduced reactivity (Fig. 6.7D). K18 V337M reactivity to 
T22 was much lower compared to the WT, whilst K18 N279K had comparable intensity 
to the WT (Fig. 6.7D). Collectively, this approach for preparing LMW tau K18 oligomers 
allowed for the characterisation of disease mutation-specific effects on the protein’s 
structure and conformation. Consistent with earlier findings for mature aggregates, 
oligomers of the V337M and N279K K18 variants adopted immunologically distinct 
conformations.  
 
 
Figure 6.7. Characterisation of the conformation, shapes and size distribution of WT 
and FTD tau K18 oligomers. (A), (B) and (C) are representative AFM images of tau K18 
WT, V337M and N279K oligomers respectively prepared by overnight incubation of 
monomers RT. (D) Dot blot reactivity as a probe of oligomer conformation using two tau 
antibodies. Three independent experiments are shown (Expts 1, 2, and 3). Arrow points to 
sites of V337M blot. (E) – (H) Representative CD plots of oligomer secondary structure 
for K18 WT, V337M and N279K respectively, and their comparative assessment on a single 
graph. Scale bars =200 nm.  
 
6.2.9 Secondary structural features of WT and FTD tau K18  
 
A hallmark of tau aggregation and its associated toxicity is the conversion of natively 
unfolded monomers to b-sheet-rich oligomers (Lasagna-Reeves et al., 2010). This rule 
however does not hold for all FTD variants because oligomer formation for K18 DK280 is 
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not characterised by b-sheet enrichment (Kaniyappan et al., 2017). Having previously 
shown that the WT K18 and its V337M variant are natively unfolded and that filamentous 
aggregation enhances b-sheet content (Karikari et al., 2017), oligomer secondary structure 
contents were investigated using CD spectroscopy. Contrary to monomers with negative 
peaks at 200 nm (Barghorn et al., 2000; Karikari et al., 2017), the oligomer had more 
appreciable b-sheet content signified by shifts in CD peaks to 203 nm for WT, 204 nm for 
V337M, and 208 nm for N279K (Fig. 6.7E-H). These CD peak profiles are intermediate 
between those of monomers and filaments (Barghorn et al., 2000; Karikari et al., 2017) and 
therefore indicate that the oligomers have less beta sheet content than the filaments. This 
means that the V337M and N279K mutations do not have detrimental effects on the ability 
of tau K18 oligomers to form b-sheet structures.  
 
6.2.10 Dominant conformers of WT and FTD tau K18 are unaltered in the 
presence of competing species 
 
Since specific mutations in tau K18 influence aggregate seed selection in the presence of 
multiple seeds of different conformations (Meyer et al., 2014a), it was investigated if the 
conformation of the tau proteins will be affected by the presence of competing conformers. 
In other words, some mutations can determine which tau seeds are preferentially 
polymerised over others. Although it has been established from the above that the WT and 
FTD tau proteins are of diverse conformations (Fig. 6.2 – 6.7), it is unclear if the observed 
conformations would persist as the dominant species should they be challenged with 
different conformers. As an initial experiment, 30-day aggregates of K18 WT (from Fig. 
6.4) were used to seed monomers of all three proteins and the dominant conformers imaged 
by AFM after 11 days. Remarkably, the structures observed (Fig. 6.8) shared striking 
similarities with unseeded experiments in the presence (Fig. 6.5) or absence (Fig. 6.6C) of 
the inducer heparin, suggesting that the dominant conformers are unchanged when 
challenged with different tau strains. K18 WT, V337M and N279K formed long filaments, 
amorphous aggregates, and ordered “track-like” aggregates respectively (Fig. 6.8 A-C) and 
that these were better visualised in low and high magnifications (Fig. 6.8 D-F).  
 
In large scale experiments designed to be consistent with the TEM and AFM 
characterisation of aggregation (Figs 6.3 and 6.5), 4-day preformed filaments from each 
protein were used to seed all three proteins and their aggregate characteristics after 4 days 
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of incubation was investigated through negative-stain TEM imaging. In control unseeded 
reactions (Fig. 6.9A), the structures observed were similar to those recorded earlier in Figs. 
6.3 – 6.5: the WT recorded PHF and SF, the V337M amorphous aggregates with a few 
straight filaments, and the N279K thick bundled filaments. Surprisingly, the seeded 
reactions recorded these same features regardless of the identity of the seed (Fig. 6.9 B – 
D). This is consistent with the previous observations that the dominant conformations of 
WT and the two FTD tau K18 are distinct.  
 
A summary of findings from the biochemical and biophysical experiments described so far 
has been provided in Table 6.2.  
 
Figure 6.8. Cross-seeding of tau K18 variants with filamentous WT aggregates does not 
alter the morphological characteristics of aggregates formed. Thirty-day aggregate 
samples of K18 WT were used to seed the aggregation of monomeric K18 WT, V337M and 
N279K for 11 days, and the structures formed characterised by low (1 µm x 1 µm) and 
high magnification (20 µm x 20 µm) AFM height images respectively for K18 WT (A and 
D), K18 V337M (B and E), and K18 N279K (C and F). Scale bar =200 nm for (A) – (C) 
and 4 µm for (D) – (F). 
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Figure 6.9. Dominant conformers of tau K18 WT, V337M and N279K are unaltered in 
the presence of competing conformers. Aliquots of 4-day aggregates of K18 WT, V337M 
and N279K were in turn used to seed the aggregation of each protein (A, no seed; B, WT 
seeded; C, V337M seeded; and D, N279K seeded) and the structural features of aggregates 
formed analysed with TEM. Scale bars = 100 nm for all images.
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Table 6.2. Summary of biochemical and biophysical characterisation of the influence of the V337M and N279K familial FTD mutations 
on the conformation and aggregation of tau K18 
 
ThT ligand-binding 
aggregation, followed by 
AFM investigation of 
endpoint samples 
 
Ultrastructural 
morphology following 
short- and long-term 
filament formation 
Stages of aggregation 
analysed by AFM 
Dot blotting and AFM 
immunological assessment 
of aggregation-induced 
conformational shift 
CD, dot blot and AFM 
analysis of oligomer 
conformation and size 
distribution 
Aggregation-seeding  
analysis of  
conformational compatibility 
Observation  Inference  Observation Inference Observation  Inference  Observatio
n  
Inference  Observation  Inference Observatio
n 
Inference 
Differential 
ThT binding 
profiles.  
Endpoint 
samples had 
different 
structures. 
WT and 
FTD tau 
K18 have 
different 
ThT 
binding 
properties.  
WT formed 
PHFs and 
SFs. V337M 
formed 
amorpohous 
aggregates 
and short 
SFs. N279K 
formed dense 
bundles of 
filaments.  
The 
V337M 
and N279K 
mutations 
lead to 
changes in 
the 
structural 
features of 
aggregated 
tau K18. 
WT K18 
monomers 
were 
converted 
sequentially to 
small and then 
large 
oligomers, and 
eventually 
PHFs or SFs. 
K18 V337M 
formed large 
oligomers 
quicker than 
the WT, 
N279K formed 
bundles of 
filaments. 
The stages 
of tau K18 
aggregation 
is altered in 
the presence 
of the 
V337M or 
N279K FTD 
mutations.    
K18 V337M 
had reduced 
total tau 
immuno-
reactivity 
whilst both 
K18 V337M 
and N279K 
had reduced 
oligomer 
reactivity. 
Endpoint 
aggregates 
had variable 
structures.  
The V337M 
and N279K 
FTD 
mutations 
alter the 
conformation 
and 
ultrastructure 
of 
aggregating 
tau K18. 
All proteins 
had similar 
oligomer 
sizes but 
variable 
immuno-
reactivity.  
Negative CD 
spectra with 
peaks at ³ 
203 nm. 
Oligomeric 
FTD 
variants of 
tau K18 
have 
distinct 
immuno-
reactivity. 
Oligomers 
were 
enriched in 
b-sheets. 
Aggregate 
characterist
ics of each 
protein 
were 
unchanged 
when 
seeded with 
preformed 
aggregates 
from other 
proteins. 
WT and FTD 
variants of tau 
K18 have 
distinct 
conformations 
and seed 
selection 
properties. 
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6.2.11 Preparation and characterisation of stabilised tau K18 
oligomers for exogenous application to neurons  
 
Differential structural properties of tau “strains” are believed to underlie variability 
in their functional cellular properties (Falcon et al., 2015). The observed 
aggregation and conformational diversity between the WT and FTD tau K18 
therefore provided an important opportunity to explore relationships between their 
in vitro structural properties and their cellular functions. To achieve this, the AF-
maleimide stabilisation approach from Chapter 5 was first used to prepare small 
oligomers of all three proteins. The oligomers produced were SDS-stable, 
fluorescent and existed mainly as trimers based on SDS PAGE profiles (Fig. 6.10 
A, B). In agreement, TEM showed the presence of granular oligomers (Fig. 6.10 C 
– E) similar to those reported by others (Lasagna-Reeves et al., 2010).  
 
Subsequently, a non-invasive biophysical method, DLS, was used to probe the 
oligomer size distribution for K18 WT. Because the oligomerisation protocol 
involved labelling with AF-maleimide in the presence of the BRB buffer, DLS 
studies were run on both the labelled tau reaction mix and BRB +AF-maleimide 
only. Two peaks were recorded for the labelled tau: a highly intense signal starting 
at ~ 458 nm and a less intense signal at ~ 4 nm (Fig. 6.11A). On the other hand, the 
signal shifted to a major peak at ~ 255 nm for BRB +AF-maleimide (likely due to 
the absence of TCEP) and a small peak at ~ 1 nm (most likely a buffer constituent; 
Fig. 6.11B). However, when the data was analysed based on size distribution by 
number (the Number PSD function), single peaks were obtained for both samples: 
one at ~ 4 nm for the labelled tau consistent with the arrowed peak in Fig. 6.11A, 
compared to a signal at  ~ 255 nm minus tau. These outcomes are consistent with 
principles of DLS: in a mixture of small and large molecules (tau K18 and AF-
maleimide respectively in this instance), the large molecules will scatter light the 
more and hence have a higher intensity score. However, the number/size 
distribution preferentially highlights the species with the highest number of 
particles (which was K18 in this case). Mean oligomer size was 4±1 nm (Fig. 
6.11C; obtained from arrowed peak in Fig. 6.11A), which can be inferred to 
correspond with the prominent trimer band in Fig. 6.10A and B. Oligomer 
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distribution was 1 – 8 nm, indicating presence of n<3 and n >3 species 
(hydrodynamic radii = 1 – 2 nm and 5 – 8 nm respectively. The correlation plot 
provides information on the time-dependent scattering of light by molecules in the 
oligomer preparation, with fluctuations in the baseline indicating the presence of 
aggregated proteins (Fig. 6.11D). The DLS data is consistent with a previous report 
that estimated hydrodynamic radii of 3±0.2 nm for monomers and 5±1 nm for 
predominantly-tetrameric oligomers (Kaniyappan et al., 2017), and confirm that the 
oligomer preparations used in the present study consisted LMW oligomers. Since 
the V337M and N279K variants had the same gel electrophoresis profiles as the 
WT (Fig. 6.10A, B), they were hypothesised to share similar particle sizes with the 
WT.    
 
Figure 6.10. Characterisation of the size distribution of fluorescently labelled tau 
K18 and its V337M and N279K pathologic variants using non-denaturing SDS-
PAGE and TEM. (A) Representative non-denaturing SDS-PAGE and ultraviolet 
exposure showed that the labelled tau proteins consisted of a mix of monomers and 
LMW oligomers (i.e., dimers and trimers). (B) Non-denaturing SDS-PAGE 
showing that trimers were the most abundant oligomer species. (C), (D) and (E) 
TEM characterisation of labelled, granular oligomers of WT, V337M and N279K 
respectively. High magnification images are shown as insets. Scale bar = 200 nm 
for main images and 20 nm for insets. 
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Figure 6.11. DLS assessment of the sizes of AF-maleimide–labelled tau K18 WT 
oligomers. (A) The DLS intensity function gave two peaks for the labelled 
oligomers in the presence of the fluorophore and buffer constituents. (B) In the 
absence of tau, a large peak with a much-reduced size (~255 nm compared to ~825 
nm in (A) was obtained. The new small peak <1 nm was likely from a buffer 
constituent which would bind to the tau oligomers. (C) Size distribution of tau K18 
oligomers. (D) The correlation plot gives insights into the mean oligomer size, with 
baseline fluctuations indicating the presence of aggregated samples. 
 
 
6.2.12 Optimisation of human neuroblastoma and neuronal cell 
culture growth conditions  
 
A major focus of this thesis was to study the in vitro structural features of tau 
aggregation and how this may influence cellular internalisation, which is an 
important step in the protein’s cell–to-cell transmission. To do this, optimal cell 
culture conditions needed to be established. SH-SY5Y neuroblastoma cells were 
grown to confluence in 3-4 days in MEM/F12 medium. On splitting, different 
concentrations of cells were seeded in CellViewTM Advanced Tissue Culture dishes 
and their adherence and viability after 24 h of incubation analysed. It was observed 
that 200,000 cells/ml was a good concentration to use since the cells exhibited good 
adherence, growth and spacing. Moreover, the live cells stained well for the nuclear 
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and plasma membrane markers Hoechst and CellMask Deep Red respectively (Fig. 
6.12A) as well as endogenous tau proteins, making them suitable for live cell assays 
of tau internalisation.  
 
Subsequently, growth conditions for a hiPSC-derived cortical neuron line were 
optimised. After ~20 days in culture, the cells exhibited common neuronal 
properties including dense neurite networks. However, the cells appeared over-
confluent with multiple layers which easily detached in a sheath-like manner. 
Culture duration was therefore shortened to 14 – 16 days, which proved sufficient 
for neurite network development (Fig. 6.12B). Additionally, the cells were 
characterised by their immuno-reactivity for several markers of differentiation. 
Differentiated neurons were immuno-negative for octamer binding transcription 
factor 4 (oct4), a marker of undifferentiated cells. They were also immuno-positive 
for the progenitor markers nestin (neuroectodermal stem cell marker), ki67 (cell 
proliferation marker) and GFAP (glial fibrillary acidic protein; astrocyte marker) 
at day 2 but expression decreased with differentiation during which Tuj1 (neuron-
specific class III beta tubulin) expression increased (data not shown).  
 
6.2.13 Familial FTD mutations increase tau oligomer internalisation in 
SH-SY5Y cells but not in hiPSC-derived cortical neurons 
Increasing evidence suggests that oligomers may be the toxic tau species that 
regulate the interneuronal transmission of pathology (Lasagna-Reeves et al., 
2012a). It however remains unknown if FTD characterised by familial tau 
mutations are transmitted through the same mechanism. To answer this question, 
recombinant tau K18 WT, V337M and N279K low-n oligomers were fluorescently 
labelled (section 5.2) and applied exogenously to cells and their internalisation 
dynamics investigated.  
 
SH-SY5Y cells (Kovalevich and Langford, 2013), were first challenged with 10 
µM oligomeric tau K18 for 24 h, after which un-internalised proteins were removed 
by washing with PBS. It was earlier observed that a single PBS wash was enough 
to remove all loosely-bound tau from cells. Tau internalisation was observed for all 
three proteins (Fig. 6.10). A careful look at the Alexa Fluor 488 channel (Fig. 6.13) 
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however suggested that internalisation was less intense for the WT compared to the 
variants. The extent of internalisation was therefore quantified. To account for both 
diffused and punctate phenotypes of internalisation (Fig. 6.13), integrated density 
(mean intensity x area occupied) was used. Internalisation was significantly 
different among the three proteins (p<0.0001). Internalisation was significantly 
higher for both V337M and N279K against the WT (p<0.0001 for each, Fig. 6.14), 
and also significantly higher for V337M compared to N279K (p=0.0241; Fig. 6.14).  
 
Internalisation in hiPSC neurons was the opposite of what was found in SH-SY5Y 
cells: internalisation was highest in the WT compared to the FTD variants 
(p<0.0001). Mean values are given in Fig. 6.15B. Internalisation was better in the 
WT against both the V337M and the N279K (p<0.0001 and p=0.0374 respectively; 
Fig. 6.15). Internalisation was also better for V337M than N279K (Fig. 6.15). This 
suggests that the distinctive internalisation of the tau K18 oligomers may be cell 
line-specific.   
 
Figure 6.12. Optimisation of parameters for cell culture studies. (A) 
Undifferentiated and differentiated SH-SY5Y neuroblastoma cells were seeded in 
CellViewTM Advanced Tissue Culture dishes for 24 hrs and their adherence and 
staining for nuclear and plasma membrane markers studied. (B) hiPSC neurons 
developed neuronal morphological properties with optimal adherence within 14 – 
16 days in culture. The cells also expressed markers of neural differentiation within 
the time frame (data not shown). Scale bars = 10 µm. 
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Figure 6.13. Uptake of exogenous tau K18 oligomers by SH-SY5Y cells.  
Representative confocal microscopy images showing uptake of K18 WT, V337M, 
and N279K oligomers (A) – (C) respectively. Scale bars = 10 µm. 
 
 
 
Figure 6.14. The V337M and N279K mutations significantly enhance the 
cellular uptake of tau K18 oligomers. Internalised tau K18 oligomers were 
quantified using integrated density (mean intensity x area occupied) to account for 
their diverse phenotypes observed. (A) Boxplot of internalised tau K18 oligomers. 
Oligomer uptake significantly differed between the three proteins (Kruskal Wallis 
test, p<0.0001), being highest for V337M, followed by N279K and then WT (see 
text for details). (B) Log10 version of the internalisation boxplot given in (A).  
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Figure 6.15. Internalisation of extracellular tau K18 oligomers in hiPSC neurons 
occurs by endocytosis, and the internalised oligomers localise to the cell soma 
and the neurites. (A) – (C) Extracellularly applied and subsequently internalised 
oligomers of tau K18 WT, V337M and N279K (A – C respectively) co-localised 
with the FM4-64 marker of endocytosis. Some of the internalised oligomers were 
found in the neurites (arrowheads), whilst others were in the cell soma (arrows). 
Scale bars = 50 µm. (D) Internalisation boxplot for the tau K18 variants. (E) Log10 
version of the internalisation plot shown in (D). 
 
6.2.14 Exogenous tau K18 oligomers are internalised by endocytosis 
To investigate the mechanisms by which the extracellular tau oligomers were 
internalised by cells, the vesicular marker FM4-64® (SynaptoRed) was used. 
Similar to previous reports (Guo and Lee, 2011; Michel et al., 2014), K18 WT 
internalisation occurred by endocytosis in SH-SY5Y cells, because internalised tau 
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were encapsulated in vesicles (Fig 6.16A) similar to the V337M and N279K 
variants (Fig 6.16 B and C respectively). Interestingly, some internalised tau and 
the vesicular marker both co-localised with the nucleus, suggesting that some 
internalised tau entered the nucleus. As a control, FM4-64® and tau oligomer 
treated cells were incubated at 4 oC which blocks endocytosis (Punnonen et al., 
1998). Internalisation was not observed in this condition (Fig. 6.16 D-F).  
 
Next, it was investigated if the observed vesicular transport was cell-type specific, 
by monitoring FM4-64 co-localisation in hiPSC neurons. Internalisation was 
recorded in this cell type for all tau proteins (Fig. 6.15), indicating that endocytosis 
is likely a common route of cell entry for exogenous tau in both cell lines.  
 
Figure 6.16. Extracellular tau K18 oligomers are taken up by SH-SY5Y cells 
through endocytosis. Internalised tau K18 WT (A), K18 V337M (B), and K18 
N279K (C) oligomers co-localised with the endocytic marker FM4-64. Control 
experiments in which tau-seeded cells were incubated at 4 oC did not show cellular 
uptake (D)–(F) for WT, V337M and N279K respectively. Scale bars = 10 µm. 
 
6.2.15 Internalised tau K18 oligomers accumulate in the cytoplasm 
and nucleus of SH-SY5Y cells, and the soma and axons of hiPSC-
derived neurons 
 
Whilst several studies have reported on tau internalisation, little is known about the 
protein’s subcellular destination. The co-localisation of the endocytic marker and 
internalised tau with the nuclei in Figs. 6.15 and 6.16 prompted the likelihood that 
internalised tau may enter the nucleus. Although nuclear localisation and/or 
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function of internalised tau has not been previously reported, nuclear envelope 
associated proteins can shuttle materials between the cell surface and the nucleus, 
suggestive of nuclear signalling functions for endocytosed proteins (Benmerah, 
2004; Chaumet et al., 2015). In SH-SY5Y cells, internalised tau was identified both 
in the cytoplasm and the nucleus (Fig. 6.17A-C). Similarly, internalised tau was 
found in the axon and soma of hiPSC neurons (Fig. 6.15A-C), indicating that 
nuclear targeting of exogenous tau may be a novel, previously overlooked 
signalling process.   
 
Figure 6.17. Internalised tau K18 oligomers localise to the cytoplasm and the 
nuclei of SH-SY5Y cells. Exogenous oligomers of tau K18 WT (A), V337M (B), 
and N279K (C) taken up by SH-SY5Y cells were localised in the cytoplasm (open 
arrow heads) or nucleus (filled arrow heads). Scale bars = 10 µm. 
 
 
6.2.16 Internalised tau K18 oligomers co-localise with the nuclear 
protein nucleolin 
Endogenous nuclear tau is mainly present at the nucleolar periphery, where it co-
localises  with the nucleolar protein nucleolin (Sjöberg et al., 2006) and protects 
against heat shock-induced DNA damage (Sultan et al., 2011). Following the 
observed nucleocytoplasmic shuttling of internalised tau in both cell lines in Figs. 
6.15 – 6.17, it was investigated if exogenously-applied and nucleo-internalised tau 
interacted with nucleolin since this association seems critical for the nuclear 
transport and functions of tau (Ginisty et al., 1999). Tau co-localised with nucleolin 
in both cell types (Figs. 6.18 and 6.19). In SH-SY5Y cells, tau-nucleolin complexes 
appeared localised to the nucleolar periphery in K18 WT and K18 V337M (Fig. 
6.18A,B). However, co-localisation diffused throughout the nucleus was observed 
for K18 N279K (Fig. 6.18C). Nucleolin co-localisation was similarly observed 
using hiPSC neurons (Fig. 6.19).  
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Figure 6.18. Exogenous tau K18 oligomers that are internalised in the nuclei of 
SH-SY5Y cells co-localise with the nucleolar protein nucleolin. This 
phenomenon was observed for tau K18 WT (A), V337M (B) and N279K (C), 
whose co-localisation has been highlighted using images without (i) and with (ii) 
the nuclear marker Hoechst. Scale bars = 10 µm. 
   
 
6.2.17 Internalised tau K18 oligomers co-localise with endogenous 
tau 
 
An important step in the cell-to-cell transmission of tau oligomers is the interaction 
of internalised tau with endogenous tau, leading to the formation of heterogeneous 
tau aggregates. It is however unclear if interneuronal transmission of exogenously-
applied-and-internalised FTD tau variants involves interaction with endogenous 
tau. Using triple-stain confocal microscopy, internalised WT K18 and its FTD 
variants were observed to partially co-localise with endogenous tau (based on 
reactivity to the HT7 antibody recognising the 159PPGQK163 epitope of full length 
tau). In hiPSC neurons, co-localisation was detected for all three proteins, occurring 
both in the neurites and soma (Fig. 6.20), suggesting that internalised tau K18 likely 
interacts with endogenous tau.  
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Figure 6.19. The nuclear protein nucleolin is a co-localisation partner of tau K18 
oligomers internalised in hiPSC neurons. Oligomers of K18 WT (A), V337M (B) 
and N279K (C) internalised in hiPSC neurons and localised to the soma were 
observed to interact with the nuclear protein nucleolin. Scale bars = 40 µm. 
 
 
Figure 6.20. Internalised tau oligomers in hiPSC neurons co-localise with 
endogenous tau. Oligomers of exogenous K18 WT (A), V337M (B) and N279K (C) 
internalised in hiPSC neurons co-localised with endogenous tau (white 
arrowheads). Scale bars = 40 µm. 
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6.2.18 Morphological phenotypes of internalised tau K18 
 
Tau proteins from diverse sources exhibit phenotypic diversity upon cellular 
internalisation (Boluda et al., 2015; Narasimhan et al., 2017; Sanders et al., 2014). 
To obtain further insights into the differential internalisation profiles for the tau 
K18 oligomers, morphological appearances of the internalised tau oligomers were 
studied. Four different phenotypes were identified and classified according to 
Sanders et al., (2014); (i) speckles: collection of tiny, bright puncta of different 
sizes, (ii) disordered: usually disc-shapes of internalised tau of non-uniform 
intensity, (iii) mosaic: a mix of ordered and disordered aggregates with visible 
puncta, and (iv) ordered: circular or spherical shapes of internalised tau of uniform 
or near-uniform intensity (Fig. 6.21C). These phenotypes were identified for all 
forms of tau internalised in both cell types (Fig. 6.21). It was uncommon to see all 
phenotypes per field of view in SH-SY5Y cells. However, the first three 
phenotypes were easily identifiable (Fig. 6.21A). In hiPSC neurons, all four 
phenotypes were found for all tau strains (Fig. 6.21B). Phenotypes of 
internalisation can therefore not be used as a distinguishing factor for K18 WT and 
its variants.  
 
6.2.19 Internalised tau K18 oligomers do not induce cell death 
 
Several studies have reported that cellular internalisation of tau K18 oligomers 
causes cell death and/or reduced viability (Guerrero-Muñoz et al., 2015; Lasagna-
Reeves et al., 2010) whilst others have suggested that oligomer treatment is 
insufficient to induce cell death (Kaniyappan et al., 2017; Kumar et al., 2014). 
However, little is known about cytotoxic effects oligomers of the V337M and 
N279K forms of tau K18. SH-SY5Y cells were therefore treated with oligomer 
preparations from the three given proteins for 72 h and cytotoxicity analysed by 
measuring LDH leakage. No significant difference in viability was recorded either 
between cells treated with variable concentrations of the same protein oligomers or 
those treated with same or different concentrations of distinct proteins (Fig. 6.22). 
This means that the oligomer concentration-dependent variability in internalisation 
observed (data not shown) is not directly related to oligomer-induced cell viability. 
Differential outcomes from previous studies could possibly be due to assay 
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specificity in terms of oligomer preparation methods as well as cell lines and 
viability assays used.  
 
Figure 6.21. Morphological phenotypes of internalised tau K18 oligomers.  
Four different phenotypes were identified and classified as speckled, disordered, 
mosaic and ordered. These phenotypes were recorded in both SH-SY5Y cells (A) 
and hiPSC neurons (B). The numbering used to annotate the different forms of 
internalisation is given in (C). Scale bars = 10 µm in (A) and 40 µm in (B). 
 
 
Figure 6.22. Internalisation of tau K18 oligomers does not lead to cell death.  
SH-SY5Y cells were treated with variable concentrations of oligomeric tau for 72 
h after which the cells were for LDH leakage. No significant difference in LDH 
released was recorded between the controls (maximum control or buffer only) and 
the three tau proteins at any of the concentrations tested (n=3 biological repeats).  
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6.3 Discussion  
Tau protein has intricate roles in the development of AD and FTD, among other 
tauopathies (Wang and Mandelkow, 2016). Whilst several theories, such as 
hyperphosphorylation (Alonso et al., 2001), have been explored towards 
understanding the mechanistic and cellular basis of AD progression to inform drug 
development, it has recently been identified that these diseases may occur due to a 
cycle of events involving: (i) the extracellular secretion of endogenous tau protein 
or its fragments, (ii) interaction of extracellular tau proteins leading to the 
accumulation of aggregated exogenous proteins, (iii) cellular entry of extracellular 
tau (may be aggregated or not) where it induces the aggregation of endogenous tau, 
and impairments in neuronal physiology and function (Guo and Lee, 2014). Whilst 
this interneuronal transmission hypothesis in AD is strongly supported by in vivo, 
in vitro and ex vivo data (Clavaguera et al., 2014; Guo and Lee, 2014), it is unclear 
if disease progression in FTD involving tau mutations occurs through the same or 
similar mechanisms. In this chapter, it has been shown from both biochemical and 
biophysical perspectives that two of the commonest FTD mutations, V337M and 
N279K, do alter the conformation and pathway of aggregation of tau K18. 
Moreover, the mutations changed the cellular internalisation of tau K18, although 
all proteins were internalised by endocytosis and had similar subcellular 
accumulation patterns. These findings may offer novel insights into both the 
similarities and distinctions between tauopathies involving the WT and mutated 
forms of tau.  
 
Recent studies have highlighted pitfalls in using the ThT assay as a sole measure 
of aggregation (Coelho-Cerqueira et al., 2014; Wong et al., 2016). The ThT assay 
used in this chapter was therefore coupled with AFM observations of tau 
aggregation. This combination revealed that the extent of protein aggregation is not 
necessarily related to its ThT binding. Based on this outcome, it can be argued that 
ThT is a probe of protein conformation rather than aggregation because distinct 
folding dynamics may alter the exposure of ThT binding surfaces of each protein. 
Similar outcomes have been reached by others studying different proteinopathic 
proteins such as amylin (Wong et al., 2016) and amyloid b (Hatami et al., 2017), 
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which reinforces this observation. Indeed, the use of ThT is based on the principle 
of its binding to cross b-sheets which herald aggregation (Lindberg et al., 2015). 
However, the ability of the dye to differentiate between changing conformations of 
already aggregated proteins may be protein-specific and complicated.  
 
Inferring from the ThT binding data, it was hypothesised that the FTD mutations 
may result in altered protein conformation and aggregation. The biochemical and 
biophysical evidence shown here that the V337M and N279K mutations alter the 
stages of aggregation, and the conformation and atomic structure of aggregated tau 
K18 (Figs. 6.3 – 6.9) support this hypothesis. The mutations drastically changed 
the immunoreactivity of tau K18 to two conformation-specific tau antibodies, 
which is an indication of new adopted conformations. Interestingly, the V337M 
recorded reduced reactivity to both antibodies whilst the N279K mutation led to 
nearly no reactivity to the oligomer-specific antibody notwithstanding its reactivity 
to the total tau antibody being comparable to the WT (Fig. 6.6). Importantly, this 
shows that each FTD mutation significantly shifts the protein conformation to a 
new, unique orientation, which in turn likely dictates its pathway to form 
aggregates of distinct structures. Moreover, the consistency in the observed 
aggregate structures of each given protein across multiple independent assays using 
different batches of protein preparations (heparin-induced aggregation in Figs. 6.2 
– 6.5 and native-state aggregation in Fig. 6.6) strongly argues for mutation-induced 
specificity in protein conformations and aggregation. These data indicate that FTD 
mutations can lead to distinct amyloid structures of tau (referred to as tau “strains”). 
 
The tau strain hypothesis suggests that altered conformations induced by FTD 
mutations may underlie the differential phenotypic and disease progression profiles 
in FTD and AD (and other tauopathies involving WT tau). However, there is little 
evidence supporting this hypothesis. It was therefore investigated if the observed 
FTD tau proteins of different conformations may either be more toxic to cells or 
alter the mechanisms by which the proteins are internalised and propagated. Here, 
similarities and differences in exogenous oligomer propagation were observed, 
which highlights the shared molecular mechanisms of AD and FTD development. 
Whilst all proteins were taken up by cells through endocytosis, co-localised with 
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endogenous tau and nucleolin, and accumulated both in the cytoplasm and nucleus 
(neurites and soma for hiPSC-derived neurons), the extent of internalisation 
significantly differed between proteins and between cell lines. Speculatively, the 
new conformations and/or aggregation dynamics of tau in the presence of the FTD 
mutations may have altered its interactions with specific cell surface proteins 
governing endocytosis, resulting in their differential cellular trafficking. For 
example, the binding of aggregated tau and other proteinopathic proteins (e.g. alpha 
synuclein and amyloid beta) to heparan sulfate proteoglycans regulates their 
internalisation and transmission and that blocking heparan sulfate proteoglycan 
expression or activity prevents internalisation (Holmes et al., 2013; Rauch et al., 
2017). Another possibility is that the internalised variant K18 had distinct 
degradation efficiencies or pathways, resulting in different extents of quantifiable 
tau. Further studies are required to elucidate the veracity of these hypotheses.   
 
The observed interaction of all three proteins with endogenous tau is an indication 
that they may all propagate disease by first recruiting endogenous tau into forming 
larger aggregates as described (Lasagna-Reeves et al., 2012a; Michel et al., 2014). 
Moreover, co-localisation with nucleolin raises the possibility that: (i) internalised 
exogenously-applied tau can be exported into the nucleus, and (ii) nucleus-destined 
internalised tau may play roles in protein biosynthesis. The association of nuclear 
tau with nucleolin has been observed in AD brain samples for which reduction in 
nuclear tau levels correlate with increased NFT abundance and reduced nucleolin 
levels (Hernández-Ortega et al., 2016). Misfolded tau interaction with specific 
ribosomal proteins impairs the protein synthesis machinery (Meier et al., 2016). 
Importantly, this observation is not limited to the expression of WT tau but is also 
evident in the presence of mutated tau P301L or DK280 (Meier et al., 2016). The 
effect of tau on the protein synthesis machinery deserves to be further studied to 
identify how different forms of tau may affect ribosomal proteins.   
 
6.4 Conclusion  
 The FTD-causing mutations V337M and N279K lead to alterations in the stages 
of aggregation and immunological reactivity of K18. Moreover, these mutations 
cause the formation of Alzheimer-like filaments that are significantly distinct from 
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the WT in terms of their structural properties. Oligomers prepared from WT tau 
K18 and its FTD variants were capable of cellular internalisation by endocytosis 
where they localised to the nucleus and cytoplasm of neuroblastoma cells and the 
axon and soma of hiPSC neurons. Furthermore, oligomers of all proteins co-
localised with endogenous tau, suggestive of their ability to recruit endogenous 
proteins into forming potentially toxic aggregates. Moreover, oligomers of all 
proteins co-localised with nucleolin, a nuclear protein involved in ribosomal 
biosynthesis, which shows for the first time that functional defects propagated by 
internalised exogenous tau may be extended into the nucleus. Nonetheless, the 
oligomers did not induce significant cell death to SH-SY5Y cells, indicating that 
oligomer toxicity may be limited to functional and structural defects to neurons 
instead of outright lethality. The two mutations significantly enhanced the cellular 
internalisation of exogenous tau K18 oligomers in SH-SY5Y cells but not hiPSC 
neurons, and this observation may be due to the distinct conformers of tau formed 
by the tau variants. Taken together, these results provide evidence of the structural 
and functional properties of WT and FTD tau which may account for both the 
heterogeneity and similarities between FTD and AD (and other tauopathies 
involving WT tau). 
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7| General Discussion  
 
The findings outlined in this thesis provide new perspectives to the cell-to-cell 
propagation theory of misfolded tau, by demonstrating that cellular internalisation 
of tau variants may be tightly regulated by the given protein’s folding and 
aggregation characteristics. This may help to explain several enigmatic aspects of 
the molecular pathogenesis of different tauopathies.  
7.1 Rationale  
Prior to this study, many studies had shown that dysfunctional tau can be passed on 
from one neuron to the other, seeding the aggregation of endogenous proteins and 
transmitting pathology across synaptically-connected brain regions. Referred to as 
the cell-to-cell propagation theory, this mechanism has been demonstrated using in 
vivo, ex vivo, and in vitro models of AD, thereby building a strong evidence base 
in its favour (section 1.6).  Some recent studies had begun to point to a new aspect 
of this hypothesis: different forms of misfolded tau vary in their ability to induce 
interneuronal spread and the robustness of the induced spread (section 6.1). For 
example, tau homogenates from human AD and CBD brains are propagated 
differently when introduced into mouse brains (Boluda et al., 2015). Based on 
these, I hypothesised that the capacity of tau proteins to enter neurons and seed 
aggregation will be dependent on their conformation, and that seeding efficiency 
will be determined by conformational interactions with endogenous proteins. Since 
specific mutations in tau lead to FTD with different pathological features from AD, 
I proposed that probing the role of conformational specificity in aspects of the cell-
to-cell propagation may help to explain differences in disease onset, duration, and 
severity. I considered that in vitro biochemical and cellular models for this project 
would likely offer meaningful characterisation of tau aggregation and conformation 
and their cellular internalisation properties.   
 
The aims of this thesis were four-fold:  
(i) To develop genetic resources and a simple method of expressing and 
purifying tau K18 and a selection of its FTD variants;  
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(ii) To develop a new method of preparing LMW tau K18 oligomers of 
enhanced stability for use in biochemical and cell biology assays; 
(iii) To study the in vitro conformation and aggregation of tau K18 WT, 
V337M, and N279K; and 
(iv) To investigate the cell biological effects of extracellular tau K18 WT 
oligomers and FTD variants.   
 
The established expression and purification methods allowed for efficient 
preparation of large quantities of WT and FTD tau K18 (Chapter 4), which were 
used for in-depth investigation of effects of the V337M and the N279K FTD 
mutations on time-dependent aggregation and conformation of the K18 fragment 
(Chapter 6). This enabled comprehensive testing of the hypothesis that these two 
disease-associated mutations alter the conformation and aggregation of WT tau 
K18. It was observed that each FTD mutation formed distinct fibril structures 
compared to the WT, and reacted differently to common anti-tau antibodies and the 
ThT stain for aggregation, leading to the conclusion that the pathological mutations 
induce changes in the conformation and aggregation of tau K18. Next, the 
extracellular-to-intracellular propagation of each tau variant was studied to 
ascertain if the observed distinctive biochemical properties would influence their 
neurobiological features. Here, the new tau oligomerisation protocol developed 
(Chapter 5) enabled the preparation of LMW oligomers of improved stability for 
use in biochemical and cell biology assays, with the added advantage of fluorescent 
live tracking. It was observed that both the WT and FTD tau oligomers were taken 
up by two human cell lines (SH-SY5Y neuroblastoma and hiPSC cortical neurons) 
through endocytosis and did co-localise with endogenous tau, suggesting a 
templated misfolding mechanism (Chapter 6). Nonetheless, the tau K18 oligomers 
were differentially internalised, leading to the hypothesis that the altered 
conformations may better associate with endocytic proteins thereby modifying their 
cellular entry. In addition to cytoplasmic and neuritic inclusions, some of the 
internalised proteins were transported into the nucleus/soma where they co-
localised with nucleolin, a protein actively involved in ribosomal biosynthesis. This 
suggests that internalised exogenous tau may have nuclear functions.  
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7.2 Design and characterisation of a plasmid library 
for expressing full length and truncated tau 
proteins  
 
The preparation of recombinant forms of tau starts with verifiable plasmids as 
genetic constructs for overexpressing the protein in suitable model systems, with 
E. coli being the model expression host of choice. Whilst plasmid sharing is a 
common practice between laboratories, it was difficult to obtain plasmids in the 
desired orientations at the start of this project. Since the planned experiments were 
aimed at direct comparison of multiple forms of tau, it was essential to use tau 
plasmids of similar design. It was therefore envisaged that creating an open access 
library of plasmids for expressing different forms tau would be beneficial both to 
the planned project and broadly the tauopathy research community. Four disease-
associated forms of WT htau40 and K18 were created (Chapter 3). These included 
N279K and V337M which have been studied in detail (Chapters 4 – 6), the 
commonly-studied P301L which is known to accelerate tau aggregation and 
neurodegeneration (Lewis et al., 2000; Rodríguez-Martín et al., 2016), and the 
C291R novel mutation (Marshall et al., 2015).  Since the availability, positioning 
and number of cysteine residues affect tau aggregation (Huvent et al., 2014; Sahara 
et al., 2007; Schweers et al., 1995; Soeda et al., 2015), plasmids for expressing both 
WT (K18 and htau40) and disease variants of tau containing zero, one (at different 
positions) or two cysteines were also created (Chapter 3). Moreover, these plasmids 
have cleavable hexahistidine tags to allow protein purification, as well as a c-Myc 
or FLAG tag for ease of immunological assessments. These tags have been 
observed not to have detrimental effects on tau aggregation (data not shown).  
 
These plasmids will be shared via open access. The practice of unrestricted peer-
to-peer sharing of plasmids and other experimental resources is common in areas 
such as synthetic biology (Constante et al., 2011) and cell biology (Chen et al., 
2005; Collins et al., 1991; Hall et al., 2017), and also in some single institutions 
(https://plasmid.med.harvard.edu/PLASMID/Home.xhtml; accessed 17th 
September 2017). 
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7.3 Developing a new protocol for high-yield 
expression and purification of tau  
 
At the start of this project the expression and purification of tau protein appeared 
difficult, time-consuming and resource intensive (Csokova et al., 2004). Only a few 
detailed protocols were available (Barghorn et al., 2005; Csokova et al., 2004). In 
an attempt to simplify the tau expression and purification process, a simple but high 
yield protocol was developed (Chapter 4). IMAC was used to purify bacterial-
expressed tau followed by optional cleavage of the polyhistidine tag and a 
chromatographic isolation of the tag-free protein. With this protocol, the expression 
and purification process could be completed in 2 or 3 days for His-tagged and tag-
free tau respectively, far shorter than for other published protocols (Barghorn et al., 
2005; Csokova et al., 2004). At the time of writing, the method used had been 
further improved to produce even higher yields of tau K18 (10 mg/ml per 500 ml 
culture) and also adapted for the production of htau40 and its variants.  
 
7.4 Preparation of stabilised tau oligomers  
 
Tau oligomers have become an attractive research focus due to their abundance in 
tauopathy brains, ability to seed tau aggregation and propagation, and most 
importantly, their correlation with neurodegeneration in cellular and organismal 
model systems that seems to be independent of fibrils. Although patient brain-
derived tau oligomers are the most disease-relevant forms of oligomers, they are 
often in short supply. Oligomers prepared from recombinant tau are therefore 
frequently used for cell biology and biochemical experiments because they closely 
resemble the naturally-occurring oligomers in structure and function. However, 
oligomer preparation methods vary considerably, in terms of buffers, inducers, and 
cross seeds (section 5.1). This likely affects experimental outcomes due to 
inconsistencies in oligomer sizes, stability and secondary structure. Moreover, 
some of the common methods have limited applications due to their deviation from 
brain-derived oligomers. For example, heparin-induced oligomers are not ideal for 
injection into live animal brains for in vivo experimentation due to the risk of 
haemorrhage induction (Clark et al., 1991). Furthermore, oligomers produced by 
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heparin induction and/or cross-seeding are unstable due to the high aggregation 
propensity (Lasagna-Reeves et al., 2010).  
 
In this project, AF-maleimide labelling of tau K18 provided a simple way to 
stabilise oligomers, in addition to providing a fluorescent marker for their cellular 
internalisation. TEM analysis showed abundance of granular oligomers compared 
to control samples which aggregated into filaments. This finding was consistent 
with that of dot blotting with an aggregation stage-specific antibody (see Section 
5.2). These observations suggest that AF-maleimide labelling can be used as a 
simple approach of preparing stable oligomers.  
 
7.5 ThT fluorescence is not a universal indicator of 
proteinopathic aggregation  
 
Outcomes of the ThT assay and the AFM single-molecule analysis of endpoint 
samples (Fig. 6.2) support the notion that the V337M and N279K polymorphisms 
lead to distinct conformations of tau K18. This exemplifies the importance of using 
complementary techniques in probing protein aggregation.  Nonetheless, the ThT 
assay, mostly used in isolation, remains arguably the most widely used indicator of 
protein aggregation (Coelho-Cerqueira et al., 2014).  The correlation between ThT 
fluorescence and protein aggregation is poorly defined but based on the current data 
and those of others (Coelho-Cerqueira et al., 2014; Hatami et al., 2017; Lindberg 
et al., 2017; Wong et al., 2016), two classes of this relationship can be proposed: 
(i) where ThT fluorescence readings have no direct relationship with the extent of 
aggregation because the test protein adopts conformations that do not support 
cumulative ThT binding, or (ii) increasing ThT fluorescence reflects enhanced 
aggregation kinetics due to direct correlation between protein conformation and 
ThT binding. The results in Fig. 6.2 provide an example of the first scenario. This 
is corroborated by independent observations for other proteinopathic proteins, 
including amyloid beta and its disease-related variants (Hatami et al., 2017) and 
amylin (Wong et al., 2016), arguing that adoption of dynamic conformations by 
neurodegenerative proteins is a common phenomenon which may not be easily 
elucidated by ThT binding. On the other hand, the second scenario (where 
increasing ThT fluorescence corresponds to aggregation kinetics) is supported by 
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data on monomeric and dimeric amyloid beta aggregation (O’Malley et al., 2016). 
The influence of experimental design and methodology on observed ThT binding 
features cannot be ruled out because the same protein can exhibit diverse ThT 
fluorescence behaviour when experimental setup (e.g., buffer composition) is 
varied (Wong et al., 2016).  However, the fact that different proteins can assume 
distinct ThT binding features in identical experimental setups, as shown in Fig. 6.2 
and by others (Hatami et al., 2017; Wong et al., 2016), strongly supports the 
proposition of ThT being an indicator of conformation and not necessary one of 
aggregation. The use of complementary structural characterisation techniques such 
as AFM or TEM is therefore recommended to avoid possible ambiguity of ThT 
signal’s association with protein conformation and aggregation.  
 
7.6 Internalisation of tau oligomers and the 
induction of neurotoxicity  
 
The observed distinction in internalisation of the WT and the FTD forms of tau K18 
could be due to a changed interaction with endocytic and/or plasma membrane 
proteins which facilitates their cellular entry because of their altered conformations. 
This hypothesis is supported by findings that internalised tau permeabilises 
endosomal membranes, a process closely regulated by tau-endosomal protein 
binding (Calafate et al., 2016). Tau internalisation can occur via multiple endocytic 
pathways and is therefore regulated by several proteins involved in these processes. 
For example, tau bound to neuronal receptors such as the muscarinic receptors M1 
and M3 can be endocytosed through clathrin-dependent mechanisms (Gómez-
Ramos et al., 2008). Other mechanisms of tau internalisation have been described, 
including those which appear to be regulated by plasma membrane proteins such 
as heparan sulfate proteoglycans (Holmes et al., 2013). In addition to these proteins 
directly involved in endocytic pathways, the binding of tau to specific AD-risk 
proteins, such as those encoded by the BIN1,  PICALM, ApoE, and CLU genes can 
modulate the protein’s internalisation (Ando et al., 2016; Avila et al., 2015).  The 
most compelling evidence so far has been shown for BIN1 which negatively 
modulates tau endocytosis: BIN1 overexpression decreases tau internalisation and 
vice versa (Calafate et al., 2016). Further studies on the interaction of WT and FTD 
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tau with these endocysis-regulating proteins may help to understand the endocytic 
pathways and steps critical for the improved cellular entry of the FTD tau K18. 
 
The previous observation that internalised tau oligomers can cause cytotoxicity was 
the motivation for studying effects of the tau K18 oligomers in the LDH leakage 
assay. The result that LDH release was not significant even at high oligomer 
concentrations was surprising given that some previous studies had reported the 
opposite (Lasagna-Reeves et al., 2010, 2012). However, the current data is 
consistent with others (Kaniyappan et al., 2017; Kumar et al., 2014; Tepper et al., 
2014). These divergent data may be due to differences in the: (i) source of 
oligomers and the preparation methods, (ii) concentration of oligomers applied to 
cells, and (iii) other treatment conditions such as the type of cytotoxicity assay used. 
For example, 3 – 72 h treatment of SH-SY5Y cells or mouse primary cortical 
neurons with up to 10 µM WT K18 oligomers prepared from recombinant sources 
or extracted from Sf9 cells did not cause significant cytotoxicity in the LDH or 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays 
(Kumar et al., 2014; Tepper et al., 2014). However, htau40 oligomers prepared by 
cross seeding with a-synuclein, amyloid b or AD brain-derived oligomers were 
significantly cytotoxic at 0.1µM – 1 µM, using the MTS (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4 sulfophenyl)-2H-tetrazolium) assay 
(Lasagna-Reeves et al., 2010, 2012a). The ability of tau oligomers to induce 
cytotoxicity can therefore be said to be assay-specific.  
 
Even if tau oligomers are cytotoxic, the immediate effect of their internalisation 
will most likely not be in the form of cell death because necrosis is a process rather 
than an event. Since one of the significant effects of tau accumulation is disturbance 
to synaptic processes (Yin et al., 2016), I hypothesise that the immediate effect will 
manifest through disruption of synaptic transmission by impairing neuronal form 
and function. As shown recently from Merck Laboratories, the internalisation of 
htau40 oligomers in hiPSC neurons can lead to impairments in neuritic processes 
and thereby corrupts neurotransmission and eventually leads to synaptic and 
neuronal loss (Usenovic et al., 2015). Moreover, internalised oligomers can cause 
synaptotoxicity in the form of dendritic spine loss and increments in reactive 
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oxygen species and intracellular calcium levels,  without being cytotoxic or 
reducing cell viability (as measured by the LDH and the MTT tests) (Kaniyappan 
et al., 2017; Kumar et al., 2014; Tepper et al., 2014). 
 
7.7 Co-localisation of internalised tau with 
endogenous tau  
 
Interaction of internalised extracellular tau with endogenous tau seems to be a focal 
point in the cell-to-cell propagation mechanism for misfolded tau and the induction 
of functional toxicity (section 1.6). It was therefore investigated if the internalised 
tau co-localised with endogenous tau, using the HT7 antibody whose epitope is in 
the mid-region of full-length tau, hence outside K18. The observed co-localisation 
between internalised K18 and HT7-positive endogenous tau points to a likelihood 
that internalised tau K18 recruit endogenous tau into forming larger aggregates. 
This suggests a templated seeding mechanism of aggregation for K18 (Fig. 7.1). 
Previous reports have recorded that internalised tau K18 indeed interacts with 
endogenous tau to form larger aggregates some of which are subsequently secreted 
perhaps to seed the internalisation cycle (Michel et al., 2014). It is rather unclear if 
there are different forms of endogenous tau with which the WT and FTD tau K18 
co-localised, because the HT7 epitope is ubiquitous to all tau isoforms. It remains 
to be shown if the WT and FTD tau K18 differ in their preference for endogenous 
tau co-localising partners, for example in terms of isoform specificity, 
phosphorylation, acetylation and truncation. Nevertheless, the findings here have 
shown that WT and FTD tau K18 may interact with endogenous mid-region-
containing tau species both in the nucleus and the cytoplasm, and lays the 
foundation for future studies.  
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Figure 7.1 Internalised WT and FTD tau K18 likely seed the aggregation of 
endogenous tau and may have critical effects on ribosomal biosynthesis.  
This proposed model of the cellular entry of exogenous tau K18 oligomers, and the 
functions and subcellular localisation of the internalised proteins suggests that: (1) 
some of the tau K18 proteins released into the extracellular environment, either 
resulting from neuronal death or secretion by physiologically active neurons, enter 
new neurons by initial uptake into endocytic vesicles which ensures their trafficking 
across the plasma membrane. The differential internalisation of the tau K18 
variants may be due to their distinctive interaction with specific components of the 
endocytosis pathway. (2) Endocytosed tau K18 are delivered intracellularly 
encapsulated in endocytic vesicles. It is unclear whether the internalised tau K18 
leave the intravesicular environment. However, the internalised tau (whether in 
vesicles or not) bind to endogenous tau and initiate a templated misfolding 
mechanism by possibly recruiting other endogenous proteins into forming larger 
aggregates. (3) Instead of neuritic deposition, some of the internalised tau K18 are 
transported into the nucleus (through a mechanism yet unknown) where they seed 
the aggregation of nuclear tau. (4) The nucleus-internalised tau K18 bind to 
nucleolin, and possibly other ribosomal proteins, and likely induces effects on 
neuronal protein synthesis. As previous reports have shown that internalised tau 
affects synaptic transmission, it is proposed that synaptic proteins will be among 
those critically affected.   
 
Experiments aimed at demonstrating the release of internalised extracellular tau 
were attempted with WB using the HT7 and total tau (Dako) antibodies but perhaps 
the extremely low levels of released tau precluded the use of this assay to 
reproducibly detect tau secretion. An alternative strategy was attempted trying to 
confocal-image the tau-free medium that had been conditioned by cells after the 
initial tau K18 treatment and PBS wash. Unfortunately, the signal detection here 
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was small and not reproducible. To circumvent these problems in the future, the 
use of enzyme-linked immunosorbent assays was planned as this technique has 
been previously used to monitor tau release in cell lines expressing physiological 
levels of tau (Kanmert et al., 2015; Karch et al., 2012).  
 
The challenges detailed above illustrate difficulties involved in the use of cells 
expressing physiological levels of tau to model the cell-to-cell spread mechanism, 
and may justify the use of cell lines overexpressing tau for WB-based detection and 
quantification of tau release. However, cell lines overexpressing tau were deemed 
unsuitable for this project. 
 
7.8 Co-localisation of internalised tau with nucleolin  
The observation that nucleolin may be an interacting partner of nucleus-destined 
tau (section 6.2.16) further extends the previous report that the NFT-specific 
antibody TG-3 binds to nucleolin, suggesting that nucleolin is a component of NFT 
(Dranovsky et al., 2001). Given that nucleolin plays critical roles in ribosomal 
biogenesis (Ginisty et al., 1999), dysfunctional tau-nucleolin interactions may be 
involved in the protein synthesis impairments recorded in AD patients (Ding et al., 
2005; Fig. 7.1). Interestingly, nucleolin expression is decreased in the substantia 
nigra pars compacta of human Parkinson’s disease (PD) patients, and that this 
appears to induce oxidative stress and proteosomal dysfunction (Caudle et al., 
2009). In line with this, reduced nucleolin expression and increased nucleolin 
phosphorylation have been reported in AD, FTD and other tauopathies (Husseman 
et al., 2000). The induction of dysfunctional protein synthesis may serve to unify 
the tau pathology found in PD and the tauopathies.  
 
It would be informative to study the mechanism of nuclear entry for the internalised 
tau, and as to whether the observed tau-nucleolin co-localisation translates to an 
interaction between the two proteins using co-immunoprecipitation techniques.  
Such experiments may also demonstrate whether this putative interaction exists 
exclusively between nucleolin and the internalised tau or if endogenous tau-
nucleolin complexes are also present. This would help identify the exact function 
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that internalised extracellular tau plays in its interaction with nucleolin, compared 
to endogenous tau.  
 
 
7.9 Conclusion  
Whilst genetic determinants provide vital information about risk factors of 
neurodegeneration, translating these data to help understand the mechanistic basis 
of disease processes is challenging. The hypothesis-driven approach used in this 
thesis has led to some findings that are likely to influence future studies. Firstly, the 
differential conformation of WT and FTD tau K18 means that therapeutic agents 
developed primarily against WT tau may not be effective against FTD tau, and vice 
versa. There are strong evidences in the literature corroborating this point of view, 
including that of Vargas-Caballero et al., (2017) who showed that WT and FTD tau 
vary in their ability to rescue amyloid b-dependent impairments in long term 
potentiation. Moreover, the R406W FTD mutation alters membrane binding 
properties of WT tau (Gauthier-Kemper et al., 2011). Furthermore, the amount of 
secreted tau varies for cells expressing WT or FTD tau (Karch et al., 2012; 
Mohamed et al., 2013). Since WT tau immunotherapy and other drug discovery 
efforts have not been successful so far (Mably et al., 2015), future attempts are 
likely to expand to FTD biomarkers. The results presented here highlight the need 
for data in drug targeting of tau variants since these proteins may behave differently 
in disease processes.  
 
Secondly, internalised extracellular tau may have functions in modulating 
ribosomal biosynthesis by virtue of their co-localisation with nucleolin in the 
human cell models used. Since neurotransmission is impaired in AD models 
(Usenovic et al., 2015), and the levels of nucleolin and other nucleolar and 
ribosomal chaperones are reduced in AD brains (Hernández-Ortega et al., 2016), 
further studies focusing on understanding the role of internalised extracellular tau 
on the synthesis of specific synaptic proteins involved in neurotransmission may 
help establish the destruction of synaptic protein synthesis as a form of toxicity 
caused by the internalised dysfunctional tau. Proteins of interest may include pre- 
and post-synaptic proteins whose levels are reduced in one or more tauopathies. 
Notably, neurogranin-1, SNAP-25, synaptotagmin and PSD-95 whose levels are 
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reduced in tau-dependent pathology, have been proposed as novel biomarkers for 
diagnosis of, and drug development for, tauopathies (Brinkmalm et al., 2014; Lista 
et al., 2017; Öhrfelt et al., 2016; Shao et al., 2011).  
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9| Appendix 
9.1 Additional methods 
 
9.1.1 Quantifying tau internalisation using pixel intensity and size 
(area) in Image J 
 
Method adapted from Jensen (2013) 
Procedure  
1. Open image in Image J 
2. Convert image to 8 bit 
3. Edit à Invert 
 
4. Image àAdjust à Threshold (adjust as appropriate, ensure tau shows red 
with no background noise) 
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5. Change “default” on pull down menu to “Huang”. Press “Apply”. Tau 
positive area changes to black  
 
 
6. Exit the threshold window 
7. Process à Binary à Watershed 
8. Analyze à Analyze particles. Select “Add to Manager”. Click OK 
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9. Close image without saving changes or closing the region of interest 
(ROI) 
 
 
10. Reopen the original, unprocessed image. The ROI manager list of 
numbers will be linked to the reopened image by selecting “Show All”  
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11. Analyze à set measurements  
12. Select preferred measurements e.g. area, mean, minimum, maximum. 
Press OK 
13.  On the ROI manager, select all (Ctrl+A on Windows or Cmd+A on Mac). 
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14. Press measure 
15. File à Save as 
 
Integrated density = Area x mean 
Reference  
Jensen, E.C., 2013. Quantitative Analysis of Histological Staining and 
Fluorescence Using ImageJ. Anat. Rec. 296, 378–381. 
https://doi.org/10.1002/ar.22641 
 
9.2 Additional results 
 
 
Figure 9.1. Non-reducing SDS PAGE analysis of the purity of purified TEV 
protease. 
M = marker protein; CE = crude extract; UPFT = unbound protein flow-
through; Wash = washing step aliquot; 1 - 15 = eluted fractions.  
 
 
